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Developmental Biology 
 
 The myosin heavy chain composition of human heart and skeletal muscles is dynamic in 
health and disease and is known to define the maximum velocity and force generated by 
contracting muscles.  The study of the individual isoforms that comprise this diversity has 
recently been aided by the development of a recombinant expression system capable of 
producing functional sarcomeric human myosin motors.  The eight primary human sarcomeric 
myosin isoforms are herein shown to differ by between 1.5- and 4.5-fold in their F-actin-
activated ATPase activities.  Due to the greatly differing contractile environments in which they 
function it has been anticipated that the kinetics of the reactions that comprise the contractile 
cycle vary to an even greater extent.  Using pre-steady-state techniques it is possible to determine 
the kinetics of the steps of myosin contraction.  Among the eight isoforms tested, we observe 
multiple biochemical patterns that differentiate the motors into fast-moving and slow, tension-
maintaining categories.  Additionally, we have characterized pathological point mutations 
associated with developmental and cardiac disease.  We find that unique patterns of alteration to 
the reactions of the myosin ATPase cycle characterize each mutation.  These alterations are 
predicted to cause significant disruptions to the reactions governing attachment and detachment 
between myosin and F-actin.  These studies lay the foundation for structure vs. function analysis 
of pathological myosin mutations and fill an important void in understanding the contributions of 
the various myosin isoforms to human muscle contraction.  
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GENERAL INTRODUCTION 
 
General muscle biology 
 The evolution of large mobile animals necessitated the development of coordinated 
systems for locomotion.  The musculoskeletal system of vertebrates consists of a set of highly 
coordinated and functionally dynamic structures.  To meet the demands of a wide variety of 
activities, muscles must be able to rapidly contract, to generate and sustain high tension, and in 
some cases to contract repetitively for decades.  Muscle systems in larger animals must also be 
capable of coordination and control by nervous system signals.  This is achieved by a highly 
conserved set of cellular processes.   
 The two primary categories of muscle are smooth muscle and striated muscle.  These can 
be distinguished microscopically.  Striated muscle cells are characterized visually by a repeated 
pattern of banded structures (Figure 1A, B), while smooth muscles lack these banded structures 
(Figure 1C, D)5.  The structure responsible for the banded pattern in striated muscles is the 
sarcomere, which is the basic contractile unit of striated muscle.  Within the muscle fiber 
sarcomeres are linked end-to-end into long cylindrical bodies, known as myofibrils (Figure 2)4, 5.  
The sarcomere is composed of interdigitated thick and thin filaments consisting primarily of 
myosin and actin, respectively (Figure 3).  The sarcomere contracts by the motor activity of 
myosin while bound to actin in what is termed a "crossbridge" between the filaments6.  Smooth 
muscles also generate contractile force by interactions between actin and myosin but do so in a 
different manner without the regular, organized, and coordinated structures of the sarcomere7. 
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Figure 1: Electron micrographs of striated and smooth muscles.  Scanning electron 
micrographs of skeletal (A) and cardiac (B) striated muscles and smooth muscles (C and D).  
Most obviously striated and smooth muscle cells differ morphologically in shape, uniformity, 
and in the characteristic banding that is seen in striated muscles and not in smooth muscles.  
These morphological differences reflect their functional differences, as striated muscles are 
responsible for rapid directional contraction and smooth muscles for slower and commonly 
constricting contraction.  Adapted from Alberts, et al. (2002) Molecular Biology of the Cell5. 
 
 
Figure 2: Fluorescence micrograph of 
ventricular myocytes.  Neonatal rat 
ventricular myocytes transfected with an α-
myosin heavy chain rod domain fusion with 
GFP shows incorporation of the exogenous 
rod protein-GFP fusion into the sarcomeres 
(GFP signal is shown as white).  The long 
tubular structures composed of end-to-end 
linked sarcomeres are myofibrils.  Each cell 
contains many myofibrils aligned with one 
another for coordinated contractile activity.  
Adapted from Buvoli, et al. (2012) Effects of 
Pathogenic Proline Mutations on Myosin 
Assembly4. 
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 Striated muscles are responsible for all voluntary muscle contraction as well as several 
involuntary functions, including control of the larynx and heart contraction8.  Striated muscle can 
be subcategorized into skeletal and cardiac muscles.  Skeletal muscles, as the name implies, are 
primarily associated with skeletal movement.  In larger animals such as humans these muscles 
can span well over a foot in length.  Skeletal muscle fibers reflect this contractile environment in 
that they are long and thin (Figure 1A).  Additionally, skeletal muscle fibers have many nuclei 
distributed through the cell near the cell surface.  The heart, by contrast, is a far more compact 
structure.  While skeletal muscles typically contract along a single axis of movement, heart 
musculature produces multidirectional contractile force in the process of constricting the heart's 
chambers.  Cardiac muscle fibers reflect this contractile environment morphologically by their 
short, columnar shape (Figure 1B), which allows for more axes of contraction within the muscle5, 
8, 9.  While skeletal and cardiac fibers differ most obviously in their shape and size, they carry 
distinct proteomes as well10, 11. 
 Cardiac muscle fibers differ in contractile protein composition among animals as well as 
regionally within the heart, between atria and ventricles, but are morphologically relatively 
uniform in adults.  Skeletal muscles have a great deal of fiber type diversity.  Skeletal muscle 
fibers have been broadly categorized into slow, type I, fibers and fast, type II, fibers.  The fiber 
types are characterized primarily by metabolic activity, from slow oxidative metabolism to fast 
glycolytic metabolism as a function of the activity ratios of metabolic enzymes, such as 
hexokinase, phosphofructokinase, and fructose-1,6-bisphosphatase12.  The fast, type II, fibers 
have been further characterized into the relatively slower type IIA, the intermediate IID/X and 
the fastest class, IIB12.  Differences in contractile velocity among fiber types are closely 
correlated with differences in the sarcomeric proteome, particularly with respect to the isoforms 
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of the molecular motor protein, myosin. 
 The release of calcium into the cytosol of muscle cells is the signal that initiates muscle 
contraction.  Triggered by neuromuscular interactions in skeletal muscle or intrinsic systems in 
the heart, a brief influx of calcium ions from outside the cell activates the release of calcium ions 
stored in the sarcoplasmic reticulum.  The calcium binds to regulatory protein complexes in the 
contractile apparatus to allow contraction to occur13, 14.  Upon activation of muscle contraction in 
this manner, the contractile apparatus of the muscle generates contractile force.  The sarcomeric 
machinery that produces muscle contraction is the subject of this thesis. 
The sarcomere 
 The sarcomere is composed of three primary structures, the Z-disc, the thin filament, and 
the thick filament (Figure 3).  The Z-disc anchors the filaments of the sarcomere and by 
cooperation with two massive proteins, nebulin and titin, forms a frame for the sarcomere15, 16.  
The thin filaments anchor to α-actinin proteins in the Z-disc15, 17, 18.  Nebulin, also anchored to 
the Z-disc, extends along the thin filament and is thought to regulate thin filament length15, 19-22.  
Titin, a large "elastic" protein, is anchored to the Z-disc and tethers thick filaments on either side 
of the Z-disc to hold them between thin filaments in a position to perform their role in sarcomere 
contraction23-30.  The Z-disc differs in size among muscle fiber types.  In cardiac and slow-
contracting muscle fibers the microscopic band associated with this structure, the Z-band, is 
around 100 to 140 nm, whereas in fast-contracting skeletal muscle fibers the Z-band is far 
narrower, at around 30 to 50 nm15, 31, 32. 
 The thin filament is primarily constructed of a helical pair of actin filaments.  Actin 
polymerization and depolymerization are known to be very active in non-muscle cells, but in 
muscle cells actin polymer dynamics are tightly regulated by capping proteins15, 33.  Actin 
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polymers have a polarity dictated by the orientation of the monomers in the filament.  The "plus" 
or "barbed" end is the end of a filament where actin monomers are added as the filament 
elongates and is opposed by the "minus" or "pointed" end.  Their descriptive names originate 
microscopically, where actin filaments decorated with bound myosin motor domains were 
observed to have a directionally oriented repeating arrowhead shape (Figure 4)34-36. 
  
Figure 3: Sarcomere structure.  Sarcomeres consist of interdigitated thin and thick filaments.  
Thin filaments consist of primarily actin polymers, which are capped at plus and minus ends by 
CapZ and tropomodulin proteins, respectively.  They are also overlaid by the large protein 
nebulin, which may influence thin filament length.  Thick filaments consist of primarily MyHC 
organized in parallel in the arms and antiparallel in the central "bare zone" where no myosin 
heads protrude.  The filaments are each tethered to the Z-discs, the thin filament rigidly and 
directly and the thick filament flexibly by the large elastic protein titin.  The bipolar orientation 
of the thick filament allows for coordinated interactions between actin and MyHC to produce 
contractile force, pulling together the Z-disks.  Exposure of MyHC binding sites on actin 
filaments is governed by additional protein complexes which are regulated by Ca2+, allowing for 
cell and tissue level coordination of contractile events.  
 
Figure 4:  Actin filament polarity.  Filamentous actin decorated by bound myosin motor 
domains has a characteristic arrowhead shape formed by the orientation of the myosin motor 
domain on the filament.  Myosins are plus-end directed motors and thus orient uniformly on the 
two parallel strands of actin in its helical filamentous form.  Adapted from Lodish et al. (2003) 
Molecular Cell Biology35. 
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 The actin filaments are anchored at their plus-ends to α-actinin in the Z-disc and capped 
by CapZ and tropomodulin proteins at their plus and minus-ends, respectively15, 33.  While each 
thin filament is stable in vitro at around 1 µm in length from the Z-disc, in live cells 
tropomodulin capping is transient and some dynamics have been shown to occur at the minus-
ends of the actin filaments37-41.  The actin filament is bound by additional proteins, which 
regulate the activity of the thin filament in sarcomeric contraction.  The troponin-tropomyosin 
complex regulates the availability of myosin binding sites on actin in the thin filament in a 
calcium-dependent manner, in response to calcium flux from the sarcoplasmic reticulum (Figure 
5).  Tropomyosin is a large protein, which interacts with actin filaments in such a way as to block 
the myosin binding site of actin.  Its conformation is influenced by a complex of three troponin 
proteins, troponin I, troponin T and troponin C.  Troponin C binds calcium and as a result 
undergoes a conformational change, which is transmitted through its binding partners troponin T 
and troponin I to alter the shape and position of tropomyosin on the thin filament, opening up 
myosin binding sites on the actin filaments to allow crossbridging42-44.  
 
Figure 5: The regulatory complex on the thin filament.  The thin filament is primarily 
constructed of two helical actin filaments.  This basic structure is decorated with a complex of 
proteins which regulate the availability of myosin binding sites on actin, coupling availability to 
calcium signals associated with cellular activation of contraction.  Tropomyosin binds to thin 
filament actin in such a way as to block binding sites on actin.  A complex of three proteins, 
troponin T, troponin I, and troponin C respond to calcium release in the cell by changing shape 
and inducing conformational changes in tropomyosin to unblock myosin binding sites on actin 
(Adapted from http//:jolisfukyu.tokai-sc.jaea.go.jp/fukyu/tayu/ACT04E/04/0406.htm). 
 The third major substructure of the sarcomere is the thick filament.  The thick filament is 
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primarily composed of myosin.  Myosin is a heterohexamer consisting of two myosin heavy 
chain proteins (MyHC) each bound by a pair of non-identical myosin light chain proteins.  
MyHCs assemble their long α-helical rod domains into coiled-coils and subsequently into large 
filaments of approximately 300 MyHC proteins to form the primary structure of the thick 
filament.  These proteins are arranged in parallel in the lateral regions of the filament and in anti-
parallel in the center.  Myosins are plus-end directed actin-based motors.  With the plus-ends of 
actin filaments oriented towards the Z-discs of the sarcomere, the activity of actin-myosin 
interactions produces leads to the contraction of the Z-discs towards one another.  The motor 
domains of MyHC proteins project outward from the thick filament, towards the surrounding 
thin filaments.  At the junction between the motor and rod domain the MyHCs are bound by 
myosin light chains to produce a stiff lever arm, which also projects outward from the thick 
filament.  Myosin binding protein-C, a thick filament protein, regulates the projection of the 
myosin motor domain away from the thick filament.  The large thick filament structure is 
suspended between the thin filaments and Z-discs by the large elastic protein titin, proximal to 
multiple thin filaments.  The interaction between the motor domains of the myosins in the thick 
filament and the actin in the thin filament leads to contraction of the sarcomere due to the 
cyclical ATP-dependent motor activity of the MyHC proteins.  MyHC's cycle of activity is the 
subject of this study. 
Myosin 
 Myosins comprise a large family of motor proteins involved in cellular activities such as 
cargo trafficking, cell division, and muscle contraction.  Sequence alignments estimate that there 
may be as many as 17 phylogenetically distinct myosin subtypes45.  The conventional myosin 
family involved in muscle contraction is the myosin II class.  These myosins act in a coordinated 
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manner, bind two myosin light chains per heavy chain, and spend a low percentage of their 
enzymatically activated cycle bound to actin.  The latter trait is referred to as having a low "duty 
ratio."   The human striated muscle myosin II isoforms have been shown to play two roles in 
muscle contraction:  fast movement and force maintenance46.  These functional features will be 
discussed in depth later on. 
 Human striated muscles contain eight major myosin isoforms and two more recently 
discovered isoforms about which far less is known.  The eight major myosins are clustered in the 
genome in two groups: the cardiac isoform group, α and β, and the skeletal isoform group, IIa, 
IIb, IId, perinatal, embryonic, and extraocular.  These isoforms are encoded by separate genes 
known as MYH6, MYH7, MYH2, MYH4, MYH1, MYH8, MYH3 and MYH13, respectively47.  
MyHC-β is expressed in both cardiac muscle and slow skeletal muscle fibers.  The roles of the 
more distantly related isoforms, MyHCs 15 and 7b, in mammalian muscles are currently being 
investigated.   
 This family of myosin isoforms is highly conserved, with amino acid sequence identities 
between 77% and 94% (Table 1).  This high degree of sequence identity historically led to the 
hypothesis that MyHC isoforms would prove to be functionally very similar.  While they are all 
F-actin-activated ATPases, the rates and affinities with which each carry out their ATPase and 
contractile functions can differ significantly even between highly related isoforms1, 2.  This 
diversity of isoforms is therefore capable of producing a high degree of functional diversity by 
their differential expression in various muscles.  
 Myosin isoforms often exist in mixtures in muscle fibers with their expression tightly 
regulated.  In muscle fibers, contractile and metabolic rates depend upon myosin composition48.  
The identities and proportions of the myosin isoforms in a fiber correlate with the fiber's 
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maximum shortening velocity49.  This dependence underlies the importance of MyHCs in muscle 
contraction and how understanding the contractile characteristics of each isoform can contribute 
to understanding the dynamics of muscle contraction. 
 α  β  IIa IIb IId Peri Emb Exoc 
α  100        
β  92 100       
IIa 80 81 100      
IIb 80 80 91 100     
IId 80 81 94 94 100    
Peri 80 80 92 90 92 100   
Emb 78 78 84 83 83 84 100  
Exoc 77 77 81 81 81 81 78 100 
Table 1:  Percent identity between human MyHC isoforms.  Percent amino acid sequence 
identities between human MyHC isoforms were determined by pairwise alignments using 
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2) and sequences obtained from NCBI 
(http://www.ncbi.nlm.nih.gov/gene).   
 Human striated muscle MyHC isoforms are expressed in distinct spatial and temporal 
patterns.  During embryonic development the embryonic, perinatal and β-MyHC isoforms 
predominate in skeletal muscles 50, 51.  At and around birth, embryonic and perinatal MyHC 
become undetectable.  Their expression in adults is only detected in regenerating injured or 
diseased muscles52.  The perinatal isoform is also expressed in the fetal heart50, 51, 53, 54.  After 
birth, in humans, skeletal muscles primarily contain the fast skeletal isoforms, IIa and IId, and 
the slow β isoform55-60.  The IIb isoform, which predominates in the skeletal muscles of small 
mammals such as mice, is not detectable in healthy human muscles, but the gene can encode a 
functional motor61.  In specialized skeletal muscles such as the extraocular and laryngeal muscles, 
many isoforms are present, including the unique extraocular isoform62-64.  In the adult human 
heart, β-MyHC predominates, accounting for >90% in the ventricles, while α represents the 
remainder65.  By contrast, in small mammals such as mice and rats, the adult heart is comprised 
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of mainly α-MyHC66. 
 MyHC contributes to muscle contraction through its coordinated activity in the sarcomere.  
MyHC proteins are ~200 kDa and contain two distinct functional domains: an α-helical rod 
domain which assembles into the thick filament, and a globular motor domain which binds actin 
and ATP (Figure 6). The motor domain is responsible for MyHC enzymatic function by coupling 
interactions with actin to a cycle of ATP hydrolysis and product release.  Thick filaments are 
bipolar with arms of parallel MyHC molecules and a central bare zone of antiparallel MyHC 
where no motor domains protrude from the filament.  In this way they are capable of contracting 
the sarcomere by motor domains in the arms binding to actin in the thin filaments and 
undergoing an ATP-dependent conformational change to produce linear movement along the 
thin filament.  Because each pole of the thick filament does this in opposition, the net effect on 
the sarcomere as a whole is the contraction of the two Z-disks towards one another, shortening 
the sarcomere. 
 
Figure 6: Myosin structure.  The myosin molecule is a heterohexamer containing two heavy 
chains (in white), joined by their α-helical coiled-coil rod domains, and two pairs of non-
identical light chains (in grey), one essential light chain (ELC) and one regulatory light chain 
(RLC), bound to each heavy chain to stiffen its lever arm.  By papain cleavage at the intersection 
of the lever arm and rod domain a soluble fragment, Subfragment 1 (S1), can be isolated. S1 
maintains all enzymatic and motor functions of the heavy chain. 
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 Subfragment 1 (S1) of myosin contains the amino-terminal motor domain of MyHC and 
the myosin light chain binding lever arm.  It lacks the carboxy-terminal α-helical coiled-coil rod 
domain, which is associated with the assembly of myosin into the thick filament.  S1 is therefore 
a soluble fragment of MyHC and retains all of the enzymatic functions of the whole protein67, 68.  
This makes S1 a suitable fragment for in vitro assays.  Subfragments of this sort were originally 
isolated from the full-length protein by proteolytic cleavage using papain and chymotrypsin.  
These proteases cleave full length MyHC at different positions and selectively in solvent 
exposed structures where the soluble proteases can access the peptide sequence.  For this reason 
these two proteases produce two different subfragments.  The papain-derived subfragment is the 
traditional S169, containing the motor domain and both light chain-binding "IQ domains," so 
named for the frequency with which the amino acids isoleucine (I) and glutamine (Q) are found 
at the beginning of the domain70.  Chymotrypsin digestion produces a smaller subfragment by 
cleaving the heavy chain between the two light chain-binding domains, such that only the 
essential light chain is associated with the heavy chain subfragment71.  This is herein referred to 
as "short-S1" or sS1. 
 The structure of the myosin motor domain has been determined by crystallographic 
methods.  These studies describe a highly interactive set of substructures which can be observed 
in multiple stable conformations associated with the steps of the myosin contractile cycle3, 72.  
The motor domain was initially subclassified by additional proteolytic fragments.  Limited 
proteolysis produced three fragments of the motor domain, which were referred to by their 
masses as the 25 kDa subunit including the amino terminus, the 50 kDa subunit including the 
bulk of the motor domain, and the 20 kDa subunit including the carboxy terminal end of the 
motor domain73.  Two soluble loops joining these subunits to one another were also named for 
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their associated subunits:  the 25-50 kDa loop or loop 1 and the 50-20 kDa loop or loop 2.  
Within subfragment 1 there are four primary functional domains.  These are the actin-binding 
pocket, the enzymatic nucleotide-binding pocket, the converter domain, and the myosin light 
chain binding lever arm (Figure 7).  The loops interact with these sites, such that loop 1 
influences the nucleotide binding pocket and loop 2 influences actin binding74.  Additional 
substructures support the functions of their domains, such as switch II which must be in the 
"closed" conformation for ATP hydrolysis activity to take place75 and the SH1 helix which 
terminates in a flexible glycine residue thought to act as a hinge, which along with the 
neighboring relay helix interact with the converter to transfer rotational conformational changes 
in the motor domain to the lever arm (Figure 7)76.   
 Crystallographic studies of S1 purified from muscle sources have indicated that S1 can 
exist in at least three conformational states, dictated by the contents of the nucleotide-binding 
pocket.  These states were coined, the "near-rigor" state in the absence of nucleotide, the "pre-
power-stroke" or "transition" state in the presence of ADP-VO4, which mimics ADP and 
inorganic phosphate (Pi) after ATP hydrolysis, and the "detached" state in the presence of ADP 
(Figure 8).  While these crystallographic views of myosin structure are important for 
understanding the general principles of myosin movement, the limitations of crystallography 
using myosins block our ability to observe the states that are most relevant to its physiological 
activity.  These limitations are the inability to observe myosin in the presence of F-actin and the 
inability to capture myosin binding to its transiently bound substrates.   
 The function of myosins as motor proteins is due to their ability to translocate relative to 
actin filaments.  Aside from their ability to bind actin, this means they must be capable of 
producing directional motion.  This is achieved by a conformational change known as the 
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"power-stroke" which follows the release of inorganic phosphate from the nucleotide-binding 
pocket after ATP hydrolysis55, 77-79.  This movement swings the lever arm through 60 to 70 
degrees of rotation with respect to the motor domain to produce a directional translocation of the 
motor domain and its attached actin filament with respect to the thick filament-associated 
carboxy-terminus76.  The size of each "step" of this motor action for muscle myosin II proteins is 
on the order of 5 nm, generating a force on the order of a few pN80, 81.  
 
Figure 7: Structural domains of MyHC subfragment 1.  MyHC subfragment 1 (S1) contains 
the minimal functional motor of myosin.  This includes the motor domain and myosin light chain 
binding lever arm.  Within the motor domain several functional domains operate in a closely 
coordinated manner, including the actin binding, ATP binding, and converter domains.  The 
motor domain can be broken down into subdomains of 50 kDa, 25 kDa, and 20 kDa by 
proteolytic cleavage, as these subdomains are joined by solvent exposed loops: the 25/50 kDa 
loop associated with the ATP binding domain and the 50/20 kDa loop associated with the actin 
binding domain.  Additional structures, such as switch II, SH1 and the relay helix, are known to 
play roles in intramolecular communication between functional domains.  Adapted from 
(http://bmf.colorado.edu/myomapr/help.psp). 
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Figure 8:  Three structural states of S1.  
MyHC S1 from scallop muscle has been 
crystalized and its structure solved in three 
conformational states.  The three states, captured 
in the presence of three different nucleotide 
pocket contents, represent the positions of the 
lever arm in pre- and post-power-stroke 
conformations.  The swing of the lever arm 
through 60 to 70 degrees of rotation with respect 
to the motor domain produces movement of the 
thick and thin filaments relative to one another.  
Adapted from Houdusse, et al. (2000) Three  
 
Disease-causing mutations in myosin genes 
 Mutations in sarcomeric genes have been known to lead to human cardiac and 
musculoskeletal diseases since before 1990, when the first mutation leading to familial 
hypertrophic cardiomyopathy was localized to the cardiac β-MyHC gene82.  In the time since 
that discovery, more than 300 mutations leading to numerous skeletal and cardiomyopathies 
have been identified in β-MyHC alone (regularly updated at http://bmf.colorado.edu/myomapr).   
 Disease-causing mutations occur in five of the human myosin II heavy chain isoforms.  
These are the cardiac isoforms α and β, the developmental isoforms embryonic and perinatal, 
and the fast skeletal isoform IIa.  Mutations in the cardiac isoforms α and β have been found to 
cause cardiac diseases, such as hypertrophic and dilated cardiomyopathies83-85, and since β 
myosin is also a major component of slow skeletal muscle, mutations in it also cause myosin 
storage myopathy and Laing distal myopathy86, 87.  Mutations in the developmental isoforms 
embryonic and perinatal have been found to cause the distal joint contracture disorders, 
Freeman-Sheldon Syndrome, Sheldon-Hall Syndrome88, and Carney complex89.  A mutation in 
Figure 8:  Three structural states of S1.  
MyHC S1 from scallop muscle has been 
crystalized and its structure solved in three 
conformational states.  The three states, 
captured in the presence of three different 
nucleotide pocket contents, represent the 
positions of the lever arm in pre- and post-
power-stroke conformations.  The swing of 
the lever arm through 60 to 70 degrees of 
rotation with respect to the motor domain 
produces movement of the thick and thin 
filaments relative to one another.  Adapted 
from Houdusse, et al. (2000) Three 
conformational states of scallop myosin S13.	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the myosin IIa gene has been shown to cause an inclusion body myopathy90.  The majority of 
these mutations are single missense mutations, indicating that even subtle changes to the 
structure of MyHC can have dramatic effects on the function of the contractile system. 
 Some of these disorders can also be caused by mutations in other members of the 
contractile machinery.  In the case of hypertrophic cardiomyopathy, the disease can be caused by 
mutations in many sarcomeric genes84. Dilated cardiomyopathy can be caused by mutations in 
sarcomeric genes as well as in other non-sarcomeric muscle specific systems83, 85.  Sarcomeric 
machinery mutations known to cause hypertrophic cardiomyopathy have been identified in 
troponin I, troponin T, troponin C, tropomyosin, actin, myosin binding protein-C, myosin 
essential light chain and myosin regulatory light chain genes in addition to MyHC isoforms α 
and β83-85.  This disease is therefore a complex cellular disease that can be caused by disruption 
of the contractile machinery. 
 In other cases, however, this diversity of disease-causing genes is not present.  In the 
cases of the developmental and skeletal myopathies, including the joint contracture and inclusion 
body myopathies, all mutations leading to these disorders that have so far been identified are in 
MyHC genes.  This dichotomy indicates that the specifics of the type of disruption to contractile 
activity must in some important way differ between these disease types.  It is therefore of great 
interest to seek to understand the contractile disruptions caused by such mutations. 
Genetic models for studying myosin function. 
 Genetic approaches in the model organisms Caenorhabditis91, 92, Dictyostelium93, 94, 
Drosophila95, 96, and Mus97 have been used to study the role of myosins in intact organisms.  By 
several methods MyHC genes have been inactivated in each organism to study their function.  In 
C. elegans and Drosophila, genetic screens have been used to study the inactivation and 
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mutation of muscle myosin genes.  Inactivation of each of the two body wall myosins in C. 
elegans has been shown to cause uncoordination or lethality98, 99.  Null mutations in the MyHC 
gene of Drosophila cause a flightless phenotype100.  In Dictyostelium homologous recombination 
approaches have been used to study the inactivation of myosin genes as well as to study 
structure-function relationships in specific regions of the myosin motor domain.  These studies 
demonstrated that MyHC genes play a vital role in development as well as adult biology.  These 
invertebrate and amoeboid model organisms have few MyHC genes and vastly different muscle 
biology from humans.   
 Murine muscles are far more similar to human muscles than invertebrate or amoeboid 
cells and possess the same complement of striated muscle MyHC II isoforms.  Genetic 
inactivation of mouse cardiac MyHCs was lethal101-103, but knockouts of two fast isoforms, IIb 
and IId, produced numerous muscular and growth defects in mice50, 103-105.  Interestingly, in 
knockouts of a MyHC that made up the majority of MyHC in that muscle, the total myosin 
content of the muscles was not reduced50, 104.  Therefore in the absence of particular myosin 
isoforms, muscle cells can compensate by expressing more of other isoforms103, 104. 
Recombinant expression of striated muscle myosins 
 Biochemical studies of MyHC proteins are of great interest in the field of muscle biology 
given the central role of MyHC in contraction.  Classical methods of protein isolation from 
muscle are limited, however, by the mixed and varied nature of the MyHC composition of 
muscle fibers.  For that reason, few studies of relatively pure single isoforms have been available 
until recently.  In the few cases where nearly pure single isoform populations of MyHC could be 
isolated, the single fiber nature of the experiments posed significant limitations on protein 
quantity, constraining experiments to extremely efficient, but also extremely limited, techniques 
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such as flash photolysis and single molecule studies106-109.  Separation of mixed isoforms has 
been similarly impractical due to the large size of myosin and biochemical similarity among the 
isoforms. 
 A system capable of producing recombinant striated muscle MyHC proteins would 
alleviate these limitations as well as allow the production of mutated versions of the protein to 
study pathogenesis.  Expression was attempted in traditional recombinant expression systems 
including both bacterial and eukaryotic cells for many years with no success, yielding only 
inactive, misfolded myosin motor domains.  Interestingly, active recombinant smooth muscle 
myosin II isoforms can be produced in SF9 insect cells using baculovirus as an expression 
vector110. 
 The mapping of an "uncoordinated" mutant in C. elegans led to the identification of a 
unique set of chaperones necessary for the proper folding of myosin motor domains.  Unc-45 and 
its mammalian homologues, Unc-45A and Unc-45B, were shown to be necessary but not 
sufficient to recover MyHC activity in recombinant expression systems111-118. 
 One solution that circumvented some of these limitations was the production of rodents 
expressing transgenic MyHC in cardiac muscle.  This approach also had the capability of 
producing mutant MyHC proteins and could yield nearly pure fibers.  However, because the 
myosin composition of rodents and humans is different, mutations in different mouse myosin 
backgrounds were found in certain cases to produce opposing molecular phenotypes: hyperactive 
or hypoactive by steady-state biochemical tests97, 119.  For this reason it is necessary to use the 
appropriate human background, and appropriate isoform, to properly analyze motor function and 
the effects of mutations therein.  As human tissue samples are a rare source for both wild-type 
and mutant muscle proteins, recombinant approaches are required to carry out such work. 
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 Winkelmann and colleagues pioneered the use of mouse myotubes differentiated from 
C2C12 mouse myoblasts as an expression platform for recombinant MyHC proteins.  They 
observed that differentiated C2C12 lysates aided the folding of MyHC in vitro117.  As C2C12 cells 
possess the intrinsic ability to properly fold endogenous myosin proteins, this group developed a 
system wherein myotubes grown in culture and infected with recombinant adenoviruses 
encoding MyHC-S1 under the transcriptional control of a constitutive cytomegalovirus (CMV) 
promoter could produce active and properly folded recombinant MyHC117, 118.  Work in the 
Leinwand lab optimized this system for the over-expression of human MyHC S1 proteins.  Using 
poly-histidine tags encoded into terminal ends of the recombinant proteins, various forms of all 
eight MyHC subfragments have been successfully purified using traditional chromatographic 
purification techniques in quantities sufficient for biochemical1, 2 and even crystallographic 
studies of human β-MyHC (PDB ID: 4DB1, manuscript in preparation). 
 The recent emergence of this technique for producing active recombinant human myosin 
subfragments has enabled studies to address several questions that had previously been 
inaccessible.  The studies presented in this thesis address the following questions:   
1. How are the various MyHC isoforms functionally specialized for the demands of their 
 contractile environments?  
2. What are the functional characteristics of human α-MyHC, and how do they differ from 
 those of human β-MyHC?   
3. How do pathogenic mutations in MyHCs alter their functional properties? 
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CHAPTER I  
Human skeletal muscle myosin isoforms are functionally diverse. 
 
INTRODUCTION 
 Human skeletal muscles are composed of mixtures of diverse fiber types55.  These 
mixtures of fibers cooperate to produce contractile activities tuned to the functional demands on 
the muscle.  For example, muscles requiring rapid contraction with relatively low load such as 
the extensor digitorum longus are composed almost entirely of fast, type II fibers, while slow 
postural muscles such as the soleus contain a large number of slow, type I fibers55.  Fast versus 
slow and type II versus type I, are so named because of their differences in metabolism and 
shortening velocity55, 120.  These differences, in turn, correlate with differences in the expression 
of elements of the contractile apparatus. 
 Both shortening velocity and force generation are key characteristics in a muscle's 
adaptation to its contractile role.  Muscle fibers with high maximal rate of fiber shortening under 
the zero load conditions common to fast-twitch muscles such as the extensor digitorum longus 
are particularly adapted to this environment where low-force contraction is the norm.  However, 
to maintain force, such fibers must twitch at high frequency, using a proportionally higher 
metabolic load121.  These fibers would therefore not be well-suited to the contractile environment 
of slow-twitch postural muscles such as the soleus, where load-bearing conditions require 
sustained force.  Slow, type I fibers, however, are well adapted to this contractile environment.  
They operate very efficiently to generate and maintain force during low-frequency experimental 
activation by both shortening and relaxing each contraction more slowly121, 122.  Under load-
bearing conditions the ability of muscle fibers to efficiently maintain force is beneficial in their 
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contractile role.  In this manner, different contractile environments are characterized by muscle 
fibers with distinct contractile features. 
 MyHC proteins play a central role in determining the contractile properties of muscle 
fibers.  The MyHC isoform composition of muscle fibers is highly correlated with maximal 
shortening velocity120, 123 and force generation124, 125.  While a wealth of factors are present in 
and around the contractile machinery in muscle cells to participate in activating or regulating 
contraction, it is unsurprising that MyHC identity should play a key role in muscle contraction, 
as it is the sole motor element in the sarcomere.  It is therefore of interest to the field of muscle 
biology to understand how the functional diversity of MyHC isoforms contributes to the ability 
of muscles to meet the demands of the various contractile environments in which they function. 
 MyHC provides the ATPase activity of myosin.  This ATPase activity is magnesium-
dependent, as the nucleotide-binding site of MyHC coordinates a Mg2+ ion, which is associated 
with stabilizing the phosphates of ATP, and is thereby necessary for ATP hydrolysis126.  Myosin 
hydrolyzes ATP into ADP and Pi and releases the two products coupled to its contractile activity.  
The dependence of myosin motor activity on the production of ATP-hydrolysis products means 
the ATPase activity of myosin can be experimentally coupled to the movement of actin filaments.  
Classical measures of MyHC activity include in vitro motility, where fluorescently labeled actin 
filaments can be microscopically observed to crawl across slide coverslips coated in myosin 
oriented with their motor domains away from the surface, in the presence of ATP1, 127.  The rates 
of filament movement in this assay reflect the ability of the myosin to contract sarcomeres in 
vivo and tend to correlate with the other measures of myosin ATPase activity1.   
 Other classical measures of myosin's ATPase activity use the measurement of product 
formation (ADP or Pi) over time.  This activity is highly dependent on myosin's binding partner 
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for contractile functions in the sarcomere, filamentous actin (F-actin).  ATPase activity has been 
measured in various experimental environments, such as muscle fibers128, isolated myofibrils129, 
130, and purified MyHC proteins1.  Whole muscle fibers, chemically permeabilized to allow for 
manipulation in vitro, have the benefit of representing the physiologically relevant environment 
of the function under study, but are complex systems with multiple reactions contributing to the 
products being measured.  Also, the time scale of chemical diffusion into fibers limits the time 
resolution possible for measuring reactions in whole fibers128, 129.  For these reasons fibers are a 
poor medium in which to study myosin.  Myofibrils, the contractile organelles isolated from 
fibers131, represent a simpler experimental system than whole fibers.  Myofibrils, formed of 
many end-to-end linked sarcomeres, possess all the essential mechanical components required to 
study contraction.  Additionally, with myofibrils it is possible to perform parallel biochemical 
and microscopic experiments to correlate biochemical activities with physical contractile 
changes, such as sarcomere length129.  However, the presence of the regulatory structures on the 
thin filament (e.g. the troponin-tropomyosin complex) obscures the activity of myosin with 
additional variables affecting the ATPase rate.  For these reasons, myosin ATPase experiments 
have most commonly been performed on isolated MyHC proteins.  
 The role of ATP in myosin activity is coupled to the contractile cycle of myosin with F-
actin, shown graphically in Figure 9.  In the absence of ATP, myosin binds F-actin strongly and 
stably.  The addition of ATP to this complex induces a conformational change in myosin, which 
leads to dissociation of the complex.  Following dissociation, a series of events follows:  myosin 
hydrolyses ATP to ADP and Pi, returns its lever arm to the pre-power-stroke angle, binds to F-
actin, and releases Pi, activating the power-stroke.  The subsequent release of ADP returns 
myosin to the original complex76-78 (Figure 9).  In the absence of F-actin the events following 
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ATP-hydrolysis are interrupted, yet similar events with respect to the conformation of the 
myosin motor domain are thought to occur to complete the cycle in the absence of F-actin.  This 
leads to "basal" ATPase activity, but this basal cycle is known to be far slower than F-actin-
activated ATPase activity1, 132-134. 
 
Figure 9:  F-actin-myosin ATPase cycle.  The F-actin-activated myosin ATPase cycle 
hydrolyzes one molecule of ATP to ADP and Pi per turnover of the cycle, per myosin motor 
domain.  The formation of a crossbridge, then release of these two products and the binding of 
another ATP molecule during the crossbridged phase of the cycle (black myosin motor domains) 
must precede further steps of hydrolysis.  The rate-limiting step of the cycle in F-actin-activated 
ATPase reactions has been determined to be in the detached state (white myosin motor domains) 
and defines kcat.  Substrates are abbreviated as follows: ADP (D), ATP (T), and inorganic 
phosphate (Pi). 
 In this way, myosin requires F-actin, its crossbridge partner in the sarcomere, to perform 
its role in physiological contraction.  ATPase measurements therefore exist in two categories:  
basal ATPase, measured in the absence of F-actin, and F-actin-activated ATPase.  Basal ATPase 
activity is simple to measure, but is not informative with regards to muscle contraction, as it 
occurs in the absence of the crossbridge.  F-actin-activated ATPase activity follows the 
physiologically relevant reaction steps for muscle contraction, but is more difficult to measure as 
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the reaction is complicated by the highly viscous nature of F-actin in solution.  Traditional 
methods also typically measure such activity at lower than physiological temperature, due to the 
constraints of the lab environment and protein longevity at higher temperatures.  In previous 
work in the Leinwand lab, Daniel R. Resnicow developed a system to overcome these limitations, 
using a Reacti-Therm heating and stirring module [Pierce] to constantly mix reactions in 
microcentrifuge tubes at 37° C.  The work described in this chapter on the steady-state ATPase 
measurements on MyHC isoforms IIa, IId, IIb, embryonic, perinatal, extraocular, and β was 
carried out collaboratively with Dr. Resnicow when he was a graduate student and resulted in 
Resnicow et al. (2010)1. 
 Measurements of ATPase activity follow a slightly varied form of traditional enzyme 
kinetics.  Traditional Michaelis-Menten kinetics concerns the direct relationship between 
enzymes and substrates.  In the F-actin-activated ATPase assay, the substrate enzymatically 
operated upon by myosin is ATP, but instead of reaction rates being measured over a range of 
ATP concentrations, from limiting to saturating, ATP concentration is held constant and in 
excess throughout the set of reactions and instead the concentration of the binding partner and 
activator, F-actin, is varied.  When rates of product formation are plotted with respect to F-actin 
concentration and the data fit by non-linear regression using the Michaelis-Menten equation, the 
traditional constants, Vmax and KM, can be determined.  The traditional definitions of these 
constants are: Vmax = the rate of the reaction at saturating substrate concentration and KM = the 
concentration of substrate that produces Vmax/2.  In the F-actin-activated ATPase assay the 
traditional definition of Vmax remains accurate, though it would be more correct to describe it as:  
the rate of the reaction at saturating ATP in the presence of saturating F-actin.  Because F-actin-
activated ATPase rates are plotted with respect to the activator, F-actin, rather than to the 
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catalytic substrate, ATP, the KM value is an unusual form of Michaelis constant.  In this case the 
relationship differs because it refers to the concentration of a cofactor, not to the catalytic 
substrate.  It is unclear in our model of the reaction to which step or steps of the ATPase cycle 
this constant should relate.  This constant is referred to herein as KATPase135, 136.   
 Steady-state ATPase reactions are governed by two additional factors that are not obvious 
a priori.  First, the reaction conditions must be ~10-fold lower than physiological ionic strength 
(14 mM versus ~150 mM), as ionic strength influences F-actin-myosin affinity in vitro such that 
kinetic differences between isoforms become indistinguishable137.  Second, the rate-limiting step 
under the reaction conditions in vitro does not necessarily reflect what factors limit the rate of 
actin-myosin interaction in activated sarcomeres.  In an activated sarcomere, the geometry of the 
filaments governs the rate of the transition from unbound to crossbridged for an individual 
myosin, but in vitro this constraint is not present2, 55, 79, 136, 138-140.  While these facts indicate that 
there are limitations in the relationship of in vitro ATPase data to the intact physiological system, 
relative comparisons of isoforms measured in the same manner and under the same conditions 
may still be valuable.   
 The subject of this chapter is the comparative analysis of the seven human skeletal 
muscle MyHC isoforms, IIa, IId, IIb, embryonic, perinatal, extraocular and β, by their F-actin-
activated ATPase activity.  This study was performed by producing and purifying recombinant 
human MyHC-S1 proteins, then testing their F-actin-activated ATPase activities using an 
enhanced form of the traditional assay. 
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METHODS 
Production of recombinant MyHC   
 Using the recombinant adenovirus construction system, the pAdEasy kit [Qbiogene], 
expression cassettes were constructed encoding S1 fragments of human MyHC isoforms under 
the transcriptional control of a CMV promoter141.  The AdEasy system is designed to produce 
replication-deficient adenovirus, with exogenous expression constructs encoded into the E1 locus 
of the viral genome under the transcriptional control of a CMV promoter (depicted graphically in 
Figure 10A).  MyHC-S1s were constructed as soluble fragments analogous to the subfragment 
produced by papain digestion of MyHC, spanning methionine-1 through proline-838 with respect 
to the human β-MyHC sequence.  These subfragments were encoded as fusions with enhanced 
green fluorescent protein (eGFP) at their carboxy termini, followed by a 6xHistidine tag for 
affinity purification (depicted graphically in Figure 10B).  The eGFP fusion to the carboxy 
termini of MyHC-S1 proteins was designed initially to allow these proteins to be used in 
collaboration with the Spudich lab at Stanford in in vitro motility experiments, where antibodies 
to eGFP could be used to anchor MyHC-S1 proteins to glass coverslip surfaces with a defined, 
motor domain "up," orientation, but also acted to aid in the initial development of the expression 
system to provide a visual indication of protein expression in live cultured cells. 
 Human MyHC subfragments were amplified from human cDNA by PCR and subcloned 
into the multiple cloning site of pShuttle-CMV plasmids downstream of the CMV promoter.  
pShuttle plasmids were then linearized by digestion with PmeI [New England Biolabs] and 
transformed into competent BJ5183 bacteria containing the replication-deficient adenoviral 
genome plasmid pAdEasy.  The pShuttle expression cassette inserted into the E1 region of 
pAdEasy by homologous recombination.  After confirming successful recombination by  
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Figure 10:  Constructs for expression of recombinant human skeletal muscle S1 proteins.  
A.  S1 isoforms spanning residues methionine-1 through proline-838, with respect to human β-
MyHC are cloned into pShuttle plasmid in frame with eGFP-6xHistidine-Stop (*), under 
transcriptional control of a CMV promoter and upstream of a polyA signal sequence.  B.  The 
proteins produced by this expression cassette consist of S1 fused at its carboxy terminus with 
eGFP and a 6xHistidine-tag.  These proteins copurify with myosin light chains (ELC and RLC) 
endogenous to the C2C12 cells in which the protein is expressed. 
 
restriction digestion and gel electrophoresis, pAdEasy DNA was produced in bacteria and 
isolated.  Isolated pAdEasy DNA was linearized by digestion with PacI and purified by phenol-
chloroform extraction.  Linearized DNA was transfected into human epithelial kidney (HEK293) 
cells expressing E1 to complement viral replication, then allowed to produce and replicate viral 
particles until plaques were visible in the cell monolayer.  Freeze-thaw cycles were used to 
liberate viral particles from cells, then clarified lysates applied to larger quantities of cells in 
escalating cycles until sufficient quantities of virus were available for purification. 
 Each recombinant adenovirus was purified using a two-step cesium chloride (CsCl) 
gradient.  First, the clarified lysates were applied over the top of a step gradient consisting of 
1.25 g/mL over 1.4 g/mL CsCl.  Gradients were centrifuged in an SW40 rotor [Beckman] at 
230,000 x g for one hour, then viral bands were isolated from above the CsCl step by side-
puncture of the centrifuge tubes with a syringe.  These initial bands were then transferred to heat-
seal tubes and the tubes filled with 1.35 g/mL CsCl, sealed, then centrifuged for at least two 
hours in a VTi65 rotor [Beckman] at 400,000 x g.  Viral bands were isolated from heat-sealed 
tubes, dropwise from bottom-punctures, then diluted 1:5 in glycerol storage buffer for storage at 
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-20° C. 
 Expression of recombinant MyHC was achieved by infection of myotubes derived from 
C2C12 myoblasts with purified recombinant adenoviruses.  C2C12 myoblasts were cultured in 
Dulbecco's Modified Eagle Media (DMEM) supplemented with 10% fetal bovine serum (FBS), 
100 units/mL penicillin and 100 µg/mL streptomycin [Gibco].  Cells were split at ~50% 
confluency.  Once sufficient cell quantities were obtained, cells were allowed to grow to 100% 
confluency.  Once confluent, the myoblasts were differentiated into myotubes by changing the 
medium to DMEM supplemented with 2% horse serum (HS) and penicillin/streptomycin.  After 
two days in HS, the cells exhibited the classical morphological characteristics of skeletal muscle 
fibers, becoming elongated and multinucleate, and were then infected with 106 to 108 plaque-
forming units (pfu) of adenovirus per 100-mm Petri dish.  Infected cells were allowed to grow 
for three to four days before collection for MyHC purification. 
Purification of recombinant MyHC-S1 proteins 
 The purification of recombinant MyHC subfragments was performed initially using 
freshly cultured myotubes after three to four days of infection.  Using this approach, 25 to 50 
100-mm Petri dishes of confluent myotubes, all infected with a given recombinant adenovirus, 
were scraped directly into chilled lysis buffer:  50 mM Tris HCl, pH 7.0, containing 20 mM 
imidazole, 100 mM NaCl, 0.5% Tween-20, 1 mM DTT and 1x protease inhibitor cocktail 
[Roche].  Cells were then lysed mechanically in a Dounce homogenizer and the lysate cleared by 
centrifugation in a Ti50 rotor [Beckman] for two to three periods of 15-minutes at 80,000 x g, 
transferring supernatants to fresh tubes between centrifugal steps.  Clarified lysates were brought 
to 0.5 M NaCl by adding ~1/10th volume of 5 M NaCl to match buffer conditions for the next 
step of purification.   
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 Fast Protein Liquid Chromatography (FPLC) was used for purification of recombinant 
MyHC-S1 proteins.  As previously described, these proteins were designed to carry carboxy 
terminal 6x histidine tags.  Poly-histidine tagged proteins have been shown to bind nickel resins 
and release by competition with high concentration imidazole solutions142, 143.  Using an 
AKTApurifier FPLC system [GE Healthcare] with a 1 mL HisTrap HP nickel-Sepharose column 
[GE Healthcare], S1 proteins were isolated from clarified cell lysates.  FPLC steps were carried 
out at a flow rate of 1 mL per minute in a temperature controlled environment at 4° C.  HisTrap 
HP columns were equilibrated to running buffer before use by flowing 10 column volumes of 
running buffer, followed by stripping the columns with 5 column volumes of 1 M imidazole 
stripping buffer and re-equilibrating with 10 column volumes of running buffer.  Lysates were 
loaded onto equilibrated columns using a running buffer of 50 mM Tris pH 7.0, containing 20 
mM imidazole, 500 mM NaCl, 0.05% Tween-20 and 1 mM DTT.  An additional 10 column 
volumes of running buffer was used to wash out unbound materials.  More stringent wash steps 
were then applied, using 10 column volumes of 30 mM imidazole wash buffer, and then 10 
column volumes of 50 mM imidazole wash buffer to eliminate non-specific binders.  Elution of 
S1 proteins was performed in 5 column volumes of elution buffer (50 mM Tris pH 7.0, 
containing 350 mM imidazole, 500 mM NaCl, 0.05% Tween-20 and 1 mM DTT).  The 5 mL 
elution was collected in 1 mL fractions. The MyHC S1 peak was uniformly found in fractions 2 
through 4.  These fractions were pooled and dialyzed overnight at 4° C into a low salt buffer:  25 
mM imidazole, pH 7.0, containing 10 mM KCl, 4 mM MgCl2, and 1 mM DTT, in preparation 
for anion-exchange chromatography.   
 After dialysis and centrifugation at ~14,000 x g to remove precipitates, eluates were 
subjected to anion-exchange chromatography.  HiTrap Q HP 1 mL Sepharose anion-exchange 
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columns [GE Healthcare] were equilibrated in running buffer:  25 mM imidazole, pH 7.0, 
containing 1 mM DTT, in the same manner as described previously, using 10 column volumes of 
running buffer, followed by 5 column volumes of stripping buffer:  25 mM imidazole, pH 7.0, 
containing 1 M NaCl and 1 mM DTT, and then re-equilibrating with 10 column volumes of 
running buffer.  Dialyzed eluates were loaded onto equilibrated columns and an additional 10 
column volumes of running buffer was used to wash out unbound sample.  Elution was carried 
out using a linear gradient from 0 to 1 M NaCl over 20 column volumes.  Fractions were 
collected in 1 mL aliquots.  S1 proteins typically eluted at ~300 mM NaCl, then were dialyzed 
overnight into reaction buffers differing depending on the assays to be performed.  
Concentrations were determined by absorbance at 280 nm using the calculated extinction 
coefficient 94000 cm-1M-1 (based on the Eldehoch model of estimating the contributions of 
tryptophan, tyrosine, and cysteine to the absorbance at 280 nm144).   
 Recent collaborations with the Rayment lab at the University of Wisconsin at Madison to 
crystallize the human β motor domain necessitated devising a method for the collection and 
long-term storage of materials such that large amounts of the protein could be purified in a single 
batch.  Thanks to the contributions of Dima Kenchin of the Rayment lab and Ariana Combs in 
the Leinwand lab, this was accomplished by the collection of three to four day infected cells by 
trypsinization off their culturing surfaces, followed by washing and pelleting in the presence of 
0.2% Pluronic® F-68 [Sigma], a polyoxyethylene-polyoxypropylene block copolymer, 
commercially sold to stabilize cell membranes against shearing and freezing damage.  These 
pellets were flash frozen in liquid nitrogen and stored at -80° C.  After thawing pellets in lysis 
buffer and continuing with purification as described above, proteins isolated from these frozen 
pellets were found to retain all activity with no apparent loss in yield.   
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ATPase assays 
 Concurrent with development of the system for over-expression and purification of 
MyHC-S1 proteins, existing biochemical methods for confirming and characterizing their 
activity were refined by Daniel R. Resnicow in the Leinwand lab.  Measuring the cyclical 
ATPase activity of these soluble motor fragments at steady-state was possible in vitro using 
methods adapted from those published by Kathleen Trybus145.  Basal ATPase activity, the 
cyclical hydrolysis of ATP by S1, independent of actin, is very slow relative to the actin 
dependent cycle.  Basal ATPase activity was measured by mixing 25 µg/mL S1 with saturating 3 
mM ATP in low-salt buffer:  4 mM imidazole, pH 7.0, containing 10 mM KCl, 4 mM MgCl2, 1 
mM NaN3, and 1 mM DTT in a Reacti-Therm heated stirring module [Pierce] and quenching 
aliquots at 1- to 5-minute timepoints into denaturing stop-solution containing 60 mM EDTA, pH 
6.5, and 6.6% SDS.  Appropriate time courses were determined for each isoform to establish 
conditions that would be within detection limits and would not significantly alter substrate 
concentration. Inorganic phosphate (Pi) was quantified at each time point using an ammonium 
molybdate based colorimetric assay as described previously145.   
 F-actin-activated ATPase was measured similarly with the additional presence of purified 
chicken filamentous-actin (F-actin), which was prepared as described previously by Pardee and 
Spudich146.  S1 protein (5 µg/mL) was first mixed with F-actin (0 to 100 µM), then mixed with 
saturating 3 mM ATP.  At specific timepoints between 20 seconds and 2 minutes, depending on 
the isoform, aliquots were quenched by 1:1 mixing with stop-solution.  Four timepoints, 
including a zero-timepoint, were taken for each reaction condition and the Pi concentration at the 
zero timepoint was subtracted from each to remove the background concentration.  To determine 
more physiologically relevant rates, ATPase assays were performed at 37° C.  Reactions were 
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performed in duplicate and on multiple biological replicates (biological replicates are herein 
defined as separate protein preparations). 
 
RESULTS 
Production and purification of recombinant MyHC subfragments 
 Functional recombinant striated muscle MyHC motor domains have historically been 
difficult to produce due to the absence of muscle-specific cofactors from traditional cell types 
used for protein expression114-118, 147.  MyHC-S1 protein was produced for this study by infection 
of mouse myotubes in culture with recombinant, replication-deficient adenoviruses expressing 
human MyHC subfragments, using a system developed based on the work of Don Winkelmann 
and colleagues111. 
 Previous work in the Leinwand lab has shown that transfection of differentiated mouse 
myotubes was not suitable for this purpose due to the inefficiency of transfection.  While C2C12 
myoblasts are readily transfectable, they do not express the muscle-specific cofactors required 
for the proper folding of the myosin motor domain.  Therefore, for this study recombinant 
adenoviruses were produced to insert MyHC expression cassettes into myotubes.  Adenoviral 
vectors readily infect mammalian cells and are effective for infecting both myoblasts and 
myotubes regardless of differentiation state.  As such, adenoviruses are suitable for inserting 
DNA into mouse myotubes.   
 Using methods as described above, MyHC-S1 proteins were produced and purified for 
the human skeletal muscle MyHC isoforms IIa, IId, IIb, embryonic, perinatal, extraocular, and β.  
A representative SDS-PAGE gel for two purified MyHC-S1 proteins is shown in Figure 11.  As 
noted, extraocular-S1 protein does not appear to have light chains associated with it, most likely 
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because C2C12 cells do not express extraocular light chain isoforms.  Embryonic-S1 protein 
variably copurified with myosin light chains.  The other five MyHC-S1 proteins copurified with 
bands of the appropriate size for mouse ELC and RLC isoforms: 18 kDa, 22 kDa, and 25 kDa 
(Figure 11, lane A; data not shown).  Copurified myosin light chains were identified by mass 
spectrometry [UCHSC Proteomics Core] as a mixture of four light chain isoforms:  alkali myosin 
light chain 1 (MLC1F), regulatory myosin light chain 2 (MLC2F), alkali myosin light chain 3 
(MLC3F), and myosin light chain 1, atrial/fetal isoform (MLC1A).  
 
Measurements of steady-state F-actin-activated and basal ATPase activity. 
 ATPase activity was quantified by measuring the concentration of Pi product in each 
quenched ATPase reaction aliquot.  Pi quantification was accomplished using the colorimetric 
assay described by Kathleen Trybus145, and comparison to a standard curve of known phosphate 
concentrations.  For each concentration of F-actin, the rate of Pi production was calculated from 
the four reaction timepoints.  These values were divided by the concentration of S1 to yield units 
of s-1.  Reaction rates were plotted with respect to F-actin concentration and the resulting 
Figure 11: Purified recombinant 
human skeletal muscle S1 proteins.  
eGFP-tagged S1 proteins are ~125 
kDa and the majority copurify with 
light chains endogenous to the C2C12 
cell expression system, as seen at 
between ~18 and 25 kDa for MyHC-
S1 IId in lane A (indicated by 
arrows).  Not all isoforms carried 
detectable amounts of light chains.  In 
the cases of embryonic and 
extraocular, it appeared that no light 
chains were present, as seen for 
extraocular MyHC-S1 in lane B. 
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saturation curves were well-described by fitting with the Michaelis-Menten equation: 
Vobs =
Vmax[S]
KM +[S]
, which can be rewritten for actin-activated ATPase as:   
Equation 1:  Vobs =
kcat[S1]•[F−Actin]
KATPase +[F− actin]
,  
where KATPase = KM, to give calculated kcat and KATPase values for each isoform (Figure 12). 
F-actin-activated ATPase kcat values from fitted functions ranged from the slowest, β-
MyHC, at 18.9±1.5 s-1, to the fastest, IIb, at 86.1±8.4 s-1, giving a range of ~4.4-fold among the 
isoforms tested, with the group's mean value at ~55 s-1 (Table 2).  KATPase values from the fitted 
functions ranged from the lowest, IIb, at 14.0±3.2 µM, to the highest, IIa, at 44.5±5.6 µM, giving 
a range of >3-fold, with the group's mean value of ~30 µM (Table 2).  Basal ATPase activity, 
measured in the absence of F-actin, at saturating ATP gave rates ranging from the slowest, 
perinatal, at 0.04±0.03 s-1, to the fastest, extraocular, at 0.12 s-1, giving a range of 3-fold, with a 
group mean of ~0.08 s-1 (Table 2). 
 
Figure 12: F-actin-activated 
myosin ATPase.  Saturation 
curves plotted from F-actin-
activated ATPase measurements 
and fit using Equation 1. 
Recombinant human MyHC 
isoforms are represented as:  IIa 
(♦), IIb (●), IId (■), Embryonic 
(▼), Perinatal (○), Extraocular 
(▲), and β (x). Published in 
similar form in Resnicow, et al. 
(2010)1. 
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 kcat (s-1) 
KATPase 
(µM) 
kcat/KM 
(s-1µM-1) 
Basal 
ATPase (s-1) 
Fold F-actin 
activation 
(kcat/basal) 
IIb 86.1±8.4 14.0±3.2 6.15 0.08±0.02 1080 
IId 65.7±2.1 15.7±1.3 4.18 0.11±0.01 597 
IIa 52.8±4.4 44.5±5.6 1.19 0.08±0.01 660 
Embryonic 41.2±3.7 35.1±1.8 1.17 0.08±0.01 515 
Perinatal 59.7±4.9 41.2±3.7 1.45 0.04±0.03 1490 
Extraocular 59.2±5.7 37.2±4.5 1.59 0.12±0.02 493 
β-MyHC 18.9±1.5 18.7±4.8 1.01 not determined not determined 
Table 2:  F-actin-activated myosin ATPase.  Steady-state F-actin-activated MyHC-S1 ATPase 
was measured over a range of F-actin concentrations, from 0-100 µM.  Calculated kinetic 
constants vary up to ~4.5-fold among the skeletal isoforms.  The fastest isoforms, IIb and IId, 
both have low KATPase values, but the slowest isoform, β, also shares this feature.  Understanding 
the diversity of this constant therefore may require measurements at the pre-steady-state level.  
Published in similar form in Resnicow, et al. (2010)1. 
 
DISCUSSION 
F-actin is an activating cofactor of myosin ATPase activity 
 The ability of F-actin to greatly increase the rate of myosin ATPase activity over its basal 
levels represents a well-adapted regulation on passive ATP usage by muscles.  While cellular 
ATP concentrations are thought to remain consistently high, binding sites for myosin on F-actin 
in the thin filament are not.  In the sarcomere the troponin-tropomyosin complex on the thin 
filament blocks the interaction of F-actin and myosin in cells at rest.  This means that 
independent of the concentration of the enzymatic substrate, the rate of catalysis can still be 
effectively regulated.  The degree of activation by F-actin of ATPase activity over basal activity 
observed in this population of motors far exceeds the degree seen in previous studies of 
equivalent MyHC II proteins.  In previous studies of myosin isolated from rabbit skeletal muscle 
and rat heart ventricle muscle the degree of F-actin activation of ATPase activity over basal 
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ATPase was found to be ~20-fold148, 149.  In this study, basal ATPase rates were each determined 
to be between 0.04±0.03 s-1 (perinatal) and 0.12±0.02 s-1 (extraocular), which was activated to 
between 18.9±1.5 s-1 (β-MyHC) and 86.1±8.4 s-1 (IIb) at saturating F-actin.  The degree of F-
actin activation over basal ATPase in these human recombinant skeletal MyHC-S1 proteins is 
between ~500-fold (extraocular) and ~1500-fold (perinatal), far greater than the degree of 
activation observed previously in other studies. 
 While previous studies reported ~20-fold activation of ATPase by F-actin, this study 
found the F-actin-activation of ATPase over basal activity to be on the order of ~1000-fold.  The 
source of this ~50-fold increase in the degree of F-actin-activation over previous studies of 
similar motors is likely due to the refinements in our ATPase assay method.  In our study, 
ATPase is measured at physiological temperature (37° C) rather than the typical assay 
temperature of ~20° C150 and with improved stirring methods using the Reacti-Therm stirring 
heatblock and a magnetic stirbar within each reaction tube1.  One feature unique to the F-actin-
activated ATPase assay and absent from the basal ATPase is the high viscosity of reactions 
containing high F-actin concentrations.  By stirring reactions we have attempted to overcome the 
localized product buildup and substrate exhaustion that can occur in viscous reaction 
environments.  The improved stirring methods of our system are likely to increase the apparent 
maximum reaction rates of F-actin-activated ATPase activity over those measured without 
stirring, but not the maximum rates of basal ATPase activity which are performed in the absence 
of F-actin and therefore are not in viscous conditions.  We believe this to be the reason for the far 
larger increase in F-actin activation measured in this study over previous studies. 
Functional diversity in the ATPase activities of the human skeletal muscle myosins 
 These data can be used to compare the relative activities of the human skeletal MyHC 
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isoforms.  The kcat values reflect a hierarchy among the skeletal isoforms in terms of relative 
activity, from faster to slower: IIb > IId > perinatal > extraocular > IIa > embryonic > β-MyHC.  
Among the fast skeletal isoforms, this hierarchy (IIb > IId > IIa) agrees with previously 
published data from both human and rodent muscle derived myosins150-153.  The isoform found to 
have the highest ATPase rate, IIb, is prevalent in small, fast rodent muscles, while the slower 
isoform, IIa, is prevalent in larger, slower human muscles, reflecting the physiological 
appropriateness of these observations.  This also supports the idea that the varied MyHC isoform 
compositions of muscles reflect specific adaptations to varied contractile demands. 
 The developmental isoforms, embryonic and perinatal, play a yet undetermined role in 
musculoskeletal development.  Previous studies of their activity from chicken and rat tissues 
indicated that the steady-state activities of the developmental isoforms may be very slow154, 155.  
This leads to the idea that developmental isoforms may play only a passive role in the muscle, 
without contributing to contractile activity significantly154, 155.  However, the existence of 
disease-causing mutations in the enzymatic site of both embryonic and perinatal MyHC88, 89 
indicate that their activity is vital to their role in the sarcomeres of developing muscles.  These 
data indicate that in fact the ATPase activity of the human perinatal isoform is faster than that of 
the most abundant fast skeletal isoform in adult human muscles, IIa.  Also, while the human 
embryonic isoform is slightly slower than IIa, it is still ~2.5-fold faster than the slow isoform, β-
MyHC.  The fact that these parameters for the developmental isoforms trend closely with the fast 
skeletal isoforms indicates that the developmental isoforms may be capable of contractile activity 
similar to that of the adult isoforms. 
 The slow, type I fiber isoform, β-MyHC, is predicted to be ~2- to 5-fold slower than the 
fast isoforms, from the relative maximum fiber shortening velocities of fast type II and slow type 
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I fibers55, 156, as shortening velocity is correlated with MyHC isoform composition49.  This 
prediction follows closely with the calculated kcat values for the human skeletal isoforms where 
β-MyHC is measured to be 2.8- to 4.6-fold slower than the fast skeletal isoforms, IIa and IIb, 
respectively.   
 The extraocular isoform presents an unusual contrast to its anticipated activity level from 
the function of muscle fibers in which the isoform is found.  Such fibers, from the muscles 
controlling movement of the eyes and the larynx, have been shown to possess among the fastest 
shortening velocities of any skeletal muscle fiber157, 158.  However, the F-actin-activated ATPase 
activity of human extraocular-MyHC has a kcat value very near the average of the skeletal 
isoforms, 59.2 s-1.  The specialization of the extraocular isoform may exist not in its steady-state 
activity as measured by ATPase, but rather in its pre-steady-state kinetics, as a rapid fiber twitch 
may only require a single reaction turnover to complete (see Chapter 2). 
 KATPase values, mathematically equivalent to KM values and derived from the Michaelis-
Menten fit to the data, are not simple to interpret, as the reaction step responsible for determining 
KATPase, as well as the rate-limiting step of the ATPase cycle, responsible for determining kcat, 
may vary from isoform to isoform.  Discussion of this constant in myosin biochemistry has 
historically focused around the crossbridge formation step and F-actin affinity as determining 
this constant159.  If this interpretation is correct, then the results showing that both the fastest 
isoform by kcat, IIb, and the slowest, β-MyHC, share among the lowest KATPase values, 14.0 and 
18.7 µM, respectively, compared to a group mean of ~30 µM, could be explained by both 
isoforms binding F-actin with relatively high affinity, and β-MyHC possessing a far slower rate-
limiting step following crossbridge formation.  To test these hypotheses it is necessary to break 
down the ATPase cycle into its component reaction steps, as described in Chapters 2 and 4. 
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 The ratio, kcat/KATPase, is used to describe the catalytic efficiency of an enzyme at low 
substrate concentrations, where "perfect" enzymes will catalyze their substrates at an essentially 
diffusion limited kcat/KM of ~108 to 109 µM-1s-1 160.  These myosins, while quite imperfect 
enzymes by this metric, show notable variability within this group.  The two fastest isoforms by 
kcat, IIb and IId, each have higher kcat/KM values of 6.15 and 4.18 µM-1s-1, respectively, while the 
rest of the isoforms group together with lower values between 1.01 and 1.59 µM-1s-1. The 
coupling of the higher kcat/KM values with the fastest two kcat values may indicate that this metric 
has a degree of relevance to myosin activity, but it is unclear from these steady-state data what 
that relevance might be.  Each of these differences found among the human skeletal muscle 
myosin isoforms are modest in scale, but indicate that there may be more to be learned from 
further study of these motors at pre-steady-state.   
Refined F-actin-activated ATPase methods produce faster rates 
 It would be desirable to directly compare these results to existing studies in order to both 
establish the comparability of proteins from this recombinant expression system to those derived 
from animal muscles and to compare the isoforms in this study to their orthologs in previous 
studies.  This is complicated by the fact that previous studies were performed primarily on 
muscles containing mixed populations of isoforms and were performed at varied reaction 
conditions.  When the results of this study are compared to existing data from lower temperatures 
and without improved mixing techniques, they are universally higher than existing data.  In the 
case of β-MyHC, existing F-actin-activated ATPase rates range from 6- to 60-fold slower161-165.  
This 10-fold range in the existing data exists even between experiments performed at the same 
temperature163, 165.  Because of these inconsistencies in the existing literature, it is desirable to 
establish a universal set of reaction conditions for these studies.  The improvements in detecting 
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Vmax using the mixing techniques described in this study lend weight to its adoption in F-actin-
activated ATPase studies more broadly. 
 While up to ~4.5-fold differences were observed using this metric, these steady-state 
measurements also disguise much of the potential diversity in contractile activity within summed 
events (Figure 9).  Therefore elucidating the specific biochemical features from which these 
differences in product formation originate will require additional tests.  Notably, this work 
describes the first ever kinetic measurements performed on recombinant human MyHC.  This 
represents a significant step forward in the study of these motors, which until this point could 
essentially only be isolated from animal muscle sources.  This technique expands the possibilities 
for study to the pure populations of single isoforms, to human isoforms, and to pathogenic 
mutant myosin proteins. 
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CHAPTER II 
Pre-steady-state skeletal muscle myosin kinetics 
 
INTRODUCTION 
MyHC in adult skeletal muscles 
 As discussed in Chapter I, skeletal muscles express a wide variety of MyHC isoforms in 
distinct temporal and spatial patterns.  In adults, IIa and IId are the primary MyHCs of human 
fast skeletal muscle fibers.  Interestingly, IIb, which is very common in rodent fast fibers, is not 
expressed in healthy human muscles, yet it is known to be a functional motor61.  The extraocular 
isoform is only found in fibers of a highly mixed isoform nature in muscles around the eye and 
larynx62-64.  By steady-state measurements, the adult fast skeletal muscle MyHC isoforms, IIa, 
IId, IIb, and extraocular, cluster within a span of ~1.5-fold in terms of kcat of F-actin-activated 
ATPase.  These isoforms diverge somewhat in terms of KATPase.  IId and IIb, with faster kcat = 
65.7 and 86.1 s-1, respectively, had lower KATPase = 15.7 and 14.0 µM, respectively. IIa and 
extraocular, with slower kcat = 52.8 and 59.2 s-1, respectively had 2- to 3-fold higher KATPase = 
44.5 and 37.2 µM, respectively (Chapter I, Table 2).  These four isoforms can be considered as a 
group, representing the adult fast skeletal muscle MyHC isoforms.  However, it is likely that this 
group possesses an additional degree of functional diversity in the steps that comprise the 
ATPase cycle, as these steady-state kinetic trends and the diversity of fast contractile fibers 
suggest.  Using pre-steady-state methods it should be possible to elucidate additional functional 
diversity in this family of fast MyHCs. 
Pre-steady-state reaction kinetics 
 Myosin undergoes a cyclical interaction with actin and ATP to contribute to muscle 
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contraction.  In Chapter I this ATPase cycle of myosin was investigated at steady-state.  Steady-
state measurements are useful in that they represent a simple activity metric by which proteins 
can be compared.  However, within the cycle of coupled reactions a large degree of functional 
diversity may be present that would not be possible to reveal by measurements at steady-state.  
The ATPase cycle is composed of numerous steps, each of which may differ in rate or substrate 
dependence among isoforms to produce different profiles of contractile cycle kinetics.  To 
identify such functional differences within the ATPase cycle, the reactions that compose the 
cycle must be observed at pre-steady-state, before the cyclical activity of these reactions makes 
observation of any individual reaction impossible.  The subject of this chapter is the pre-steady-
state analysis of the reactions that compose the ATPase cycle for the MyHC isoforms of human 
adult fast skeletal muscles.   
 Biochemical reaction kinetics concerns the rates of interactions between enzymes and 
their substrates, which depend in part upon the affinities of such binding interactions.  Together 
these features of reactions can be described by determining the constants that govern the rates 
and substrate dependences of the system under study.  Reaction events, such as the enzymatic 
activity of an ATPase, occur at rates based on various physical factors of the interaction.  At a 
given set of physical parameters, a rate constant describes the relationship of how fast a reaction 
occurs with respect to the concentrations of reaction participants in a solution.  A rate constant is 
represented as:  kx, where "x" indicates the type of reaction being described.  For example, k+1, 
represents an association reaction where the arbitrary molecules "A" and "B" bind to one another, 
as can be described by the expression:  A + B → AB.  The rate of this reaction relates to the 
constant, k+1, in a manner dependent upon the concentrations of reactants by the expression:  rate 
= k+1[A][B].  Because a reaction rate is expressed in terms of concentration per units of time, 
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such as M/s, the association rate constant reflects this with units per concentration, per unit time, 
such as M-1s-1.  Similarly, k-1, is a dissociation constant, where for example:  AB → A + B, 
giving:  rate = k-1[AB].  The units of k-1 are therefore s-1.  In experimental measurements, another 
rate constant is used.  The observed rate of a given reaction at a given set of conditions is 
referred to as kobserved or kobs, and has units of (s-1) 166. 
 At a given set of physical conditions, binding equilibria are also described by constants 
known as equilibrium constants and are represented as Kx, where again "x" indicates the type of 
reaction being described.  The constant, KD, represents a dissociation constant, which describes 
the equilibrium of the reaction A + B → AB.  Its relationship to this equilibrium can be defined 
using the rates of forward and reverse reactions as described above:  KD = k-1/k+1 and therefore 
has units of s-1/(M-1s-1) = M.  A "Binding" or "association" equilibrium constant is represented as 
KA and is the inverse of the dissociation constant for the associated reaction, such that:  KA = 
k+1/k-1.  Equilibrium constants can be described in terms of the product and reactant 
concentrations reached at equilibrium, as:  KD =  and KA =  166.  Using these 
kinetic principles, the rates and substrate dependences of the reactions of the MyHC ATPase 
cycle can be quantitatively described and compared. 
Pre-steady-state studies of MyHC 
 Studying pre-steady-state kinetics of the myosin ATPase cycle allows for close 
examination of the reaction steps that ultimately lead to sarcomeric contraction. MyHC isoforms 
often work in synergistic mixtures in muscle fibers, such as α-MyHC and β-MyHC in cardiac 
muscle fibers167 and IIa, IIb, IId and extraocular in various mixtures in fast skeletal muscle 
fibers62-64.  Since it has been shown that alterations in the balance of these isoforms in a fiber 
affect contractility168-172, it is of interest to understand their separate activities in an attempt to 
[A][B]
[AB]
[AB]
[A][B]
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learn how these might combine to produce muscle function. 
 Pre-steady-state assay techniques using stopped-flow and quench-flow systems have been 
used to observe the reactions that comprise the myosin ATPase cycle.  These techniques have 
proven capable of characterizing differences among groups of MyHC isoforms132, 133.  These 
studies have been limited to observations of muscle-derived S1 proteins, and so have been 
limited by the available muscle sources with respect to MyHC isoforms and species.  Using the 
recombinant MyHC expression system described above, it has been possible to overcome these 
limitations.  To perform pre-steady-state studies on these recombinant human MyHC proteins, a 
collaboration was established with the Geeves lab at the University of Kent in Canterbury, UK.  
In previous studies, the Geeves lab fully characterized the pre-steady-state kinetics of S1 from 
slow type I fibers, using the type I fiber-rich bovine masseter muscle, and of S1 from fast type II 
fiber-rich rabbit skeletal muscle132, 133.  These established pre-steady-state methods were used in 
the studies described in this thesis and the Geeves lab's kinetic data derived from fast and slow 
S1 proteins purified from animal muscles gave us a comparison base.  
The reactions of the F-actin-activated myosin ATPase cycle 
 The F-actin-activated myosin ATPase cycle can be simplified to five steps, depicted 
graphically in Figure 13.  Starting arbitrarily from the rigor state, where myosin is strongly 
bound to F-actin in the absence of nucleotide:  in Step 1A, the actin-myosin complex binds ATP, 
which causes a conformational change, Step 2A, drastically lowering the affinity of the actin-
myosin interaction and leading to rapid dissociation of the actin-myosin complex.  In Step 3, 
myosin hydrolyzes the bound ATP to ADP and Pi.  Associated with ATP hydrolysis, a 
conformational change increases affinity for F-actin.  In Step 4A the strongly bound actin-
myosin complex is reformed, then releases Pi and undergoes its characteristic contractile 
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conformational change:  the power-stroke.  At this stage, myosin's nucleotide binding pocket is 
still occupied by ADP, blocking ATP-binding to induce crossbridge detachment, and so it must 
release ADP in step 5A before the cycle can begin again2, 76, 78, 132, 133.  Similar conformational 
changes occur upon cyclical nucleotide binding interactions in the absence of actin, but with 
often vastly differing kinetics, in what was described above as the basal ATPase cycle.  The steps 
of the basal ATPase cycle are shown graphically in the inner ring of Figure 13. 
 Notably absent from this reaction model are rates for actin-myosin dissociation and re-
association before and after Step 3.  Dissociation of the actin-myosin crossbridge following Step 
2A has been shown to occur immediately and at a rate inseparable from that of Step 2A, as 
parallel measurements of Step 2A reaction progress by fluorescence and of complex dissociation 
by light scattering both follow the same rate, as demonstrated previously (135, 173, 174) and 
represented in Figure 14.  Further, these observed dissociation events have been shown to be 
temperature dependent.  The protein conformational change in Step 2A has been therefore 
defined as the rate-limiting step of dissociation followed by the rapid separation of the complex, 
which itself does not influence the kinetics of the cycle.  The crossbridge formation step 
following Step 3 in the physiological sarcomeric environment is thought to be governed by the 
geometry of the sarcomere, which cannot be modeled in our experimental system.  Crossbridge 
formation is therefore not measured in this study. 
 While analyzing these steps represents a more detailed analysis than steady-state ATPase 
measurements, in each case these steps encompass multiple reactions as well.  Nucleotide 
binding, for instance, is a multi-step process, including a rapid equilibrium step and associated 
slower conformational change175, 176.  For the purposes of this kinetic analysis the reactions are 
simplified to the steps shown in Figure 13, and rate and equilibrium constants assigned to the  
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Figure 13: Reaction scheme for the actin-myosin ATPase cycle.  The interaction of myosin 
with F-actin and nucleotides is represented here in a simplified ATPase cycle.  ATP, ADP, and 
inorganic phosphate are represented by T, D and Pi respectively.  Strong actin-MyHC binding is 
represented by black motor domains and detached or weakly-bound states by white motor 
domains.  Steps occurring while bound to F-actin are indicated as Step 1A-5A, and steps in the 
absence of actin as Steps 1-5.  The highlighted path is the physiological, active contractile cycle.  
Steps 1 and 1A are dependent upon the equilibrium constants of ATP binding (K1 and K1A, 
respectively).  Steps 2 and 2A are dependent upon the rate constants of a conformational change 
in the motor domain associated with loss of F-actin affinity (k+2 and k+2A, respectively).  Step 3 is 
dependent upon the rate constant of ATP hydrolysis (k+3+k-3).  Steps 4 and 4A are dependent 
upon the rate constants of Pi release (not measured here).  Step 5 and 5A are dependent upon the 
rate constants of ADP release (k+5 and k+5A, respectively).  Dissociation of myosin from F-actin 
in the absence of nucleotide is governed by the dissociation constant KD(Actin).  Dissociation of 
myosin from F-actin in the presence of ADP is governed by the dissociation constant KD(ADP-
Actin).  Dissociation of myosin from F-actin after Step 2A is essentially diffusion limited.  
Published in similar form in Deacon, et al. (2012)2. 
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reaction steps as depicted in schemes accompanying each measurement henceforth.  To 
distinguish reactions occurring in the presence of actin from parallel reactions in the absence of 
actin, steps in the presence of actin are referred to as Steps 1A - 5A, and in the absence of actin 
as Steps 1 - 5.  Rate and equilibrium constants are associated with these steps using subscript 
descriptors of the same nomenclature, 1A - 5A or 1 - 5, respectively.  It is important to note that 
the subscript "A's" in these descriptors indicate the presence of actin and do not denote 
"association" constants, as in the nomenclature, KA. 
 In this chapter the steps of the ATPase cycle for the fast skeletal muscle MyHC isoforms 
IIa, IId, IIb and extraocular are examined at pre-steady-state.  Experimental measurements were 
designed to determine properties of the actin-myosin ATPase cycle that would best contribute to 
understanding physiologically relevant characteristics of the MyHC isoforms in this study. 
 
 
 
Figure 14:  Rapid actin-myosin dissociation follows Step 2A.  Dissociation of the actin-
myosin complex is modeled to proceed rapidly following Step 2A of the actin-myosin ATPase 
cycle.  By observing the dissociation reaction in parallel by a fluorescence signal known to 
change following Step 2A (Pyrene-actin) and a signal known to change upon reduction in 
particle size (Light scattering), dissociation clearly occurs at a rate governed by Step 2A.  It is 
therefore assumed that separation of actin and myosin following Step 2A is essentially diffusion 
limited.  Adapted from De La Cruz and Ostap (2009)135. 
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METHODS 
Stopped-flow measurements 
 Because of the rapid nature of certain of these reactions at the necessary temperature and 
reagent concentrations, these measurements require specialized experimental systems.  Stopped-
flow systems are designed to rapidly mix two or more solutions by pneumatically driving two 
syringes coupled to a single piston, pushing the solutions together through a mixing chamber and 
through an optical flowcell.  In the flowcell, reaction mixtures can be observed as the reaction 
progresses by multiple optical techniques.  The movement of the solutions is stopped by the 
backpressure of a stop syringe downstream of the flowcell.  This maintains the position of the 
reaction aliquot in the flowcell for observation as the reaction progresses and gives the system its 
name, "stopped-flow."  Optical readouts commonly measured with such systems include 
absorbance/transmittance, light scattering, circular dichroism, and fluorescence.   
 Stopped-flow measurements were performed using a HiTech Scientific SF-61DX2 
stopped-flow system.  To observe reactions at pre-steady-state, all assays were performed in 
high-salt buffer:  20 mM MOPS pH 7.0, containing 100 mM KCl, 5 mM MgCl2, and 1 mM DTT.  
All reactions were performed at 20° C unless otherwise noted.  Measurements were made using 
fluorescent signals of reaction progress.  Data handling and non-linear regression analysis were 
performed using the stopped-flow's included software package, Kinetic Studio.  Since the MyHC 
isoforms described in this chapter were constructed as S1-eGFP fusion proteins, there was a need 
to remove the fluorescence of eGFP from the data signal.  This was achieved using a Kodak 47B 
filter, which was ~50 to 60% transparent to reaction signal wavelengths and opaque to eGFP 
emission fluorescence.  
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Fluorescence approaches to observing myosin kinetics 
 In order to measure actin-myosin ATPase cycle reactions in the presence of F-actin, a 
fluorescent marker of actin-myosin dissociation was used.  F-actin can be covalently labeled with 
N-(1-pyrenyl)iodoacetamide (pyrene-actin) at cysteine-374 by previously established methods132, 
173.  Briefly, F-actin was dialyzed overnight into 10 mM MOPS, pH 7.6, buffer containing 100 
µM CaCl2, 100 mM KCl, 1 mM MgCl2, 500 µM Na2ATP, and 1 mM NaN3, then diluted to 50 
µM in the dialysis buffer in the presence of 200 µM N-(1-pyrenyl)iodoacetamide.  The F-actin 
was rocked overnight in a light-shielded container at room temperature, then pelleted by 
ultracentrifugation at 200,000 x g for 90 minutes at 4° C.  The pellet was resuspended in 2 mM 
MOPS, pH 7.6, containing 100 µM CaCl2, 200 µM Na2ATP, 1 mM NaN3 and 1 mM DTT using 
a Dounce homogenizer, then depolymerized back to G-actin and subsequently repolymerized to 
F-actin as described previously by Pardee and Spudich146.  Depolymerization-repolymerization 
cycles were used to remove damaged or dysfunctional proteins resulting from the labeling 
reaction, as damaged actin is expected to be unable to repolymerize.  This approach has been 
shown to improve the quality and purity of actin samples146, 173. 
 Fluorescence from pyrene-actin was excited at 365 nm and the emission, with a 
maximum at ~407 nm, observed through a KV389 long-pass filter.  In the strongly bound 
complex, pyrene-actin-S1, pyrene fluorescence is ~70% quenched, likely due to allosteric effects 
in actin as a result of S1 binding173, 177.  Upon dissociation of the complex immediately following 
Step 2A, fluorescence is unquenched, allowing pyrene-actin-S1 dissociation to be observed as an 
increase in fluorescence signal intensity2, 76, 78, 132, 133, 135, 138, 173, 174, 178-182.   
 In the absence of actin, the intrinsic protein fluorescence of MyHC-S1 proteins was 
measured by excitation at 280 nm and emission observed through a WG320 long-pass filter.  
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Intrinsic protein fluorescence intensity is known to be modulated in MyHC-S1 proteins in 
response to nucleotide binding and ATP hydrolysis.  These fluorescence changes are thought to 
be due to the shielding/deshielding of tryptophan residues resulting from conformational changes 
in the motor domain.  Two tryptophan residues may signal nucleotide binding events at amino 
acid positions 112 and 130, as these residues lie within the nucleotide binding pocket76, 183, 184.  
The tryptophan residue thought to signal ATP hydrolysis is at amino acid position 508, as this 
residue lies near the converter and is modeled to transition from an exposed to a shielded 
environment as a result of a hydrolysis-coupled conformational change in the motor domain76, 126, 
185 (amino acid positions are reported with respect to the human β-MyHC sequence). 
 For stopped-flow reactions, concentrations are traditionally reported at their post-mixing 
concentrations, under the conditions in which the reactions occur.  In this thesis, concentrations 
reported for stopped-flow assays use this convention unless otherwise specified. 
Measuring crossbridge detachment 
 Actin-associated reactions can be examined on the stopped-flow by observing pyrene-
actin fluorescence.  As described above, pyrene-actin fluorescence intensity is greater in free 
pyrene-actin than in the pyrene-actin-S1 complex.  Therefore, an increase in fluorescence 
intensity as a result of pyrene-actin dissociation from S1 can be observed following Step 2A of 
the ATPase cycle (Figure 14).  This dissociation reaction can be induced by the addition of ATP 
to the pyrene-actin-S1 complex.  On the stopped-flow, measurements of ATP-induced actin-S1 
dissociation were performed by loading syringe 1 with equimolar pyrene-actin and MyHC-S1 to 
form the complex, and loading syringe 2 with ATP.  The contents of the two syringes were then 
rapidly mixed and the signal change observed as the reaction progressed in the flowcell.  This 
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reaction is designed to include Steps 1A and 2A, and therefore is dependent upon the affinity of 
pyrene-actin-S1 for ATP (K1A) and the rate constant for Step 2A (k+2A).   
 To observe actin-S1 crossbridge detachment and determine the constants K1A and k+2A, 
pyrene fluorescence experiments were conducted on the stopped-flow.  Syringe 1 was loaded 
with pyrene-actin and MyHC-S1 to form the pyrene-actin-S1 complex, and syringe 2 was loaded 
with ATP.  After mixing on the stopped-flow, pyrene-actin-S1 was at a final concentration of 
0.25 µM.  Reactions were repeated from 5 µM to as much as 2 mM ATP.  These reactions were 
performed at 20° C, and fluorescence recorded for up to 10 seconds after mixing (until the 
fluorescence signal reached plateau).  For these measurements pyrene was excited at 365 nm and 
a KV389 band-pass filter was used to isolate the pyrene emission signal at ~407 nm as well as a 
Kodak 47B filter to block eGFP background.  Each reaction was repeated for 3 to 5 mixing 
events and the traces averaged to produce a single fluorescence trace.  Each averaged 
fluorescence trace was fit by non-linear regression using the single exponential function: 
Equation 2:  F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
 
to determine the rate of the observed reaction.  kobs values were plotted with respect to ATP 
concentration and fit using the hyperbolic function:   
Equation 3A: .  
Since kmax = k+2A and K1/2 = 1/K1A, by replacing terms and multiplying the function by 1 = , 
the equation can be rewritten as: 
Equation 3B:  .  
This set of reactions was repeated for 3 separate preparations of each protein. 
kobs =
kmax[ATP]
K1/2 +[ATP]
K1A
K1A
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
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Measuring ADP affinity of actin-S1 
 To measure the affinity of actin-S1 for ADP, ADP can be used as an inhibitor of the 
ATP-induced actin-S1 dissociation reaction.  Since ADP also binds the nucleotide-binding site 
on S1, it can block ATP binding, and therefore inhibit dissociation.  On the stopped-flow, 
measurements to determine ADP affinity can be performed by loading syringe 1 with pyrene-
actin-S1, and loading syringe 2 with a fixed, low concentration of ATP and varied ADP 
concentrations.  This reaction is designed to use ADP as a competitive inhibitor of ATP-induced 
actin-S1 dissociation, and therefore is dependent upon the affinity of actin-S1 for ADP (K5A) as 
well as the rate of the uninhibited ATP-induced dissociation reaction, defined as k0. 
 To investigate ADP binding to actin-S1 and determine the constant K5A, pyrene 
flourescence experiments were conducted on the stopped-flow.  Syringe 1 was loaded with 
pyrene-actin and MyHC-S1 to form the pyrene-actin-S1 complex and syringe 2 was loaded with 
ATP and ADP.  After mixing on the stopped-flow, pyrene-actin-S1 was at a final concentration 
of 0.25 µM and ATP was at a final concentration of 50 µM.  Reactions were performed with no 
ADP to establish k0, then repeated with from 2.5 µM to as much as 1 mM ADP.  These reactions 
were performed at 20° C, and fluorescence recorded for up to 10 seconds after mixing (until the 
fluorescence signal reached plateau).  For these measurements pyrene was excited at 365 nm and 
a KV389 band-pass filter was used to isolate the pyrene emission signal at ~407 nm as well as a 
Kodak 47B filter to block eGFP background.  Each reaction was repeated for 3 to 5 mixing 
events and the traces averaged to produce a single fluorescence trace.  Each averaged 
fluorescence trace was fit by non-linear regression using Equation 2 rate of the observed 
reaction.  This set of reactions was repeated for three separate preparations of each protein. 
	  	   52	  
 These data were fit using a model of Michaelis-Menten kinetics in the presence of a 
competitive inhibitor:  , where "I" is the inhibitor and KI is the dissociation 
constant for the inhibitor.  This can be rewritten with terms for this context as:  
.  This can be modified by dividing both sides of the equation by 
k0, where k0 is the rate of the reaction in the absence of inhibitor, as described above:   
 , and since at low ATP concentrations, such as those used in these 
reactions, the [ATP] terms drop out of the equation, this yields:    
Equation 5:  135, 181, 186. 
 To determine the rate constant k+5A, which governs ADP-dissociation from actin-S1, 
saturating ADP (500 µM for IIa, IIb, and IId and 1 mM for extraocular, before mixing) was pre-
incubated with pyrene-actin-S1 and loaded in syringe 1, and syringe 2 was loaded with several-
fold excess ATP.  These reactions were performed at 20° C, and fluorescence was recorded for 2 
seconds after mixing.  For these measurements, pyrene was excited at 365 nm and a KV389 
band-pass filter was used to isolate the pyrene emission signal at ~407 nm, as well as a Kodak 
47B filter to block eGFP background.  Each reaction was repeated for 3 to 5 mixing events and 
the traces averaged to produce a single fluorescence trace.  Each averaged fluorescence trace was 
fit by non-linear regression using Equation 2 to determine the rate of the observed reaction.  
With the actin-S1 complex saturated by ADP before mixing, upon mixing with excess ATP, kobs 
vo =
vmax[S]
KM(1+
[I]
KI
)+[S]
kobs =
k
+2A[ATP]
1
K1A
(1+ [ADP]
K5A
)+[ATP]
k0 = kobs =
k
+2A[ATP]
1
K1A
+[ATP]
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
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is expected to be limited by the maximum rate of ADP-dissociation (governed by k+5A) unless 
that rate exceeds the rate of ATP binding, in which case kobs is expected to approximate k+2A. 
Measuring ATP binding to S1 in the absence of actin 
 In the absence of actin, measurements can be made using intrinsic protein fluorescence 
from tryptophan residues in S1.  As described above, changes in tryptophan fluorescence 
intensity are known to signal conformational changes in S1 proteins in response to 1) binding 
ATP and 2) hydrolyzing ATP to ADP and Pi76, 126, 183-185.  On the stopped-flow, measurements of 
ATP binding to S1 in the absence of actin were performed by loading syringe 1 with S1 and 
loading syringe 2 with ATP.  The contents of the two syringes were then rapidly mixed and the 
tryptophan fluorescence signal change observed as the reaction progressed in the flowcell. After 
mixing, S1 was at a concentration of 0.25 µM.  Reactions were repeated from 5 µM to 500 µM 
(IIa, IIb, IId) or 1 mM ATP (extraocular) after mixing.  These reactions were performed at 20° C, 
and fluorescence recorded for up to 5 seconds after mixing.  For these measurements, tryptophan 
fluorescence was excited at 295 nm and a WG320 band-pass filter was used to isolate the 
tryptophan emission signal at ~348 nm.  Each reaction was repeated for 3 to 5 mixing events and 
the traces averaged to produce a single fluorescence trace.  Each averaged fluorescence trace was 
fit by non-linear regression using Equation 2.  kobs values were plotted with respect to ATP 
concentration and the plot was fit by non-linear regression using Equation 3A. 
Measuring ADP binding to S1 in the absence of actin 
 ADP binding to S1 directly gives a weak tryptophan signal change, and so ADP binding 
is instead investigated by its inhibition of ATP binding.  Since ADP also binds the nucleotide-
binding site on S1, it can block ATP binding, and therefore inhibit the appearance of the ATP 
binding tryptophan signal.  On the stopped-flow, measurements of ADP binding to S1 in the 
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absence of actin were performed by loading syringe 1 with S1 pre-incubated with ADP and 
loading syringe 2 with ATP.  After mixing, S1 was at a final concentration of 0.25 µM and ATP 
was at a final concentration of 100 µM.  Reactions were performed with no ADP, then repeated 
with from 0.1 µM to as much as 20 µM ADP in syringe 1, before mixing.  At the moment of 
mixing, two populations are expected be present in syringe 1: S1 and S1-ADP, in proportion to 
each isoform's affinity for ADP (governed by K5) and the concentration of ADP in syringe 1.  
These populations are expected to react at two different rates when mixed with ATP:  rapidly 
inducing a signal in the population of S1, but waiting for ADP-dissociation (Step 5) to occur 
before binding the S1-ADP population and producing a fluorescence signal.  The amplitudes of 
these two phases of the reaction are expected to reflect the relative concentrations of the two 
populations in syringe 1 and can therefore be used to determine K5.   
 To determine the rate constant governing ADP-dissociation, the S1 in syringe 1 can be 
saturated by ADP, then mixed with saturating ATP to maximize the rate of signal appearance 
after ADP-dissociation.  Under these conditions, the rate of the observed reaction should be 
governed by the rate constant for ADP-release, k+5, unless that constant is greater than that of the 
rate-limiting step of ATP binding, k+2. 
 These reactions were performed at 20° C, and fluorescence recorded for up to 10 seconds 
after mixing, using a logarithmic timebase for data collection to enhance resolution of the faster 
phase of the reaction, while also measuring with sufficient resolution the far slower phase of the 
reaction.  For these measurements, tryptophan fluorescence was excited at 295 nm and a WG320 
band-pass filter was used to isolate the tryptophan emission signal at ~348 nm.  Each reaction 
was repeated for 3 to 5 mixing events and the traces averaged to produce a single fluorescence 
trace.  Each averaged fluorescence trace was fit by non-linear regression using the sum of two 
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exponential terms, Equation 4, to determine amplitudes for both fast and slow phases of the 
reaction traces.  The relative amplitudes for the slow and fast phases plotted with respect to ADP 
concentration were respectively fit using:   
Equation 6A:    
and  
Equation 6B:   2, 132, 133. 
 
RESULTS 
ATP-induced dissociation of actin-S1 (Steps 1A and 2A) 
 In order to investigate the ATP-induced crossbridge detachment of the skeletal myosins, 
we wanted to determine the affinity of the actin-S1 complex for ATP in Step 1A and the rate 
constant, k+2A, which governs the rate-limiting step of detachment, the conformational change in 
Step 2A (Figure 15).   
 
Figure 15: ATP-induced actin-S1 dissociation schemes. The participants in the reactions 
described are abbreviated as A = actin, M = myosin S1, and T = ATP. M* represents a different 
conformational state of myosin S1 with low actin affinity.  A. The reaction steps following the 
mixing of ATP with AM are a rapid equilibrium step where ATP binds to AM (Step 1A) and a 
rate limiting conformational change (Step 2A) preceding a diffusion limited dissociation (kdiss)173, 
174.  B. Step 1A is governed by the association constant, K1A, and Step 2A is governed by the rate 
constant, k+2A.   
 These reactions occur in the presence of actin.  Actin-associated reactions can be 
examined on the stopped-flow by observing pyrene-actin fluorescence.  As described above, 
A =
Amax[ADP]
K5 +[ADP]
+Amin
A =
AmaxK5
K5 +[ADP]
+Amin
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pyrene-actin fluorescence intensity is greater in free pyrene-actin than in the pyrene-actin-S1 
complex.  Therefore, an increase in fluorescence intensity as a result of pyrene-actin dissociation 
from S1 can be observed following Step 2A of the ATPase cycle (Figure 15).  This dissociation 
reaction can be induced by the addition of ATP to the pyrene-actin-S1 complex.  On the stopped-
flow, measurements of ATP-induced actin-S1 dissociation were performed by loading syringe 1 
with equimolar pyrene-actin and S1 to form the complex, and loading syringe 2 with ATP.  The 
contents of the two syringes were then rapidly mixed and pyrene fluorescence observed as the 
reaction progressed in the flowcell.  This reaction is designed to include Steps 1A and 2A, and 
therefore is dependent upon the affinity of pyrene-actin-S1 for ATP (K1A) and the rate constant 
for Step 2A (k+2A).  
 Upon mixing ATP with actin-S1 complex the dissociation reaction is modeled to progress 
through a two-step process:  A rapid equilibrium step (Step 1A) followed by a rate-limiting 
conformational change (Step 2A), with hyperbolic dependence of the dissociation rate on the 
concentration of ATP.   
 The formation of the collision complex in Step 1A is assumed to be a rapid equilibrium 
step.  This has been demonstrated for similar myosins in previous work (2, 76, 78, 94, 132, 133, 138, 173, 
174, 179-182, 186, 187) and the assumption is supported for these myosins by adherence to our model  
in the hyperbolic dependence of the two-step dissociation reaction on ATP observed in this study 
(data shown below).  The rate-limiting conformational change in Step 2A limits the maximum 
rate of the observed dissociation reaction and is followed by separation of the actin-S1 complex 
at a rate constant assumed to be essentially diffusion limited.  The studies that established the 
utility of the pyrene fluorescence signal in observing the actin-S1 dissociation step determined 
that the signal arises following a temperature dependent first-order reaction step, Step 2A173, 174, 
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179, 180.  The temperature dependence of this reaction step indicated the involvement of protein 
movement, as is modeled for Step 2A, and the lack of any other observed events limiting the 
dissociation reaction indicated that dissociation following Step 2A proceeded at a rate greatly in 
excess of Step 2A.  This was demonstrated by observing that the rate of complex separation at 
the end of the ATP-induced actin-S1 dissociation reaction, measured by light scattering (shown 
above in Figure 14), matched the rate of the pyrene fluorescence change173, 174.  We therefore 
assume rapid complex dissociation following Step 2A.  
 ATP concentration was varied in order to observe the reaction at well below the KD for 
ATP (1/K1A), at saturating ATP concentration, and at sufficient points between the two in order 
to accurately model the substrate dependence of the reaction rate.  Fluorescence transients 
resulting from these mixing events were monophasic and could be well described by non-linear 
regression analysis using the single exponential function, Equation 2: F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
   
Figure 16A shows a representative trace from extraocular-S1. 
 
Figure 16: ATP-induced actin-S1 dissociation of extraocular-S1. A. Pyrene fluorescence 
change observed following mixing of pyrene-actin-extraocular-S1 with ATP, to final 
concentrations of 0.25 µM and 5 µM, respectively. The best-fit single exponential function is 
superimposed and gives a kobs for this representative trace of kobs = 12.4 s-1. B.  The single phase 
transient observed for this reaction fits our model of a rapid equilibrium step (Step 1A) followed 
by a rate-limiting conformational change (Step 2A).  
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 Because this reaction involves an initial step dependent upon a binding equilibrium (Step 
1A), followed by a rate-limiting step (Step 2A), kmax for this reaction is defined by the rate 
constant for Step 2A, k+2A.  Therefore, at saturating ATP, kobs = k+2A.  kobs values obtained from 
these exponential functions were plotted with respect to their associated ATP concentrations to 
produce saturation curves.  These curves were fit by non-linear regression analysis using the 
hyperbolic function, Equation 3B:  2, 132, 174.  For each isoform, this set of 
reactions was performed on three independent preparations of protein.  Figure 17 shows 
representative curves from single preparations of each isoform. 
 
 At high ATP concentrations the rate of the dissociation reaction becomes very fast and 
approaches the detection limit of the stopped-flow.  Because of this, fits to reactions at low ATP 
concentrations have a higher confidence than at high ATP concentrations.  At low ATP 
concentrations the plot of kobs with respect to ATP concentration is linear and 
 simplifies to: 
Equation 7:  kobs = K1Ak+2A,  
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
Figure 17: ATP-induced actin-S1 
dissociation of fast skeletal S1.  Plots 
of kobs for the skeletal isoforms IIa (¢), 
IIb (), IId (r), and extraocular (u) 
following binding of ATP are well-
described by the hyperbolic function, 
Equation 3B, and best-fit curves are 
superimposed. Representative curves 
from single preparations of each 
isoform are shown, displaying variation 
in both saturation kmax (=k+2A) and K1/2 
(=1/K1A) values. 
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with an estimated worst case error of ~20% for ATP concentrations where K1A[ATP] < 0.2.  This 
error falls within the range of confidence of our measurements.  We therefore use linear fits to 
aid in the estimation of kinetic constants from ATP-induced actin-S1 dissociation reactions.  The 
hyperbolic fits to the curves represented in Figure 17 as well as linear fits to the low ATP linear 
phase were used to calculate values for the kinetic constants, K1Ak+2A, 1/K1A and k+2A.  These 
measurements and calculations were repeated over three independent protein preparations for 
each isoform and the values averaged and reported as mean values in Table 3. From the linear 
fits, the apparent second-order rate constant for the ATP-induced actin-S1 dissociation reaction, 
K1Ak+2A, differentiated the isoforms into the faster isoform:  3.2±0.4 µM-1s-1 for extraocular-S1, 
and the slower group: 1.4±0.07, 1.7±0.1, and 1.8±0.6 µM-1s-1, for IIb, IId and IIa respectively 
(Table 3).  At high ATP concentrations the reaction rates were very fast and difficult to measure.  
At low ATP concentrations the reaction rates were slower and well defined.  While for IIa and 
IId the reaction rates were measured at ATP concentrations greater than the reliability point of 3-
times 1/K1A, this could not be achieved for extraocular or IIb.  From the hyperbolic fits, the rate 
constant for the rate-limiting conformational change, k+2A, was seen to be very fast for all four 
isoforms, from 814 s-1 for IId to >1400 s-1 for IIb.  Given the limitations of the data at high ATP 
concentrations for the isoforms extraocular and IIb, and typical for ATP-induced actin-myosin 
dissociation measurements, 1/K1A values were calculated using the linear phase fits with 
Equation 7, giving a range of tighter affinities: 360±49, 450±151, and 660±60 µM, for 
extraocular, IId, and IIa, respectively, and a far weaker affinity of  >1000 µM for IIb (Table 3). 
ADP inhibition of ATP-induced dissociation of actin-S1 (Step 5A) 
 In order to investigate the ADP-binding characteristics of the skeletal myosins, we 
wanted to determine the affinity of the actin-S1 complex for ADP and the rate of ADP-
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dissociation from actin-S1 in Step 5A (Figure 18).  To observe these characteristics in the 
presence of actin we again used pyrene-actin fluorescence to signal the ATP-induced 
dissociation of the actin-S1 complex, and added ADP to the reactions as a competitive inhibitor 
of ATP binding. 
 
Figure 18:  ADP inhibition of ATP-induced actin-S1 dissociation schemes.  The participants 
in the reactions described are abbreviated as A = actin, M = myosin S1, D = ADP, and T = ATP. 
M* represents a different conformational state of myosin S1 with low actin affinity.  A.  The 
reaction steps following the mixing of ATP and ADP with AM include two possible paths, where 
AM mixed with ATP and ADP may progress through ATP-induced AM dissociation as 
described above, or may first bind ADP in the reverse reaction of Step 5A.  B.  Step 5A is 
governed by the dissociation constant K5A, Step 1A is governed by the association constant K1A 
and Step 2A is governed by the rate constant k+2A. 
 
 ADP was added to the syringe containing ATP to act as a competitive inhibitor for 
binding actin-S1.  With ATP at a fixed low concentration, well below the KD of actin-S1 for 
ATP, ADP concentration was varied in sequential reaction mixtures in order to observe the 
reaction at well below the KD of actin-S1 for ADP (K5A), at saturating ADP concentration, and at 
sufficient points between the two in order to accurately model the inhibition.  Fluorescence 
transients resulting from these mixing events were monophasic and could be well described by 
non-linear regression analysis using the single exponential function, Equation 2: 
F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
.  kobs values from these fits were converted to krel values by dividing by 
k0, and krel was plotted with respect to ADP concentration.  These plots were fit using Equation 
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5: .  Figure 19A shows representative curves from single 
preparations of each isoform. 
 
Figure 19: ADP inhibition of ATP-induced actin-S1 dissociation of fast skeletal S1.  A. Plots 
of krel for the skeletal isoforms IIa (¢), IIb (), IId (£), and extraocular (¯) with respect to 
ADP concentration.  B.  A fit of Equation 5 to this data yields the dissociation constant of the 
actin-S1 complex for ADP in Step 5A, K5A. 
 These ADP inhibition of ATP-induced actin-S1 dissociation measurements were repeated 
on three independent protein preparations of each isoform and the K5A values averaged and 
reported as mean values in Table 3.  K5A values range from a tighter binding group of IIb, IIa and 
IId, with K5A = 42±6, 80±15 and 109±29 µM, respectively, to the far lower affinity extraocular 
isoform, with K5A = 350±9 µM (Table 3).   
 Investigations of the rate constant governing ADP dissociation from actin-S1 were 
performed by pre-incubating actin-S1 with saturating ADP in syringe 1 before mixing with 
excess ATP in syringe 2.  For each of the fast skeletal isoforms it was found that the presence of 
ADP did not separate kobs from k+2A.  The ADP dissociation step, therefore, must occur more 
rapidly than the ATP binding step and so could not be observed.  For each skeletal isoform the 
rate constant for ADP-dissociation in Step 5A, k+5A, is set to the minimum value of > k+2A, since 
k+2A limits the observable rate of ADP-dissociation from actin-S1 for these isoforms.   
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
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Actin-independent ATP binding and hydrolysis (Steps 1-3) 
 In order to investigate the interaction of S1 with ATP in the absence of actin we wanted 
to determine the affinity of S1 for ATP, governed by the association constant, K1, the rate 
constant governing Step 2, k+2, and the rate constant for the ATP hydrolysis step, k+3 + k-3, in 
Step 3 (Figure 20). 
 
Figure 20:  Actin-independent ATP binding and hydrolysis schemes.  The participants in the 
reactions described are abbreviated as M = myosin S1, D = ADP, T = ATP, and Pi = inorganic 
phosphate.  M* represents a different conformational state of myosin S1.  A. The reaction steps 
following the mixing of ATP with myosin S1 are a rapid equilibrium step where ATP binds to 
S1 (Step 1), a conformational change (Step 2), and hydrolysis of ATP into ADP and Pi (Step 3).  
B.  Step 1 is governed by the association constant K1, Step 2 is governed by the rate constant k+2, 
and in Step 3 the rate of ATP hydrolysis is defined by the sum, k+3 + k-3.  
 These reactions occur in the absence of actin and we therefore could not use the pyrene 
fluorescence signal to detect reaction progress after mixing in the stopped-flow.  For these 
reactions we observed changes in intrinsic protein fluorescence.  As described above, several 
tryptophan residues in S1 are known exhibit changes in fluorescence signal as a result of 
conformational changes induced in S1 by Steps 2 and 3 of the contractile cycle.  These reactions 
were experimentally investigated on the stopped-flow by loading syringe 1 with S1 and syringe 2 
with ATP, then rapidly mixing and observing tryptophan fluorescence.  This experimental design 
includes Steps 1, 2 and 3, and fluorescence changes are expected to result from Steps 2 and 3.  
Reaction mixtures were repeated with ATP concentration varied in order to observe the reaction 
at well below the KD for ATP (1/K1), at saturating ATP concentrations and at sufficient points 
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between the two in order to accurately model the substrate dependence of the reaction rate.  
Fluorescence transients resulting from these mixing events were monophasic and could be well 
described by non-linear regression analysis using the single exponential function, Equation 2: 
F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
.  Figure 21A shows a representative trace from IId-S1.  kobs values from 
these fits were plotted with respect to ATP concentration and the resulting curves were analyzed 
by fitting Equation 3A:  .  For each isoform, this set of reactions was 
performed on three independent preparations of protein.  Figure 21B shows a representative 
curve from a single preparation of IId-S1. 
 
Figure 21:  Actin-independent ATP binding to IId-S1.  
A. In the stopped-flow, 0.25 µM S1 was rapidly mixed 
with 160 µM ATP.  The averaged fluorescence transient 
was fit using Equation 2, yielding, kobs = 153 s-1.  B. 
Reactions were measured from 5 µM to 500 µM ATP 
and the resulting kobs plotted with respect to ATP 
concentration.  The resulting plot was fit using Equation 
3A and saturated at kmax = 178 s-1.  C.  Following ATP 
binding to S1 in Step 1, Steps 2 and 3 both are expected 
to give tryptophan signals.  This monophasic reaction 
represents either Step 2 or Step 3. 
 The monophasic nature of the ATP-binding reaction traces indicated that only one of the 
kobs =
kmax[ATP]
K1/2 +[ATP]
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two possible reaction steps, Step 2 or Step 3, was observable using this reaction setup for the fast 
skeletal isoforms.  We interpret this to mean that the other reaction of the two must occur faster 
than the observed reaction, though it is also possible that Step 2 was observed and a slower Step 
3 exists, but gave no fluorescence signal.  To clarify the assignment of these fluorescence 
changes to their appropriate reaction step we typically use quench-flow assays measuring the rate 
of ADP product formed resulting from mixing S1 with ATP and incubating for a short time 
before stopping the reaction (described in detail in Chapter IV, Methods).  This second assay 
method provides an independent measure of Step 3 and aids in distinguishing between Steps 2 
and 3 for this analysis.  For these isoforms this process is still underway and the necessary 
quench-flow experiments have not yet been performed due to the limitations of recombinant 
protein production.  We therefore can only determine that these data represent one of the two rate 
constants, k+2 or k+3 + k-3. 
 Given these limitations, the hyperbolic fits yielded unassigned kmax values and fits to the 
linear phase using Equation 7 at low ATP concentrations where its derivation holds, yielded 
putative second order rate constants for the binding interaction, K1k+2, depending upon the 
observed rate-limiting reaction representing k+2.  These isoforms displayed a very similar range 
of values for the rate-limiting reaction (k+2 or k+3 + k-3), from the lowest, IIa at 141±28 s-1, to the 
highest, IId at 195±11 s-1, with a group mean value of 170 s-1.  The putative second order rate 
constants, K1k+2, were found to differ more greatly, ranging from the lowest, extraocular at 
1.0±0.2 µM-1s-1, to the highest, IId at 3.8±0.2 µM-1s-1, with a group mean of 2.2 µM-1s-1 (Table 
3). 
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Actin-independent ADP binding (Step 5) 
 In order to investigate the interaction of S1 with ADP in the absence of actin we wanted 
to determine the affinity of S1 for ADP, governed by the dissociation constant, K5, and the rate 
constant governing ADP-dissociation from S1 in Step 5, k+5 (Figure 22). 
 
Figure 22: Actin-independent ADP binding and release schemes. The participants in the 
reactions described are abbreviated as M = myosin S1, D = ADP, T = ATP, and Pi = inorganic 
phosphate.  M* represents a different conformational state of myosin S1.  A. The reaction steps 
following the mixing of ATP with S1-ADP are a slow ADP-dissociation step (Step 5), a rapid 
equilibrium step where ATP binds to S1 (Step 1), a conformational change (Step 2), and 
hydrolysis of ATP into ADP and Pi (Step 3).  B.  Step 5 is governed by the dissociation constant, 
K5, and the rate constant k+5, Step 1 is governed by the association constant K1, Step 2 is 
governed by the rate constant k+2, and in Step 3 the rate of ATP hydrolysis is defined by the sum, 
k+3 + k-3. 
 Tryptophan fluorescence was again used to observe reactions in the absence of actin.  We 
observed that the tryptophan fluorescence change upon binding of S1 to ADP was very small and 
insufficient to accurately define the reaction, given our limitations with respect to protein 
production.  Because the ATP-binding tryptophan fluorescence change was far greater, reactions 
were designed to infer parameters associated with ADP binding from reactions observing ATP-
binding tryptophan signals.  Because ADP and ATP share the same binding site on S1, ADP can 
block ATP binding and thereby inhibit the appearance of the ATP-binding tryptophan signal. 
 ADP binding parameters of the skeletal isoforms of S1 in the absence of actin were 
experimentally investigated on the stopped-flow by loading syringe 1 with pre-incubated S1 and 
ADP, and syringe 2 with ATP, then rapidly mixing and observing tryptophan fluorescence.  
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Given the monophasic nature of ATP binding to S1 for these isoforms, this experimental setup is 
designed to produce two phases in the ATP binding fluorescence transient, due to the two S1 
populations in syringe 1.  Syringe 1 contains both S1 and S1-ADP in complex before mixing 
with ATP from syringe 2.  The ATP-binding signal occurs rapidly in the free S1 population and 
slower in the S1-ADP population due to the extra reaction step of ADP-dissociation.  The signal 
amplitudes of these fast and slow phases reflect the respective concentrations of the two 
populations in syringe 1 before mixing.  The relative concentrations of S1 and S1-ADP are 
governed by the dissociation constant K5.  As the ADP concentrations increase, the amplitude of 
the slow phase should increase and the amplitude of the fast phase should decrease, reflecting a 
shift in the two populations.  By analyzing the amplitudes of the fast and slow phases with 
respect to ADP concentration, K5 can be determined. 
 Reaction mixtures were repeated with pre-mixing ADP concentration varied in order to 
observe the reaction at well below the KD of S1 for ADP (K5), at saturating ADP concentrations 
and at sufficient points between the two in order to accurately model the substrate dependence of 
the amplitudes for each phase of the reaction.  Fluorescence transients resulting from these 
mixing events were, as anticipated, biphasic.  The transients could be well described by the sum 
of two exponential functions, Equation 4: F = Afast ⋅ (1− e
(−kobs ( fast )⋅t ) )+Aslow ⋅ (1− e
(−kobs (slow )⋅t ) )+ F
∞
, 
when using ATP concentrations high enough to significantly separate the two phases of the 
reaction (~100-fold, Figure 23A).  A representative trace from IId-S1 is shown in Figure 23A. 
 Amplitudes (A) for each exponential term in the function were defined as the percent 
fluorescence change during the reaction with respect to the fluorescence value at the end point of 
the reaction, and were obtained from fits to the fluorescence transients.  Relative amplitudes for 
the slow and fast phases were plotted with respect to pre-mixing ADP concentration and fit using 
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Equations 6A:  A =
Amax[ADP]
K5 +[ADP]
+Amin  and 6B: A =
AmaxK5
K5 +[ADP]
+Amin , respectively (Figure 
23B).  From these fits to the data, we yielded two K5 values for each isoform, for each 
preparation of protein, which were averaged and are reported as a single K5 value in Table 3.  K5 
values for the fast skeletal isoforms ranged from a tighter binding group, 0.7±0.2, 1.0±0.3, and 
1.4±0.1 µM, for extraocular, IIa and IIb, repectively, to the weaker binding, IId at K5 = 3.0±0.5 
µM.  At saturating ADP (100 µM) and excess ATP (2 mM), kobs should be defined by k+5, 
assuming Step 5 occurs slower than and limits the rate of ATP binding.  For these isoforms, k+5 
was indeed slower.  Measurements at these conditions yielded rate constants governing ADP-
dissociation, k+5, of between 0.7±0.1 s-1 for extraocular, and 2.0 s-1 for IIb (Table 3), with a 
group mean of 1.28 s-1. 
 
Figure 23:  ADP binding to IId-S1.  A. On the stopped-flow 0.25 µM, post-mixing, IId-S1, pre-
incubated with ADP at 3.2 µM, before mixing, was rapidly mixed ATP at 100 µM, post-mixing.  
The fluorescence transient was best fit by the sum of two exponential terms, Equation 4, yielding 
a fast phase of kobs = 144 s-1 with an amplitude of 2.4%, and a slow phase of kobs = 1.6 s-1 with an 
amplitude of 4%.  B. The dependence of the amplitudes of the two phases of the reaction were fit 
using Equations 6A and 6B.  These functions gave K5 values of 3.2 µM and 3.7 µM for the fast 
phase and slow phase, respectively. 
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 Extra-ocular IIa IId IIb 
Rabbit  
fast S1* 
Bovine 
slow S1# 
ATP binding to actin-S1 
K1Ak+2A (µM-1s-1) 
1/K1A (µM) 
k+2A (s-1) 
 
3.2±0.4 
360±49 
1152±60 
 
1.7±0.1  
660±60 
1125±78  
 
1.8±0.6 
450±151 
814±40 
 
1.4±0.07 
>1000 
>1400 
 
2.4 
520 
1250 
 
1.24 
984 
1220 
ADP binding to actin-S1 
K5A (µM) 
 
350±9 
 
80±15  
 
109±29 
 
42±6 
 
120 
 
9.6 
ATP binding to S1 
K1k+2 (µM-1s-1) † 
k+2 OR k+3 + k-3 (s-1) † 
 
1.0±0.2 
177±8 
 
2.5 ±0.5  
141±28  
 
3.8±0.2 
195±11 
 
1.6±0.3  
167±16 
 
1.9 
>200 
 
0.97 
117 
ADP binding to S1 
K5 (µM) 
k+5 (s-1) 
 
0.7±0.2  
0.7±0.1 
 
1.0±0.3  
0.9±0.1  
 
3.0±0.5 
1.5±0.2 
 
1.4±0.1 
2.0±0.1 
 
2.0 
1.4 
 
2.0 
1.0 
Table 3: Stopped-flow kinetics of the fast skeletal myosins.  Recombinant S1 proteins bearing 
carboxy terminal eGFP-tags were observed interacting with ATP, ADP, and pyrene-actin.  The 
mean values for calculated rate and equilibrium constants are given and variance reported as 
standard error of the mean.  These data represent three biological replicates each.  (†) These data 
require confirmation by quench-flow before they can be accurately attributed to their respective 
reactions.  (*) Rabbit fast skeletal muscle S1 and (#) Bovine slow masseter muscle S1 are 
included for reference to previous measurements of fast and slow skeletal isoforms, including 
data from: 132, 180, 184.  For each constant, these isoforms generally reflect the activity of the rabbit 
fast S1, with the possible exception of IIb, which trends more with bovine slow S1. 
Interference from the eGFP-tag  
 The presence of the eGFP-tag on the fast skeletal myosin constructs necessitated the use 
of the Kodak 47B filter for measurements using pyrene fluorescence.  This removed nearly half 
of the total fluorescence signal from many reactions and therefore required higher quantities of 
protein to measure myosin activities.  We therefore eliminated this tag from future myosin 
constructs and, as will be described in Chapter IV, this greatly improved signal to noise in 
stopped-flow measurements.  Comparison of the kinetics of constructs with and without the 
eGFP-tag were generally similar, but possible differences were found (see Chapter IV, Results). 
 
 
 
	  	   69	  
DISCUSSION 
Extraocular has very fast crossbridge detachment kinetics 
 The apparent second order rate constant for crossbridge detachment, K1Ak+2A, can be used 
as a convenient metric for comparing overall detachment rates from the nucleotide-free actin-S1 
state2, 132, 133, 138, 181.  In this set of human fast skeletal MyHC isoforms the traditional skeletal 
muscle trio, IIa, IId, and IIb group together closely by this metric at between 1.4±0.07 and 
1.8±0.6 µM-1s-1.  The specialized fast skeletal isoform, extraocular, is modestly faster than the 
traditional IIa, IId, and IIb group by this metric at 3.2±0.4 µM-1s-1.  This is largely due to 
extraocular's actin-S1 to ATP binding being the tightest of the group, 1/K1A = 360±49 µM, 
versus 660±60, and >1000 µM for IIa and IIb, although IId may be similarly tight at 450±151 
µM. 
 ADP dissociation rate from actin-S1, governed by k+5A, is known to limit crossbridge 
detachment in slow but not fast MyHC isoforms, in which the rate of ADP-dissociation in Step 
5A, exceeds that of the ATP-binding rate-limiting step, Step 2A2, 132, 133, 181.  The ADP affinity of 
actin-S1 (K5A) trends with ADP-dissociation rate, such that slow isoforms with detachment rate-
limiting ADP-dissociation steps tend to have tighter ADP affinities than fast isoforms with fast 
ADP-dissociation2, 132, 181.  Among this group of human fast skeletal muscle isoforms, 
extraocular-MyHC binds ADP ~3- to 9-fold weaker (K5A = 350±9 µM) than IIa, IId, or IIb (K5A 
= 80±15, 109±29, and 42±6 µM, respectively).  While this feature does not necessarily reflect a 
difference with physiological relevance to the contractile cycle, it trends towards "faster" 
detachment kinetics.  These features combine to describe extraocular-MyHC as a very fast 
isoform.  Further study of its ATP hydrolysis step will be of interest to determine its duty ratio 
and overall cycle time to complete the picture of its contractile character. 
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Human MyHC-IIb has the kinetic attributes of slower myosins 
 Fast skeletal muscle myosins are characterized as binding ATP tightly and rapidly 
dissociating the actin-myosin crossbridge.  These characteristics can be seen in rabbit fast 
skeletal muscle S1, which has a high K1Ak+2A value and low value for the ATP dissociation 
constant, 1/K1A relative to bovine slow skeletal muscle S1 (Table 3).  MyHC-IIb in rodents is 
associated with the fastest fiber types, and is therefore thought to be very fast by these kinetic 
descriptors.  However, the human isoform is not expressed as protein in healthy human muscles61.  
These measurements indicate that, unlike a fast skeletal myosin, human IIb-S1 binds ATP very 
weakly, 1/K1A >1000 µM.  The human MyHC-IIb S1 resembles the bovine slow masseter 
muscle S1 in actin-associated reaction kinetics more than either rabbit fast skeletal S1 or the 
human fast skeletal isoforms, IIa and IId.  Human MyHC-IIb S1 has the slow-isoform traits of 
slow apparent second order kinetics of ATP-induced actin-S1 dissociation (K1Ak+2A), weak ATP 
binding (K1A), and trends towards tighter ADP binding (K5A).  It is conceivable that in humans 
the absence of MyHC-IIb expression in healthy muscles has effectively protected the gene from 
selection to resist genetic drift.  Its ability to act as a functional motor and drift towards the 
highly selected for (in its own contractile environment) role of a slow myosin is surprising and 
potentially contradictory to this hypothesis.  Further study of human MyHC-IIb function would 
be of interest to investigate these questions. 
ADP-dissociation is fast in the presence of actin and slow in its absence 
 In the F-actin-activated reaction designed to investigate Step 5A, ADP-dissociation 
occurred fast enough to be undetectable, as it did not influence the maximum rate of ATP-
induced actin-S1 dissociation at saturating ADP concentrations.  This indicates that the ADP-
dissociation step does not limit the rate of crossbridge detachment for these fast skeletal MyHC 
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isoforms, and thus does not determine fiber-shortening velocity in the fibers containing these 
isoforms.   
 In contrast to the very rapid rate of ADP-dissociation in the presence of actin, the fast 
skeletal isoforms release ADP very slowly in the absence of actin.  The minimum values for the 
actin-dependent ADP-dissociation rate constant, k+5A, limited by k+2A, are estimated to be on the 
order of ~1000 s-1 for these isoforms, whereas, in the absence of actin, the rate constant, k+5, 
ranged from 0.7 to 2.0 s-1.  This indicates that ADP-dissociation occurs on the order of 1000-fold 
slower when actin is not present.  Likewise, the basal ATPase activities of these isoforms were 
on the order of 1000-fold slower than their F-actin-activated ATPase activities, as described in 
Chapter I.  Therefore, the ADP-dissociation step, Step 5, may be responsible for limiting the rate 
of ATP consumption in the absence of F-actin by acting as the rate-limiting step of the basal 
ATPase cycle. 
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CHAPTER III 
Human embryonic-MyHC and Freeman-Sheldon Syndrome 
 
INTRODUCTION 
Embryonic-MyHC 
 The Embryonic-MyHC isoform is expressed early in fetal development and is absent in 
the adult, except during muscle regeneration.  Given the vastly different environment of muscles 
in utero versus in adult life, the embryonic-MyHC isoform may function differently from the 
adult skeletal isoforms.  For example, the developmental contractile environment does not likely 
involve significant voluntary contractile activity, nor any high-tension contraction, but may 
instead play a role in guiding the development of muscle structures.  Embryonic-MyHC has also 
been detected in muscles regenerating after injury.  Previous studies of developmental myosins 
have indicated that the developmental myosin isoforms may be far slower than adult isoforms, as 
chicken embryo myosins have slower in vitro motility than adult chicken myosin155, and myosin 
from fast-twitch muscle fibers in neonatal rats has increasing ATPase activity with age154.  
However, ATPase measurements of pure recombinant isoforms in Chapter I indicate that 
embryonic-MyHC is within ~2-fold of the rate all of the fast skeletal isoforms by ATPase kcat.  
Further, the presence of disease-causing mutations in functional sites in the embryonic-MyHC 
motor domain indicates that its physiological role likely requires functional contractile activity.  
The activity of embryonic-MyHC in developmental and regenerating muscles therefore warrants 
closer examination.  
Freeman-Sheldon Syndrome 
 Freeman-Sheldon Syndrome (FSS) is among the most severe of the congenital disorders 
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classified as distal arthrogryposes.  Distal arthrogryposes include congenital conditions of 
isolated and multiple joint contractures, the most common of which is clubfoot.  These disorders 
have a prevalence of between 1 in 500 births in the case of clubfoot, and 1 in 3000 births with 
multiple joint contractures188.  While there are varied biological origins leading to the various 
distal arthrogryposes189, FSS is known to be caused thus far, solely by dominant mutations in the 
motor domain of embryonic-MyHC188, 190.  FSS is characterized by multiple distal joint 
contractures as well as facial muscle contractures.  As the mutations causing this syndrome are in 
an isoform of myosin restricted to fetal development, it is non-progressive after birth but can still 
lead to significant and persistant abnormalities190.  One of the most frequent sites of mutation is 
in arginine-672, which has been found mutated to histidine or cysteine88, 190 in many FSS patients.   
 Arginine-672 is a highly conserved residue, which lies in the nucleotide-binding pocket 
of the MyHC motor domain (Figure 24).  It is positioned in the central β-sheet with its sidechain 
facing a neighboring strand containing the residue threonine-178 (Figure 24, inset).  Threonine-
178 is immediately adjacent to the phosphate-binding loop of the active site.  The polar 
guanidino and hydroxyl groups of these two residues are modeled to be within 2.9 - 3.2 Å of one 
another by crystallographic studies of human β-MyHC motor domain and scallop myosin S1, 
respectively (PDB IDs: 4DB1 and 1QV1, respectively), indicating that these residues may 
hydrogen bond to one another.  The mutation of residue threonine-178 in embryonic-MyHC to 
isoleucine has been found to cause a similar distal arthrogryposis disorder, known as Sheldon-
Hall Syndrome88, 191.  The coincidence of these two mutations in this site indicates its high 
importance in the proper contractile function of embryonic-MyHC.  The high degree of 
similarity between the disorders may indicate that this site controls very specific aspects of 
embryonic-MyHC's function.  For this reason and to understand its impact in human disease, the 
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functional effects of the FSS-causing mutation R672H in embryonic-MyHC are examined in this 
chapter. 
 
Figure 24:  Freeman-Sheldon Syndrome mutation R672H.  The arginine-672 residue of 
embryonic-MyHC, is located in the nucleotide-binding pocket in the central beta-sheet in the 
motor domain.  When this site is mutated to a histidine residue it causes Freeman-Sheldon 
Syndrome.  On the adjacent beta-strand, the nearby residue threonine-178 is also found to be 
mutated in embryonic-MyHC, causing a distal arthrogryposis disorder, Sheldon-Hall Syndrome.  
Shown within crystal structure PDB ID: 1QV1. 
 
METHODS 
Production of recombinant embryonic-MyHC subfragments 
 Human embryonic-MyHC was cloned from human embryonic cDNA.  The region 
encoding S1, including methionine-1 through alanine-844, was subcloned into pShuttle, in frame 
with a 6x histidine-tag at the carboxy terminus prior to the translation stop codon (Figure 25).  
	  	   75	  
This cloning vector was used to produce recombinant adenovirus using methods described in 
Chapter I.  The point mutation R672H was inserted into the coding region of embryonic-S1 in 
the pShuttle vector using PCR primers containing single nucleotide mismatches overlapping the 
mutation target sequence to introduce the point mutation into PCR products.  Using these PCR 
products, the S1 cloning region was reproduced by recombinant PCR and reinserted into pShuttle 
in frame with the 6x histidine-tag.  These pShuttle plasmids were used to produce recombinant 
adenoviruses encoding human embryonic-S1 (Emb-WT) and human embryonic-R672H-S1 
(Emb-R672H) proteins. 
 
Figure 25:  Embryonic-S1 expression construct.  A.  Embryonic-S1 spanning methionine-1 
through alanine-844 was cloned into pShuttle in frame with 6xHistidine-Stop (*), under 
transcriptional control of a CMV promotor and upstream of a polyA signal sequence.  B.  The 
protein produced by this expression cassette, Emb-WT, consists of S1 fused at its carboxy 
terminus with a 6xHistidine purification tag.  This protein is expected to copurify with myosin 
light chains (ELC and RLC) endogenous to the C2C12 cells in which the protein is expressed. 
 Recombinant adenoviruses encoding these constructs were used to infect myotubes 
derived from C2C12 mouse myoblasts in culture.  Protein production in myotubes was performed 
as described in Chapter I, then Emb-WT and Emb-R672H S1 proteins were purified from frozen 
cell pellets by FPLC, also as described in Chapter I. 
Stopped-flow measurements 
 Stopped-flow measurements were performed using a HiTech Scientific SF-61DX2 
stopped-flow system.  To observe reactions at pre-steady-state, assays were performed in high-
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salt buffer:  20 mM MOPS pH 7.0, containing 100 mM KCl, 5 mM MgCl2, and 1 mM DTT.  
Reactions were performed at 20°C, unless otherwise noted.  Measurements were made using 
fluorescence signals of reaction progress.  Data averaging to produce representative fluorescence 
transients and non-linear regressions of fluorescence transients were performed using the 
stopped-flow's included software, Kinetic Studio.  The MyHC isoforms in this chapter were 
constructed into S1 proteins without eGFP, to eliminate the signal background observed in 
Chapter II. 
Fluorescence approaches to observing myosin kinetics 
 As described in detail in Chapter II, two fluorescence signals were used to observe the 
interactions of S1 and actin-S1 with ATP and ADP in the experiments described in this chapter.  
For reactions in the presence of actin, pyrene-labeled actin (production described in Chapter II, 
Methods) was used.  Pyrene-actin signals the dissociation of the actin-S1 complex by increasing 
its fluorescence intensity.  Fluorescence from pyrene-actin was excited at 365 nm and the 
emission, with a maximum at ~407 nm, observed through a KV389 long-pass filter.  For 
reactions in the absence of actin, the intrinsic protein fluorescence of MyHC-S1 proteins was 
measured by excitation at 295 nm and emission observed through a WG320 long-pass filter.  
Intrinsic protein fluorescence intensity is known to be modulated in MyHC-S1 proteins in 
response to nucleotide binding and ATP hydrolysis, as is described in more detail in Chapter II, 
Methods. 
Measuring crossbridge detachment 
 As described above, pyrene-actin fluorescence intensity is greater in free pyrene-actin 
than in the pyrene-actin-S1 complex.  Therefore, an increase in fluorescence intensity as a result 
of pyrene-actin dissociation from S1 can be observed following Step 2A of the ATPase cycle 
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(Figure 13).  This dissociation reaction can be induced by the addition of ATP to the pyrene-
actin-S1 complex.  On the stopped-flow, measurements of ATP-induced actin-S1 dissociation 
were performed by loading syringe 1 with equimolar pyrene-actin and S1 to form the complex, 
and loading syringe 2 with ATP.  The contents of the two syringes were then rapidly mixed and 
the signal change observed as the reaction progressed in the flowcell.  This reaction is designed 
to include Steps 1A and 2A, and therefore is dependent upon the affinity of pyrene-actin-S1 for 
ATP (governed by 1/K1A) and the rate constant for Step 2A (k+2A).   
 To observe actin-S1 crossbridge detachment and determine the constants K1A and k+2A, 
pyrene fluorescence experiments were conducted on the stopped-flow.  Syringe 1 was loaded 
with pyrene-actin and Emb-WT or Emb-R672H S1 to form the pyrene-actin-S1 complex and 
syringe 2 was loaded with ATP.  After mixing on the stopped-flow, pyrene-actin-S1 was at a 
final concentration of 0.025 µM.  Reactions were repeated from 10 µM to as much as 2 mM 
ATP.  These reactions were performed at 20° C, and fluorescence recorded for 1 second after 
mixing (until the fluorescence signal reached plateau).  For these measurements pyrene was 
excited at 365 nm and a KV389 band-pass filter was used to isolate the pyrene emission signal at 
~407 nm.  Each reaction was repeated for 3 to 5 mixing events and the traces averaged to 
produce a single fluorescence trace.  Each averaged fluorescence trace was fit by non-linear 
regression using Equation 2:  F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
, to determine the rate of the observed 
reaction.  kobs values were plotted with respect to ATP concentration.  These data were fit using 
the hyperbolic function, Equation 3B: , as defined above in Chapter II, 
Methods.  These reactions were repeated for two separate preparations of each protein. 
 
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
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Measuring ADP affinity of actin-S1  
 As described above, the affinity of actin-S1 for ADP can be investigated using the ATP-
induced actin-S1 dissociation signal.  Since ADP and ATP share the same binding site on S1, 
ADP can be used as an inhibitor of ATP binding and therefore inhibit dissociation.  On the 
stopped-flow, measurements to determine ADP affinity were performed in two ways.   
 Emb-WT S1 was analyzed by using ADP as a competitive inhibitor of ATP binding, as 
described in Chapter II, Methods.  These experiments were conducted by observing the pyrene 
fluorescence signal for actin-S1 dissociation on the stopped-flow.  Syringe 1 was loaded with 
pyrene-actin and Emb-WT S1 to form the pyrene-actin-S1 complex and syringe 2 was loaded 
with ATP and ADP.  After mixing on the stopped-flow, pyrene-actin-S1 was at a final 
concentration of 25 nM and ATP was at a final concentration of 10 µM.  Reactions were 
performed with no ADP, then repeated with from 5 µM to as much as 400 µM ADP.  These 
reactions were performed at 20° C, and fluorescence recorded for up to 10 seconds after mixing.  
For these measurements pyrene was excited at 365 nm and a KV389 band-pass filter was used to 
isolate the pyrene emission signal at ~407 nm.  Each reaction was repeated for 3 to 5 mixing 
events and the traces averaged to produce a single fluorescence trace.  Each averaged 
fluorescence trace was fit by non-linear regression using Equation 2 to determine the rate of the 
observed reaction.  kobs values were plotted with respect to ADP concentration and the resulting 
plot fit using Equation 5:  , as derived and defined in detail in 
Chapter II, Methods.  This set of reactions was repeated for two separate preparations of Emb-
WT S1. 
 Emb-R672H S1 protein binding to ADP was analyzed by pre-incubating pyrene-actin-S1 
with ADP in syringe 1 and mixing with ATP in syringe 2, as described for ADP binding to free 
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
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S1 in Chapter II, with pyrene fluorescence signaling reaction progress rather than tryptophan 
fluorescence.  On the stopped-flow, measurements of ADP binding to Emb-R672H actin-S1 
were performed by loading syringe 1 with Emb-R672H, pyrene-actin, and ADP and loading 
syringe 2 with ATP.  After mixing, Emb-R672H was at a final concentration of 25 nM and ATP 
was at a final concentration of 10 µM.  Reactions were performed with no ADP, then repeated 
with from 2.5 µM to 40 µM ADP in syringe 1, before mixing.  Syringe 1 is expected to contain 
two populations in the presence of ADP, pyrene-actin-S1 and pyrene-actin-S1-ADP, which are 
expected to produce a biphasic fluorescence transient where the amplitudes of each phase reflect 
the relative concentrations of each population, as described in Chapter II, Methods and Results.  
For these measurements, pyrene fluorescence was excited at 365 nm and a KV389 band-pass 
filter was used to isolate the pyrene emission signal at ~407 nm.  Each reaction was repeated for 
3 to 5 mixing events and the traces averaged to produce a single fluorescence trace.  Each 
averaged trace was fit by non-linear regression using the sum of two exponential terms, Equation 
4, to determine amplitudes for both fast and slow phases of the reaction traces.  The relative 
amplitudes for the slow and fast phases plotted with respect to ADP concentration were 
respectively fit using Equations 6A and 6B, with the dissociation constant K5A substituted for K5:  
A =
Amax[ADP]
K5A +[ADP]
+Amin  and A =
AmaxK5A
K5A +[ADP]
+Amin , as defined in Chapter II.  These reactions 
were repeated for two separate preparations of Emb-R672H S1 protein. 
 To determine the rate constant k+5A, which governs ADP-dissociation from actin-S1, 
saturating ADP (500 µM for Emb-WT S1 and 50 µM for Emb-R672H S1, before mixing) was 
pre-incubated with pyrene-actin-S1 and loaded in syringe 1, and syringe 2 was loaded with 
saturating, 2 mM ATP.  These reactions were performed at 20° C, and fluorescence recorded for 
up to 10 seconds after mixing.  For these measurements pyrene was excited at 365 nm and a 
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KV389 band-pass filter was used to isolate the pyrene emission signal at ~407 nm.  These 
measurements were repeated for 3 mixing events and the traces averaged to produce a single 
fluorescence trace.  The averaged fluorescence traces were fit by non-linear regression using 
Equation 2 to determine the rate of the observed reaction.  With the actin-S1 complex saturated 
by ADP before mixing, upon mixing with high ATP concentrations kobs is expected to be limited 
by the maximum rate of ADP-dissociation (governed by k+5A) unless that rate exceeds the rate of 
ATP binding, in which case kobs will approximate k+2A.  Emb-WT was pre-incubated with 400 
µM ADP and Emb-R672H was pre-incubated with 40 µM ADP before each were mixed with 2 
mM ATP to determine the rate constant of ADP-dissociation from actin-S1, k+5A.  The reaction 
was repeated 3 times and the traces averaged to produce a single fluorescence transient.  The 
transient was fit using the single exponential function, Equation 2. 
 
RESULTS 
Purification of Emb-WT and Emb-R672H proteins 
 Emb-WT and Emb-R672H S1 proteins were purified from frozen infected C2C12 cell 
pellets, but yielded low protein concentrations.  Peak concentrations were 2.0 µM and 1.2 µM in 
the two Emb-WT preparations used for this work.  By SDS-PAGE these purified S1 proteins 
appeared to copurify with mixed endogenous C2C12 ELC and RLC isoforms, which were seen as 
bands of ~15 kDa, ~18 kDa, and ~22 kDa (Figure 26). 
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ATP-induced dissociation of actin-S1 (Steps 1A and 2A) 
 In order to investigate the ATP-induced crossbridge detachment of Emb-WT and Emb-
R672H, we wanted to determine the affinity of the actin-S1 complex for ATP in Step 1A and the 
rate constant, k+2A, governing the rate-limiting step of detachment, the conformational change in 
Step 2A (Figure 27).   
 
Figure 27: ATP-induced actin-S1 dissociation schemes. The participants in the reactions 
described are abbreviated as A = actin, M = myosin S1, and T = ATP. M* represents a different 
conformational state of myosin S1 with low actin affinity.  A. The reaction steps following the 
mixing of ATP with AM are a rapid equilibrium step where ATP binds to AM (Step 1A) and a 
rate limiting conformational change (Step 2A) preceding a diffusion limited dissociation (kdiss), 
as described in detail in Chapter II173, 174.  B. Step 1A is governed by the association constant K1A 
and Step 2A is governed by the rate constant k+2A.   
Figure 26: Purified 
recombinant Emb-R672H S1 
protein.  SDS-PAGE of the 
mutant S1 construct appears 
identical to its wild-type 
counterpart in both apparent 
molecular weight and light chain 
composition and is representative 
of both purified S1 constructs.  
Emb-R672H protein runs at the 
expected size and along with 
bands of approximately the 
appropriate size to be C2C12 
endogenous myosin light chains, 
between ~15 and ~25 kDa.	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 Since these reactions occur in the presence of actin, pyrene-actin fluorescence is used to 
signal dissociation of the actin-S1 complex.  As described above, pyrene-actin fluorescence 
intensity is greater in free pyrene-actin than in the pyrene-actin-S1 complex.  Therefore, an 
increase in fluorescence intensity as a result of pyrene-actin dissociation from S1 can be 
observed following Step 2A of the ATPase cycle, as described in detail in Chapter II, Results.  
Dissociation can be induced by mixing pyrene-actin-S1 with ATP on the stopped-flow.  
Measurements of ATP-induced dissociation of Emb-WT and Emb-R672H actin-S1 were 
performed on the stopped-flow by loading syringe 1 with equimolar pyrene-actin and S1 to form 
the complex, and loading syringe 2 with ATP.  The contents of the two syringes were then 
rapidly mixed and pyrene fluorescence observed as the reaction progressed in the flowcell.  This 
reaction is designed to include Steps 1A and 2A, and therefore is dependent upon the affinity of 
pyrene-actin-S1 for ATP (K1A) and the rate constant for Step 2A (k+2A).  ATP concentration was 
varied in order to observe the reaction at well below the KD for ATP (1/K1A), at saturating ATP 
concentration, and at sufficient points between the two in order to accurately model the substrate 
dependence of the reaction rate.  Fluorescence transients resulting from these mixing events were 
monophasic and could be well described by non-linear regression analysis using the single 
exponential function, Equation 2: F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
.  Figure 28A shows representative 
traces from Emb-WT and Emb-R672H S1. 
 At high ATP concentrations, signal was insufficiently distinguishable from noise for 
Emb-WT, due to low S1 concentrations and the fast reaction rate at high ATP concentrations.  
The highest measureable concentration for Emb-WT was 500 µM ATP.  kobs values from these 
functions were plotted with respect to ATP concentration and the resulting plots fit using 
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Equation 3B:  (Figure 28B).  For Emb-WT, the fitted function yielded k+2A 
values with a mean of 808±75 s-1.  Since these data were limited to low substrate concentrations, 
the slope of the initial linear phase was more trusted than the hyperbolic fit, and fitting Equation 
7, kobs = K1Ak+2A at low ATP concentrations (defined in Chapter II) to the linear phase gave 
K1Ak+2A = 2.7±0.3 µM-1s-1.  For Emb-WT, both calculation using the linear phase fit and the K1/2 
point from the hyperbolic fit estimated 1/K1A = ~300 µM and we therefore report that value as an 
approximation of 1/K1A.  We also report k+2A, taken from the hyperbolic fit as an approximation 
of ~800 s-1, given the limitations of the data at high ATP concentrations (Table 4).  For Emb-
R672H, the fitted hyperbolic function yielded k+2A = 475±31 s-1.  The slope of the linear phase of 
this plot at low ATP concentrations was fit using Equation 7, yielding K1Ak+2A = 1.0±0.2 µM-1s-1.  
For Emb-R672H, the dissociation constant for ATP was calculated as, 1/K1A = ~590 µM (Figure 
28, Table 4). 
 
Figure 28:  ATP-induced actin-S1 dissociation of Emb-WT and Emb-R672H.  A. 
Fuorescence transients resulting from rapidly mixing pyrene-actin-S1 with ATP on the stopped-
flow to final concentrations of 25 nM pyrene-actin-S1 and 10 µM ATP were fit using Equation 2.  
B.  Plots of kobs with respect to ATP concentration were fit using Equation 3B.  The function 
fitted to Emb-WT saturates at k+2 = 808 s-1 and a fit of Equation 7 to the low ATP phase yields 
K1Ak+2A = 2.7 µM-1s-1.  The functions fit to Emb-R672H gave k+2A = 475 s-1 and K1Ak+2A = 1.0 
µM-1s-1.  
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
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ADP inhibition of ATP-induced dissociation of actin-S1 (Step 5A) 
 In order to investigate the ADP-binding characteristics of Emb-WT and Emb-R672H, we 
wanted to determine the affinity of the actin-S1 complex for ADP and the rate of ADP release 
from actin-S1 in Step 5A (Figure 29).  To observe these characteristics in the presence of actin 
we again used pyrene-actin fluorescence to signal the ATP-induced dissociation of the actin-S1 
complex, and added ADP to the reactions as a competitive inhibitor of ATP binding. 
 
Figure 29:  ADP inhibition of ATP-induced actin-S1 dissociation schemes.  The participants 
in the reactions described are abbreviated as A = actin, M = myosin S1, D = ADP and T = ATP. 
M* represents a different conformational state of myosin S1 with low actin affinity.  A.  
Reactions where ATP and ADP are mixed with AM lead to two possible reaction paths, where 
AM may progress through ATP-induced AM dissociation as described above, or may first bind 
ADP in the reverse reaction of Step 5A.  Reactions where ATP is mixed with a pre-incubated 
solution of ADP and AM follow two reaction paths, where the population of AM in the pre-
incubated solution progresses through ATP-induced AM dissociation and the population of 
AMD first must undergo Step 5A, ADP-dissociation from AMD, before progressing through 
ATP-induced AM dissociation.  B.  Step 5A is governed by the dissociation constant K5A, Step 
1A is governed by the association constant K1A and Step 2A is governed by the rate constant k+2A. 
 
 As described in detail in Chapter II, ADP can affect the progress of ATP binding 
reactions with actin-S1 by competitive inhibition.  Using this principle, ADP binding to actin-S1 
can be indirectly measured in two ways.  For Emb-WT, ADP was added to the syringe 
containing ATP to act as a competitive inhibitor for binding actin-S1.  With ATP at a fixed low 
concentration, well below the KD of actin-S1 for ATP, ADP concentration was varied in 
sequential reaction mixtures in order to observe the reaction at well below the KD of actin-S1 for 
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ADP (K5A), at saturating ADP concentration, and at sufficient points between the two in order to 
accurately model the inhibition.  Fluorescence transients resulting from these mixing events were 
monophasic and could be well described by fitting the single exponential function, Equation 2: 
F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
.  In the absence of ADP, kobs = 28 s-1 was defined as k0.  kobs values were 
plotted with respect to post-mixing ADP concentration and the plots fitted using Equation 5: 
.  A representative plot is shown in Figure 30A.  These fits, 
repeated for two independent preparations of protein, yielded a mean K5A value of 56±6 µM for 
Emb-WT. 
  For Emb-R672H, ADP was pre-incubated with the actin-S1 in syringe 1, then mixed 
with ATP, such that the two populations of actin-S1 in syringe 1, pyrene-actin-S1 and pyrene-
actin-S1-ADP, reacted at easily separable rates.  As described in detail for S1 in the absence of 
actin in Chapter II, Results, by analyzing the amplitudes of the two phases of the reaction with 
respect to ADP concentration it is possible to infer the relative concentrations of the two 
populations of actin-S1 in syringe 1 before mixing and therefore determine the dissociation 
constant of actin-S1 for ADP, K5A.  Fluorescence transients resulting from these mixing events 
were biphasic and fit using the sum of two exponential terms, Equation 4.  Relative amplitudes 
for the slow and fast phases were plotted with respect to pre-mixing ADP concentration and fit 
using Equation 6A: A =
Amax[ADP]
K5A +[ADP]
+Amin  and Equation 6B: A =
AmaxK5A
K5A +[ADP]
+Amin , 
respectively.  A representative plot is shown in Figure 30B.  From these fits to the data, we 
yielded two K5A values for Emb-R672H, for each preparation of protein, which were averaged 
and are reported as a single mean K5A value in Table 4. 
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
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 At saturating ADP and excess ATP, kobs will be limited by the rate constant governing 
ADP-dissociation, k+5, unless that step occurs faster than k+2A.  Measurements at these conditions 
did not separate and define a slower rate of dissociation for Emb-WT in the presence of 
saturating ADP.  For Emb-WT, we interpret this to mean that k+5A does not limit the rate of the 
ATP-induced dissociation reaction and therefore k+5A > k+2A.  Using these measurements we can 
only set a lower limit on the k+5A value for Emb-WT of >200 s-1, at which point the fast rate of 
reaction and low signal to noise from low S1 protein concentrations made accurate 
measurements impossible.  For the tighter ADP-binding Emb-R672H, the kobs at saturating ADP 
Figure 30:  ADP binding to Emb-WT and Emb-
R672H S1 proteins.  A.  ADP binding to Emb-WT 
was measured by mixing pyrene-actin-S1 with ATP 
supplemented with ADP as a competitive inhibitor, 
from 0 to 400 µM ADP.  kobs values were plotted 
with respect to ADP concentration and fit using 
Equation 5, yielding K5A = 56 µM for Emb-WT.  B. 
Emb-R672H pyrene-actin-S1was pre-incubated with 
ADP, then rapidly mixed with ATP to induce 
dissociation.  The amplitudes of the slow and fast 
phases were plotted with respect to ADP 
concentration and fit using Equations 6A and 6B, 
respectively, yielding K5A = 3.2 and 2.1 µM, 
respectively. C. Reaction scheme for the ADP 
inhibition of ATP-induced actin-S1 dissociation.	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separated from k+2A, such that kobs = k+5A = 12±0.2 s-1 (Table 4).  
 Emb-WT Emb-R672H  Rabbit fast skeletal S1* 
Bovine slow 
masseter S1# 
ATP-binding to actin-S1 
K1Ak+2A  (µM-1s-1) 
1/K1A     (µM) 
k+2A        (s-1) 
 
2.7±0.3 
~300 
~800 
 
1.0±0.2 
590±124 
475±31 
  
2.4 
520 
1250 
 
1.24 
984 
1220 
ADP-binding to actin-S1 
K5A   (µM) 
k+5     (s-1) 
 
56±6 
>200 
 
2.6±0.6 
12±0.2 
  
120 
>1200 
 
9.6 
94 
 
Table 4:  Stopped-flow kinetics of Emb-WT and Emb-R672H.  Constants governing the 
interaction of S1 proteins with ATP, ADP, and pyrene-actin.  The mean values for calculated rate 
and equilibrium constants are given and variance reported as standard error of the mean.  (*) 
Rabbit fast skeletal muscle S1 and (#) Bovine slow masseter muscle S1 are included for reference 
to previous measurements of fast and slow skeletal isoforms, including data from: 132, 180, 184. 
 
DISCUSSION 
Embryonic-MyHC kinetics are similar to those of fast skeletal isoforms 
 ADP-dissociation and ATP binding, sequentially, must occur in the actin-S1 complex in 
order for crossbridge detachment to follow. As described above, the kinetics of crossbridge 
detachment in the MyHC of a muscle fiber are relevant because this step governs the maximum 
rate of fiber shortening.  These results place the human embryonic MyHC isoform among the 
fast skeletal isoforms described in Chapter II in terms of the kinetics of crossbridge detachment.  
For the fast skeletal isoforms, IIa, IId, IIb, and extraocular described in Chapter II, the apparent 
second order rate constant of ATP-induced actin-S1 dissociation, K1Ak+2A, clustered into two 
groups.  The traditional fast skeletal muscle isoforms, IIa, IId and IIb, agreed closely with one 
another with a mean value of 1.6 µM-1s-1, while the specialized isoform, extraocular, was ~2-fold 
faster at 3.2 µM-1s-1.  Emb-WT is at the faster end of this range:  K1Ak+2A = 2.7 µM-1s-1, primarily 
due to its high affinity for ATP, 1/K1A = ~300 µM, which is a higher affinity (i.e. lower 
	  	   88	  
dissociation constant) than any muscle MyHC isoform measured so far.  The other contributor to 
this second order rate constant, k+2A = 808 s-1, clusters with the lowest value measured for this 
constant:  k+2A = 814 s-1 for MyHC-IId.  This latter step of ATP-induced actin-S1 dissociation, 
Step 2A, may therefore control the rate of detachment for embryonic MyHC.  One caveat to 
these conclusions is the low quality of the data for Emb-WT at high ATP concentrations.  For 
this reason, these measurements will be repeated in future work with higher concentration 
protein preparations to adequately address these areas of the data. 
 ADP-release is known to determine the rate of crossbridge detachment of slow isoforms49.  
Past studies of myosins isolated from chicken embryos concluded that developmentally 
expressed MyHC isoforms were slow in steady-state155.  This led to the hypothesis that human 
embryonic MyHC would function kinetically in a similar manner to slow isoforms, such as 
bovine masseter myosin-S1, which binds ADP tightly enough for ADP-dissociation to limit its 
rate of crossbridge detachment.  However, the ADP-affinity of Emb-WT is more similar to the 
fast skeletal isoforms rather than to the slow masseter-S1.  Among the fast skeletal isoforms 
discussed in Chapter II, the embryonic isoform binds ADP most similarly to the tightest binding 
fast skeletal isoform, IIb, which in many respects was similar to a slow myosin, and so Emb-WT 
can be placed somewhere between fast and slow categories in terms of ADP-affinity.  While the 
rate constant governing ADP-dissociation from Emb-WT actin-S1, k+5A, could not be determined 
precisely, its measurement at >200 s-1 may indicate that it exceeds that of the ATP-binding step 
(limited by Step 2, k+2A), which would further categorize it with the fast skeletal isoforms. 
 Together, these results for embryonic-MyHC S1 describe a myosin with fast detachment 
kinetics and which likely does not bind ADP tightly enough to limit its rate of crossbridge 
detachment.  This pattern is typical of fast skeletal myosins, rather than the slow isoforms with 
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which previous studies predicted the embryonic isoform would share its activity.  The results 
which led to this prediction, published by Lowey, et al., were based on in vitro motility 
measurements.  The rate-limiting step governing this assay and therefore their conclusions may 
be a step of the ATPase cycle not measured for Emb-WT in this study, such as the ATP-
hydrolysis step.  Previous work carried out by Daniel R. Resnicow in the Leinwand lab in 
collaboration with Hans Warrick in the Spudich lab at Stanford tested the in vitro motility of 
purified embryonic-eGFP-S1, produced also for the ATPase experiments in Chapter I.  These 
measurements agreed with the work of Lowey, et al. that the embryonic isoform was among the 
slowest isoforms by in vitro motility2.  Further study of Emb-WT to characterize more steps in 
its ATPase cycle should be able to clarify these conflicting conclusions. 
Functional alterations in embryonic-S1 resulting from the R672H mutation 
 The contractile class into which these results place the human embryonic MyHC isoform 
is that of a fast skeletal type.  The ability of MyHC isoforms of this type to generate and sustain 
contractile tension is dependent upon a high frequency of contraction.  Embryonic muscles are 
not known to be very active, so we can conclude that this motor is unlikely to be intended to 
generate or sustain tension. 
 The alterations to the kinetics of Emb-WT resulting from the R672H mutation change its 
contractile class.  The R672H mutation results in a nearly 3-fold decrease in the apparent second 
order rate constant for ATP-induced actin-S1 dissociation, from K1Ak+2A = 2.7 to 1.0 µM-1s-1, 
which was contributed to by a nearly 2-fold drop in ATP affinity, from 1/K1A = ~300 to 590 µM, 
as well as by a nearly 2-fold drop in k+2A, from ~800 s-1 to 475 s-1 for Emb-WT and Emb-R672H, 
respectively (Figure 31).  Most strikingly, R672H had a large effect on ADP binding to actin-S1, 
increasing ADP affinity ~20-fold, from K5A = 56 µM to 2.6 µM, leading to a decrease in the rate 
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constant for ADP-dissociation of at least ~20-fold, from k+5A  > 200 s-1 to 12 s-1.  If the rate of 
ADP-dissociation for Emb-WT is in fact in excess of the rate limiting step of ATP binding, k+2A, 
then the decrease in this constant in Emb-R672H could be as much as ~70-fold, from k+2A = 
~800 s-1 for Emb-WT to k+5A = 12 s-1 for Emb-R672H. 
 
Figure 31: Relative rate and equilibrium constants for Emb-WT and Emb-R672H.  The 
alterations imparted on the contractile kinetics of Emb-WT as a result of the R672H mutation are 
shown graphically:  A nearly 3-fold decrease in ATP-induced cross-bridge detachment, K1Ak+2A, 
a nearly 2-fold decrease in ATP affinity, K1A, a nearly 2-fold decrease in maximal rate of 
detachment, k+2A, and a ~20-fold increase in ADP affinity, K5A.  Most detrimentally, the rate 
constant governing ADP-dissociation is decreased at least ~20-fold.  These alterations all 
contribute to extending the lifetime of the cross-bridge. 
 These defects all influence the crossbridge detachment reaction in such a way as to 
elongate the lifetime of the actin-bound phase of the ATPase cycle.  By comparison with the fast 
and slow S1 kinetics in Table 4, Emb-WT shares most kinetic features in common with rabbit 
fast skeletal muscle S1.  Emb-R672H appears most similar to the bovine slow masseter muscle 
S1, but with nearly 10-fold slower ADP-dissociation than even the classic "slow" S1 from 
bovine masseter.  In a muscle environment where Emb-WT is adapted to have fast detachment 
kinetics, as these data indicate is likely the case in embryonic muscle, the extension of the 
crossbridge lifetime at least 20-fold is expected to have major consequences.  Interestingly, the 
disease caused by the R672H mutation is of the class of contracture disorders, which produces a 
phenotype in which muscles of the face and distal limbs seem to be irreversibly contracted.  
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Although this in vitro system is not sufficient for predicting the consequences of Emb-R672H 
kinetics in vivo, it is conceivable that a crossbridge detachment defect in a major myosin of 
embryonic muscles leads to the inability of the muscles to release tension during development, 
and could thereby contribute to the formation of distal joint and facial muscle contractures. 
 This large alteration of ADP binding and the location of the altered residue in the core of 
the protein, near the active site of the motor domain make this mutation a good candidate for 
structure versus function studies aimed at determining the structural determinants of ADP 
affinity and dissociation. 
 
 
 
  
	  	   92	  
CHAPTER IV 
Pre-steady-state cardiac muscle myosin kinetics  
 
INTRODUCTION 
Cardiac MyHC isoforms 
 The two MyHC isoforms in human cardiac muscle, α- and β-, share 91% amino acid 
identity in S1192. Due to this high degree of identity, it was hypothesized that the contractile 
kinetics of these isoforms would be quite similar.  However, steady-state measurements of their 
ATPase as well as in vitro motility indicate 2- to 3-fold differences between α- and β-MyHC, 
with α-MyHC being the faster of the two165.  No previous studies of α-MyHC before this work 
have measured α-MyHC pre-steady-state kinetics, though several kinetic studies have been 
performed on slow muscle β-MyHC from species other than human132, 133, 186. 
 In the healthy human heart ventricle, MyHC composition is ~90% β and 10% α.  The 
importance of the small proportion of α in the human heart is emphasized by the effects of 
certain cardiac disease states, where α-MyHC becomes undetectable167.  The loss of detectable 
α-MyHC in the heart is correlated with loss of contractile function.  Following pharmacological 
intervention, α-MyHC becomes detectable again only in the hearts of patients with improved 
cardiac function167, 193, 194.  Animal models produced to investigate the result of variations in the 
α- and β-MyHC balance in the heart indicate that this balance of MyHC expression has a strong 
influence on the contractile function of isolated muscle fibers and cardiac myocytes168-172.   
Disease-causing mutations in cardiac MyHC 
 Greater than 300 mutations in β-MyHC are known to cause various cardiac and skeletal 
muscle diseases195.  Determining how mutations affect the contractile properties of the motor 
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may contribute both to understanding the molecular origins of the disease phenotypes as well as 
to understanding the differences between the cardiac and skeletal contractile niches.  In this 
study the disease-causing mutation in β-MyHC, R453C, is examined.  The residue arginine-453 
is located at the edge of the nucleotide-binding pocket, approximately 29 Å from the catalytic 
site.  It lies on the surface of the motor domain, facing the actin-binding pocket196 (Figure 32).  
Because of this location it is thought to play a role in actin binding, nucleotide binding, and/or 
communication between the two sites.  R453C is a dominant mutation found in β-MyHC, which 
causes hypertrophic cardiomyopathy (HCM)197.  HCM is a severe form of heart disease 
characterized by a disproportionate thickening of the ventricle walls such that the chamber space 
becomes restricted and cardiac output is decreased.  This is associated with cardiac myocellular 
disarray and fibrosis and is the most common cause of sudden cardiac death in people under 35 
years of age197-199.  HCM can be inherited through mutations in sarcomeric proteins, such as β-
MyHC200, 201.  In this study the effects of the R453C mutation on human β-MyHC kinetics are 
examined. 
 
Figure 32:  Arginine-453 in 
myosin S1. Arginine-453 of 
human β-MyHC (white 
sphere), lies at the edge of the 
nucleotide-binding pocket of 
S1 (dark grey), facing the 
actin-binding site.  When this 
site in the human β-MyHC 
gene is mutated, altering this 
residue to cysteine, it is 
known to cause hypertrophic 
cardiomyopathy.  Shown 
within the crystal structure of 
PDB ID: 1QV1.	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METHODS 
Production of recombinant cardiac MyHC subfragments 
 Human α- and β-MyHC were cloned from human heart cDNA.  The regions encoding S1, 
including methionine-1 through alanine-843, with respect to the human β-MyHC sequence 
(alanine-845 in α-MyHC), were subcloned into pShuttle, in frame with a 6x histidine-tag at the 
carboxy terminus, prior to the translation stop codon (Figure 33A).  These cloning vectors were 
used to produce recombinant adenoviruses using the methods described in Chapter I, which 
encoded the protein constructs β-S1 and α-S1.   
 To study a totally humanized cardiac myosin, a shorter subfragment of MyHC, analogous 
to chymotrypsin-digested MyHC, was produced by subcloning the region encoding methionine-1 
through arginine-808 of β-MyHC, followed by a translation-stop codon, into the multiple cloning 
site of pShuttle.  This cloning vector was used to produce a recombinant adenovirus encoding the 
protein construct, β-sS1.  To investigate the effects of having the correct human cardiac light 
chain on the function of the motor domain, the human ventricular ELC, MYL3, was cloned from 
human heart cDNA into pShuttle, in frame with a sequence encoding a start codon and 6x 
histidine-tag at the amino terminus.  This cloning vector was used to produce a recombinant 
adenovirus encoding the protein, MYL3.   
α- and β-S1 proteins were produced in myotubes independently, and both were purified 
by affinity to the 6x histidine-tag on the carboxy terminus of S1.  α- and β-S1 proteins co-
purified with endogenous C2C12 myosin light chains.  β-sS1, with no affinity tag, and MYL3, 
with a 6x histidine-tag on its amino terminus, were coexpressed, and purification by affinity to 
the 6x histidine-tag isolated β-sS1 only as a heterodimer with MYL3 (Figure 33B).  
Recombinant adenoviruses encoding β-sS1 and MYL3 were used to co-infect myotubes at a 1:1 
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ratio.  This sS1 construct was tested in conjunction with β-S1 to compare the effects on kinetics 
of β-MyHC complexed with ELC endogenous to the heart, compared with β-MyHC complexed 
with C2C12 mouse light chains. 
 
Figure 33: Protein constructs for recombinant cardiac S1 and sS1.  A.  Cardiac S1 constructs 
contain residues Met-1 through Ala-843, with respect to the human β sequence, are C-terminally 
6x histidine-tagged and copurify with endogenous C2C12 light chains.  B.  β-sS1 contains 
residues Met-1 through Arg-808, lacking the RLC binding domain, and is coexpressed along 
with the human ventricular ELC, MYL3, to produce a heterodimer more similar to how β-MyHC 
is found in the human heart. 
 The point mutation R453C was inserted into the coding region of β-sS1 in the pShuttle 
vector using PCR primers containing single nucleotide mismatches, overlapping the mutation 
target sequence, to introduce the point mutation into PCR products.  Using these PCR products, 
the S1 cloning region was reproduced by recombinant PCR and reinserted into pShuttle, in frame 
with the 6x histidine-tag.  This pShuttle vector was used to produce recombinant adenovirus 
encoding β-R453C-sS1.  
Stopped-flow measurements 
 Stopped-flow measurements were performed using a HiTech Scientific SF-61DX2 
stopped-flow system.  To observe reactions at pre-steady-state, assays were performed in high-
salt buffer:  20 mM MOPS pH 7.0, containing 100 mM KCl, 5 mM MgCl2, and 1 mM DTT.  
Reactions were performed at 20°C, unless otherwise noted.  Measurements were made using 
fluorescence signals of reaction progress.  Data averaging to produce representative fluorescence 
transients and non-linear regressions of fluorescence transients were performed using the 
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stopped-flow's included software, Kinetic Studio.  The MyHC isoforms in this chapter were 
constructed into S1 proteins without eGFP, to eliminate the signal background observed in 
Chapter II. 
Fluorescence approaches to observing myosin kinetics 
 As described in detail in Chapter II, two fluorescence signals were used to observe the 
interactions of S1 and actin-S1 with ATP and ADP in the experiments described in this chapter.  
For reactions in the presence of actin, pyrene-labeled actin was used.  Pyrene-actin signals the 
dissociation of the actin-S1 complex by increasing its fluorescence intensity.  Fluorescence from 
pyrene-actin was excited at 365 nm and the emission, with a maximum at ~407 nm, observed 
through a KV389 long-pass filter.  For reactions in the absence of actin, the intrinsic protein 
fluorescence of MyHC-S1 proteins was measured by excitation at 295 nm and emission observed 
through a WG320 long-pass filter.  Intrinsic protein fluorescence intensity is known to be 
modulated in MyHC-S1 proteins in response to nucleotide binding and ATP hydrolysis, as is 
described in detail in Chapter II, Methods. 
Measuring crossbridge detachment 
 As described above, pyrene-actin fluorescence intensity is greater in free pyrene-actin 
than in the pyrene-actin-S1 complex.  Therefore, an increase in fluorescence intensity as a result 
of pyrene-actin dissociation from S1 can be observed following Step 2A of the ATPase cycle 
(Figure 13, discussed in detail in Chapter II, Methods and Results).  This dissociation reaction 
can be induced by the addition of ATP to the pyrene-actin-S1 complex.  On the stopped-flow, 
measurements of ATP-induced actin-S1 dissociation were performed by loading syringe 1 with 
equimolar pyrene-actin and S1 to form the complex, and loading syringe 2 with ATP.  The 
contents of the syringes were then rapidly mixed and the signal change observed as the reaction 
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progressed in the flowcell.  This reaction is designed to include Steps 1A and 2A, and therefore 
is dependent upon the affinity of pyrene-actin-S1 for ATP (governed by 1/K1A) and the rate 
constant for Step 2A (k+2A).   
 To observe actin-S1 crossbridge detachment and determine the constants K1A and k+2A, 
pyrene fluorescence experiments were conducted on the stopped-flow.  Syringe 1 was loaded 
with pyrene-actin and α- or β-S1 to form the pyrene-actin-S1 complex and syringe 2 was loaded 
with ATP.  After mixing on the stopped-flow, pyrene-actin-S1 was at a final concentration of 0.1 
µM.  Reactions were repeated from 5 µM to as much as 2 mM ATP, post-mixing.  These 
reactions were performed at 20° C, and fluorescence recorded for 1 second after mixing (until the 
fluorescence signal reached plateau).  For these measurements pyrene was excited at 365 nm and 
a KV389 band-pass filter was used to isolate the pyrene emission signal at ~407 nm.  Each 
reaction was repeated for 3 to 5 mixing events and the traces averaged to produce a single 
fluorescence trace.  Each averaged fluorescence trace was biphasic and so was fit by non-linear 
regression using Equation 4: F = Afast ⋅ (1− e
(−kobs ( fast )⋅t ) )+Aslow ⋅ (1− e
(−kobs (slow )⋅t ) )+ F
∞
, to determine the 
rates present in the observed reaction.  kobs values were plotted with respect to ATP 
concentration and the fast phase was fit using the hyperbolic function, Equation 3B: 
, as defined above in Chapter II, Methods.  These reactions were repeated for 
three separate preparations of each protein. 
Measuring ADP binding to actin-S1 
 As described above, the affinity of actin-S1 for ADP can be investigated using the ATP-
induced actin-S1 dissociation signal.  Since ADP and ATP share the same binding site on S1, 
ADP can be used as an inhibitor of ATP binding and therefore inhibit dissociation.  These 
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
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experiments were conducted by observing the pyrene fluorescence signal for actin-S1 
dissociation on the stopped-flow.  Syringe 1 was loaded with pyrene-actin and α- or β-S1 to 
form the pyrene-actin-S1 complex and syringe 2 was loaded with ATP and ADP.  After mixing 
on the stopped-flow, pyrene-actin-S1 was at a final concentration of 0.1 µM and ATP was at a 
final concentration of 25 µM for α-S1 or 50 µM for β-S1.  Reactions were performed with no 
ADP, then repeated with from 2.5 µM to as much as 640 µM ADP for α-S1, or 320 µM ADP for 
β-S1, post-mixing.  These reactions were performed at 20° C, and fluorescence recorded for up 
to 10 seconds after mixing.  For these measurements pyrene was excited at 365 nm and a KV389 
band-pass filter was used to isolate the pyrene emission signal at ~407 nm.  Each reaction was 
repeated for 3 to 5 mixing events and the traces averaged to produce a single fluorescence trace.  
Each averaged fluorescence trace was fit by non-linear regression using Equation 4 to determine 
the rates present in the observed reaction.  kobs values for the fast phase were plotted with respect 
to ADP concentration and the resulting plot fit using Equation 5:  , 
as derived and defined in detail in Chapter II, Methods.  This set of reactions was repeated for 
three separate preparations each protein. 
 To determine the rate constant k+5A, which governs ADP-dissociation from actin-S1, 
saturating ADP was pre-incubated with pyrene-actin-S1 and loaded in syringe 1, and syringe 2 
was loaded with excess ATP.  These reactions were performed at 20° C, and fluorescence 
recorded for up to 10 seconds after mixing.  For these measurements pyrene was excited at 365 
nm and a KV389 band-pass filter was used to isolate the pyrene emission signal at ~407 nm.  
These measurements were repeated for 3 mixing events and the traces averaged to produce a 
single fluorescence trace.  The averaged biphasic fluorescence traces were fit by non-linear 
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
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regression using Equation 4 to determine the rates present in the observed reaction.  With the 
actin-S1 complex saturated by ADP before mixing, upon mixing with high ATP concentrations 
kobs is expected to be limited by the maximum rate of ADP-dissociation (governed by k+5A) 
unless that rate exceeds the rate of ATP binding, in which case kobs will approximate k+2A.  
Measuring ATP binding and hydrolysis by S1 in the absence of actin 
 In the absence of actin, measurements can be made using intrinsic protein fluorescence 
from tryptophan residues in S1.  As described in detail in Chapter II, changes in tryptophan 
fluorescence intensity are known to signal conformational changes in S1 proteins in response to 
1) binding ATP and 2) hydrolyzing ATP to ADP and Pi.76, 126, 183-185.  On the stopped-flow, 
measurements of ATP binding to S1 in the absence of actin were performed by loading syringe 1 
with S1 and loading syringe 2 with ATP.  The contents of the two syringes were then rapidly 
mixed and the tryptophan fluorescence signal change observed as the reaction progressed in the 
flowcell. After mixing, S1 was at a concentration of 0.25 µM.  Reactions were repeated from 5 
µM to 500 µM (IIa, IIb, IId) or 1 mM ATP (extraocular) after mixing.  These reactions were 
performed at 20° C, and fluorescence recorded for up to 5 seconds after mixing.  For these 
measurements, tryptophan fluorescence was excited at 295 nm and a WG320 band-pass filter 
was used to isolate the tryptophan emission signal at ~348 nm.  Each reaction was repeated for 3 
to 5 mixing events and the traces averaged to produce a single fluorescence trace.  Each averaged 
fluorescence trace was fit by non-linear regression using Equation 2 for monophasic transients or 
Equation 4 for biphasic transients.  kobs values were plotted with respect to ATP concentration 
and the plots fit by non-linear regression using Equation 3A.  To determine which reaction step 
in the ATPase cycle each phase of the fluorescence transients represent, a second method of 
quantifying ATP hydrolysis rate was used (quench-flow), which is described below. 
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Measuring ADP binding to S1 in the absence of actin 
 As described in Chapter II, ADP binding to S1 directly gives a weak tryptophan signal 
change, and so ADP binding is instead investigated by its inhibition of ATP binding.  Since ADP 
also binds the nucleotide-binding site on S1, it can block ATP binding, and therefore inhibit the 
appearance of the ATP binding tryptophan signal.  On the stopped-flow, measurements of ADP 
binding to S1 in the absence of actin were performed by loading syringe 1 with S1 pre-incubated 
with ADP, and loading syringe 2 with ATP.  After mixing, S1 was at a final concentration of 0.2 
µM and ATP was at a final concentration of 100 µM.  Reactions were performed with no ADP, 
then repeated with from 0.1 µM to as much as 1.6 µM ADP for β-S1 or 20 µM ADP for α-S1 in 
syringe 1, before mixing.  At the moment of mixing, two populations are expected be present in 
syringe 1:  free S1 and S1-ADP, in proportion to each isoform's affinity for ADP (governed by 
K5) and the concentration of ADP in syringe 1.  These populations are expected to react at two 
different rates when mixed with ATP:  rapidly inducing a signal in the free S1, but waiting for 
ADP-dissociation (Step 5) to occur before binding the S1-ADP population and producing a 
fluorescence signal.  The amplitudes of these two phases of the reaction are expected to reflect 
the relative concentrations of the two populations in syringe 1 and can therefore be used to 
determine K5.   
 These reactions were performed at 20° C, and fluorescence recorded for up to 10 seconds 
after mixing, using a logarithmic timebase for data collection to enhance resolution of the faster 
phase of the reaction, while also measuring with sufficient resolution the far slower phase of the 
reaction.  For these measurements, tryptophan fluorescence was excited at 295 nm and a WG320 
band-pass filter was used to isolate the tryptophan emission signal at ~348 nm.  Each reaction 
was repeated for 3 to 5 mixing events and the traces averaged to produce a single fluorescence 
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trace.  Each averaged fluorescence trace was fit by non-linear regression using the sum of two 
exponential terms, Equation 4, to determine amplitudes for both fast and slow phases of the 
reaction traces.  The relative amplitudes for the slow and fast phases were plotted with respect to 
ADP concentration, and were respectively fit using Equation 6A:   and 
Equation 6B:   2, 132, 133. 
 To determine the rate constant governing ADP-dissociation, the S1 in syringe 1 can be 
saturated by ADP, then mixed with saturating ATP to maximize the rate of signal appearance 
after ADP-dissociation.  Under these conditions, the rate of the observed reaction should be 
governed by the rate constant for ADP-release, k+5, unless that constant is greater than that of the 
rate-limiting step of ATP binding, k+2. 
Measuring S1 binding to F-actin 
 Pyrene-actin fluorescence signal is quenched in the pyrene-actin-S1 complex.  The 
amplitude of a dissociation reaction, coming only from the population of pyrene-actin in 
complex with S1 before mixing with ATP, must be related to the affinity of the S1 isoform for 
pyrene-actin.  This affinity can therefore be measured by incubating a fixed concentration of 
pyrene-actin with varied concentrations of S1, from limiting to excess, in syringe 1 and rapidly 
mixing the resulting complex with a fixed, low concentration of ATP in syringe 2 (low ATP is 
used to give a slower reaction rate and therefore a more easily characterized fluorescence 
transient).  
 On the stopped-flow, actin-affinity was investigated by loading 30 nM pyrene-actin in 
syringe 1, pre-incubated with S1, and loading ATP in syringe 2.  After mixing, ATP was at 20 
µM.  These measurements were repeated with S1 at concentrations of from 10 nM to 800 nM for 
A =
Amax[ADP]
K5 +[ADP]
+Amin
A =
AmaxK5
K5 +[ADP]
+Amin
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α-S1, or to 650 nM for β-S1, before mixing.  Reactions were performed at 20° C.  Each reaction 
was repeated for 3 to 5 mixing events, and the resulting fluorescence traces averaged to produce 
a single average fluorescence transient.  These biphasic averaged fluorescence transients were fit 
using Equation 4.  Amplitudes for the fast phase of the reaction were plotted with respect to S1 
concentration.  Due to limitations on the S1 concentrations and quantities our system was able to 
produce, these plots were not expected to reach saturation for observable concentrations of 
pyrene-actin, so the plots were fit using the quadratic function: 
Equation 8:  ,  
where "A" is the fraction of actin bound to S1 and "KD" is the dissociation constant of S1 for 
actin, KD(Actin), as described in Bloemink, et al. (2007)132.  This method was applied also with the 
addition of saturating 500 µM ADP to the actin-S1 complex prior to mixing to give the 
dissociation constant of S1-ADP for actin, KD(ADP-Actin)178. 
Quench-flow measurements 
 Pre-steady-state measurements of the ATP hydrolysis step were also made by quench-
flow.  Quench-flow systems allow for rapid mixing of reagents followed by quenching quickly 
enough to capture the burst phase of product formation.  While this method is highly regarded 
for characterizing the hydrolysis step of myosins, its high demand on protein quantity makes 
complete characterizations impractical, given limitations in protein production.  Therefore only 
those experiments necessary to complement stopped-flow measurements were performed using 
this technique.  Quench-flow experiments were performed using a Hi-Tech RQF-63.  
Measurements were made in high salt buffers:  20 mM MOPS pH 7.0, containing 100 mM KCl, 
5 mM MgCl2 and 1 mM DTT.  S1 was mixed with ten-fold excess ATP and incubated at 20° C 
A =
[S1]+KD +[actin]− ([S1]+KD +[actin])2 − 4[S1][actin]
2[actin]
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for various time points (10–500 ms), then quenched by 1:1 addition of 6.25% (w/v) trichloro-
acetic acid. After neutralization with NaOH, reaction solutions were centrifuged at 3,000 x g for 
5 minutes to remove any precipitates.  ADP and ATP were separated by HPLC using a Hypersil 
ODS (3 lm) column by isocratic flow.  ADP and ATP associated peaks were quantified by 
integrating peak areas.  For each time point, product formation was determined as a fraction of 
the peak areas:  ADP
ADP+ATP
.  This fraction was used to calculate the absolute concentration of 
product formed from the initial nucleotide concentration, and this value was used to calculate the 
hydrolysis rate for S1.  Reactions were performed in triplicate and on two separate preparations 
of protein. 	  	  
RESULTS 
Purification of cardiac MyHC subfragment proteins 
 Recombinant human cardiac MyHC α-S1, β-S1, and β-sS1 proteins were purified by 
FPLC, as described in Chapter I.  Using SDS-PAGE with Imperial Protein Stain [Thermo], 
MyHC subfragments appear at expected molecular weights:  ~98 kDa for α- and β-S1, and ~93 
kDa for β-sS1.  α- and β-S1 subfragments co-purify with bands of the appropriate size for mouse 
ELC and RLC isoforms (~18 kDa and ~22 kDa).  β-sS1 co-purifies with the recombinant human 
ventricular isoform of ELC, MYL3 (~25 kDa) (Figure 34).   
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ATP-induced dissociation of actin-S1 (Steps 1A and 2A) 
 In order to investigate the ATP-induced crossbridge detachment of the cardiac myosins, 
we wanted to determine the affinity of the actin-S1 complex for ATP in Step 1A and the rate 
constant, k+2A, which governs the rate-limiting step of detachment, the conformational change in 
Step 2A (Figure 35).   
 
 
Figure 35: ATP-induced actin-S1 dissociation schemes. The participants in the reactions 
described are abbreviated as A = actin, M = myosin S1, and T = ATP. M* represents a different 
conformational state of myosin S1 with low actin affinity.  A. The reaction steps following the 
mixing of ATP with AM are a rapid equilibrium step where ATP binds to AM (Step 1A) and a 
rate limiting conformational change (Step 2A) preceding a diffusion limited dissociation (kdiss)173, 
174.  B. Step 1A is governed by the association constant, K1A, and Step 2A is governed by the rate 
constant, k+2A.   
Figure 34:  Purified recombinant cardiac 
MyHC subfragments.  SDS-PAGE of 
recombinant α-S1, β-S1, and β-sS1 with 
MYL3, stained with Imperial Protein Stain 
[Thermo] and run along side the molecular 
weight marker, Precision Plus Protein 
Standards [Bio-Rad] shows bands 
corresponding to S1 in lanes 2 and 3 (~98 
kDa) and to sS1 in lane 4 (~93 kDa).  Bands 
of the appropriate size for copurified ELC 
and RLC proteins are present in lanes 2 and 
3 (<20 and ~22 kDa) and a single band of 
the appropriate size for MYL3 is present in 
lane 4 (~25 kDa).  Published in similar form 
in Deacon, et al. (2012)2. 
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 These reactions occur in the presence of actin.  Actin-associated reactions can be 
examined on the stopped-flow by observing pyrene-actin fluorescence.  As described above, 
pyrene-actin fluorescence intensity is greater in free pyrene-actin than in the pyrene-actin-S1 
complex.  Therefore, an increase in fluorescence intensity as a result of pyrene-actin dissociation 
from S1 can be observed following Step 2A of the ATPase cycle, as described in detail in 
Chapter II (Figure 35).  This dissociation reaction can be induced by the addition of ATP to the 
pyrene-actin-S1 complex.  On the stopped-flow, measurements of ATP-induced actin-S1 
dissociation were performed by loading syringe 1 with equimolar pyrene-actin and S1 to form 
the complex, and loading syringe 2 with ATP.  The contents of the two syringes were then 
rapidly mixed, and pyrene fluorescence observed as the reaction progressed in the flowcell.  This 
reaction is designed to include Steps 1A and 2A, and therefore is dependent upon the affinity of 
pyrene-actin-S1 for ATP (governed by 1/K1A) and the rate constant for Step 2A (k+2A).   
 ATP concentration was varied in order to observe the reaction at well below the KD of 
actin-S1 for ATP (1/K1A), at saturating ATP concentration, and at sufficient points between the 
two in order to accurately model the substrate dependence of the reaction rate.  Fluorescence 
transients resulting from these mixing events were biphasic and were well described by non-
linear regression analysis using the sum of two exponential functions, Equation 4.  Figure 36A 
shows representative traces from α- and β-S1.  kobs for both the fast and slow phases of the 
observed reactions were plotted with respect to ATP concentration.  The rate of the fast phase 
showed a hyperbolic dependence on ATP concentration, while the slow phase was not dependent 
on ATP concentration.  The fast phases for α- and β-S1 were fit using Equation 3B: 
 (Figure 36B). kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
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Figure 36: ATP-induced actin-S1 dissociation of α- and β-S1.  A.  Fluorescence transients 
observed after rapidly mixing pyrene-actin-α- or β-S1 with ATP, to final concentrations of 0.1 
µM and 0.5 mM, respectively, were best fit by the sum of two exponential functions, Equation 4.  
B.  Plots of kobs with respect to ATP concentration for the fast phases of α- (¢) and β-S1 (p) 
showed hyperbolic dependence on ATP concentration, saturating at 1667 and 1432 s-1, 
respectively, while the slow phases of the transients from α (£) and β (r) showed no ATP-
dependence.  Published in similar form in Deacon, et al. (2012)2. 
 The biphasic nature of these traces was anticipated for the slow isoform, β-S1, which was 
expected to be kinetically similar to the slow, bovine masseter S1, which has been shown 
previously to exhibit biphasic ATP binding in the presence of actin132.  This was modeled to be 
due to the opening and closing of the nucleotide-binding pocket, limiting binding or dissociation 
to or from the pocket in the "closed" state2, 132.  This biphasic nature was also observed for α-S1, 
indicating that α-S1 also undergoes a pocket opening/closing reaction during Step 1A. 
 Hyperbolic fits to the fast phase for α- and β-S1 were augmented by fits to the low-ATP 
linear phase using Equation 7: kobs = K1Ak+2A (at low ATP concentrations).  These fits yielded 
the calculated constants K1Ak+2A, 1/K1A, and k+2A, as described in detail in Chapter II.  α-S1 was 
found to be moderately faster than β-S1 in terms of the apparent second order rate constant, 
K1Ak+2A = 2.5±0.3 µM-1s-1 for α-S1 and 1.1±0.1 µM-1s-1 for β-S1.  The hyperbolic fits yielded 
very similar kmax = k+2A values, of 1500±167 s-1 for α-S1 and 1445±150 s-1 for β-S1.  The major 
contribution to the difference in their apparent second order rate constants was therefore the 
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dissociation constant of actin-S1 for ATP, 1/K1A = 626±143 µM for α-S1 and 1140±65 µM for 
β-S1 (Figure 36, Table 5). 
ADP inhibition of ATP-induced dissociation of actin-S1 (Step 5A) 
 In order to investigate the ADP-binding characteristics of α- and β-S1, we wanted to 
determine the affinity of the actin-S1 complex for ADP and the rate of ADP-dissociation from 
actin-S1 in Step 5A (Figure 37).  To observe these characteristics in the presence of actin we 
again used pyrene-actin fluorescence to signal the ATP-induced dissociation of the actin-S1 
complex, and added ADP to the reactions as a competitive inhibitor of ATP binding. 
 
Figure 37:  ADP inhibition of ATP-induced actin-S1 dissociation schemes.  The participants 
in the reactions described are abbreviated as A = actin, M = myosin S1, D = ADP, and T = ATP. 
M* represents a different conformational state of myosin S1 with low actin affinity.  A.  The 
reaction steps following the mixing of ATP and ADP with AM include two possible paths, where 
AM mixed with ATP and ADP may progress through ATP-induced AM dissociation as 
described above, or may first bind ADP in the reverse reaction of Step 5A.  B.  Step 5A is 
governed by the dissociation constant K5A, Step 1A is governed by the association constant K1A 
and Step 2A is governed by the rate constant k+2A. 
 
 Using the experimental setup for ATP-induced actin-S1 dissociation, ADP was added to 
the syringe containing ATP to act as a competitive inhibitor for binding actin-S1.  With ATP at a 
fixed low concentration, well below the KD of actin-S1 for ATP, ADP concentration was varied 
in sequential reaction mixtures in order to observe the reaction at well below the KD of actin-S1 
for ADP (K5A), at saturating ADP concentration, and at sufficient points between the two in 
order to accurately model the inhibition.  Fluorescence transients resulting from these mixing 
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events were biphasic, as they were for ATP-induced actin-S1 dissociation, and could be well 
described by non-linear regression analysis using the sum of two exponential functions, Equation 
4.  kobs values from the fast phase of these fits were converted to krel values by dividing by k0 and 
krel was plotted with respect to ADP concentration.  These plots were fit using Equation 5: 
.  For α- and β-S1, this set of reactions was performed on three 
independent preparations of protein.  Figure 38A shows representative curves from single 
preparations of α- and β-S1.  The fits to these data yielded the dissociation constant, K5A = 
152±25 µM for α-S1 and 21±3 µM for β-S1, revealing ~7-fold tighter binding of ADP in β-S1, 
compared to that of α-S1, when complexed with actin.  
 ADP dissociation from actin-S1 was measured by incubating pyrene-actin-S1 with 
saturating ADP and rapidly mixing with excess ATP.  For β-S1, this yielded a Step 5-limited 
dissociation rate, kobs = k+5A = 93 s-1 (Figure 38C), at well below k+2A.  For α-S1, even after 
reducing reaction temperature to 12°C to extend the range of ATP concentrations able to be 
measured on the time scale of the stopped-flow to 16 mM, the saturating rate of ATP-induced 
actin-S1 dissociation in the presence and absence of ADP could not be discerned from one 
another (Figure 38B).   This indicates that for α actin-S1 the ADP-dissociation reaction occurs 
very fast, with a rate constant greater than for the rate limiting constant of the ATP-induced 
actin-S1 dissociation reaction, k+2A, and therefore cannot be measured using this reaction. 
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
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Figure 38:  ADP binding to α- and β-MyHC actin-S1.  A.  0.1 µM α (¢) and β (p) pyrene-
actin-S1 was rapidly mixed with 25 µM (α) or 50 µM (β) ATP and a range of [ADP].  Single 
exponent fits to resulting transients were plotted as krel vs. ADP concentration and fit as 
described above.  B. Plots of ATP-induced actin-S1 dissociation of α in the presence (¢) and 
absence (£) of ADP at 12°C both saturate at ~800 s-1, and thus ADP-dissociation occurs too fast 
for measurement in this manner for α. C. 0.5 µM pyrene-actin-β-S1 incubated with 100 µM 
ADP and mixed with excess ATP was best fit by a two exponential function (solid line) giving 
kobs = k+5A = 84 s-1. A single exponential fit (light grey line) is shown for comparison. D.  
Reactions involved in this set of experiments include Steps 5A, 1A, and 2A.  Published in similar 
form in Deacon, et al. (2012)2. 
Actin binding of α- and β-S1 (KD(Actin) and KD(ADP-Actin)) 
 In order to investigate the binding interaction between F-actin and S1, we wanted to 
determine the affinity of α- and β-S1 for F-actin, at the rigor state, prior to Steps 1 and 1A, and 
in the ADP-bound state, prior to Steps 5 and 5A (Figure 39).  The dissociation constants 
governing the binding of F-actin by S1 and S1-ADP are referred to herein as, KD(Actin) and 
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KD(ADP-Actin). 
 
Figure 39: F-actin binding to S1 and S1-ADP schemes.  The participants in the reactions 
described are abbreviated as A = actin, M = myosin S1, D = ADP and T = ATP. M* represents a 
different conformational state of myosin S1 with low actin affinity.  A.  Prior to Step 1A, AM is 
in equilibrium with A+M.  Prior to Step 5A, AMD is in equilibrium with A+MD.  B.  The 
dissociation constants governing F-actin binding to M and MD are KD(Actin) and KD(ADP-Actin), 
respectively. 
 The signal amplitude of ATP-induced actin-S1 dissociation was performed and the 
concentration of S1 varied.  In these reactions, the concentration of actin-S1 formed by pre-
incubating a fixed pyrene-actin concentration with varied concentrations of α- or β-S1 was 
analyzed by following signal amplitude from the ATP-induced actin-S1 dissociation reaction.  
Since the concentration of actin-S1 complex formed by pre-incubating pyrene-actin with S1 was 
dependent upon the concentration of S1 and the dissociation constant, KD(Actin), the amplitude of 
the actin-S1 dissociation signal was in part defined by dissociation constant, KD(Actin).   
 Fluorescence transients resulting from these mixing events on the stopped-flow were 
biphasic for both α- and β-S1, as was anticipated for ATP-induced actin-S1 dissociation with 
these isoforms.  As S1 concentration increased, the pyrene signal amplitudes resulting from the 
dissociation reaction visibly increased (Figure 40A).  Averaged transients from 3 to 5 mixing 
events were fit using Equation 4, and the amplitudes from the fast phase of each reaction for β- 
and α-S1 were plotted with respect to S1 concentration.  These plots were fit using the quadratic 
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function, Equation 8:  (Figure 40B and 40C, 
respectively).  The physiologically relevant root of the fitted functions yielded KD values, which 
we attributed to the dissociation constant for actin binding, KD(Actin).  β-S1 was found to bind F-
actin ~4.5-fold more tightly than α-S1, as KD(Actin) = 37 nM and 8 nM for α- and β-S1, 
respectively (Table 5).   
 The same set of experiments was performed in the presence of saturating ADP in syringe 
1, pre-incubated with actin-S1.  The fits of signal amplitude with respect to S1 concentration in 
the presence of ADP yielded KD(ADP-Actin). β-S1-ADP was found to bind F-actin ~10-fold more 
tightly than α-S1-ADP, as KD(ADP-Actin) = 1.8 µM and 190 nM for α- and β-S1, respectively 
(Table 5, Figure 40).  The ratio, KD(ADP-Actin) / KD(Actin), was found to be ~2.5-fold larger for α-S1 
than for β-S1, as KD(ADP-Actin) / KD(Actin) = ~50 for α-S1 and ~20 for β-S1.  The limitation of these 
measurements to low S1 concentration was due to the limits of the recombinant expression 
system, which is currently capable of producing S1 concentrations of up to ~5 µM. 
 
 
 
A =
[S1]+KD +[actin]− ([S1]+KD +[actin])2 − 4[S1][actin]
2[actin]
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Figure 40:  F-actin binding to α- and β-S1.  A.  Fluorescents transients measured upon the 
dissociation of 30 nM pyrene-actin and various β-S1 concentrations with 20 µM ATP steadily 
increased in signal amplitude proportional to S1 concentration.  B.  Amplitudes of the signal 
from A for β-S1 (r) and β-S1 in the presence of 500 µM ADP (p), plotted with respect to S1 
concentration and fit using the quadratic function, Equation 8.  C.  A plot of the amplitudes of 
the titrated dissociation signal for α-S1 (£) and α-S1 in the presence of ADP (¢) shows a 
drastic affect on KD in the presence ADP. D. The equilibrium constants studied herein govern 
transitions between states occurring prior to Steps 1A and 1, and prior to Steps 5A and 5.  
Published in similar form in Deacon, et al. (2012)2. 
Actin-independent ATP binding and hydrolysis (Steps 1-3) 
 In order to investigate the interaction of α- and β-S1 with ATP in the absence of actin we 
wanted to determine the affinity of α- and β-S1 for ATP, governed by the association constant, 
K1, the rate constant governing Step 2, k+2, and the rate constant for the ATP hydrolysis step, k+3 
+ k-3, in Step 3 (Figure 41). 
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Figure 41:  Actin-independent ATP binding and hydrolysis schemes.  The participants in the 
reactions described are abbreviated as M = myosin S1, D = ADP, T = ATP, and Pi = inorganic 
phosphate.  M* represents a different conformational state of myosin S1.  A. The reaction steps 
following the mixing of ATP with myosin S1 are a rapid equilibrium step where ATP binds to 
S1 (Step 1), a conformational change (Step 2), and hydrolysis of ATP into ADP and Pi (Step 3).  
B.  Step 1 is governed by the association constant K1, Step 2 is governed by the rate constant k+2, 
and in Step 3 the rate of ATP hydrolysis is defined by the sum, k+3 + k-3.  
 These reactions occur in the absence of actin and we therefore used intrinsic protein 
fluorescence in S1 to observe ATP binding reactions, as described in detail in Chapter II.  As 
described above, fluorescence signal changes are known to follow Steps 2 and 3 of the 
contractile cycle (Figure 41).  These reactions were experimentally investigated on the stopped-
flow by loading syringe 1 with S1 and syringe 2 with ATP, then rapidly mixing and observing 
tryptophan fluorescence.  This experimental design includes Steps 1, 2 and 3, and fluorescence 
changes are expected to result from Steps 2 and 3.  Reaction mixtures were repeated with ATP 
concentration varied in order to observe the reaction at well below the KD for ATP (1/K1), at 
saturating ATP concentrations and at sufficient points between the two in order to accurately 
model the substrate dependence of the reaction rate.   
 Fluorescence transients resulting from these mixing events were monophasic for α-S1 
and biphasic for β-S1, and were therefore fit using Equation 2 and Equation 4, respectively.  
Figure 42A shows representative traces for α- and β-S1.  kobs values from these fits were plotted 
with respect to ATP concentration and the resulting curves for α-S1 and the fast phase for β-S1 
were analyzed by fitting Equation 3A:  .  For each isoform, this set of kobs =
kmax[ATP]
K1/2 +[ATP]
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reactions was performed on three independent preparations of protein.  Figure 42B shows 
representative curve from a single preparation of α- and β-S1. 
	  
Figure 42: ATP binding to α- and β-S1.  A.  Fluorescence transients resulting from the rapid 
mixing of 0.2 µM α- and β-S1 with 500 µM ATP were monophasic for α-S1 and biphasic for β-
S1.  A single exponent fit of the β-S1 transient, using Equation 2, is shown for comparison 
(dotted line).  B.  Plots of kobs for the fast phase with respect to ATP concentration for α (¢) and 
β (p) fit using Equation 3A. Published in similar form in Deacon, et al. (2012)2. 
 The hyperbolic fits saturated at mean kmax values of 168 s-1 and 158 s-1, for α- and β-S1, 
respectively.  The mean of the slow phase for β-S1 was found to saturate at ~17 s-1 and was 
somewhat ATP-dependent.  Given the multiple reaction steps modeled to contribute to the 
fluorescence signal in this experimental setup, determining which step produced each phase of 
the observed reactions required additional data.  To assign the fast and slow phases to the 
appropriate reaction steps, quench-flow assays were performed.  Quench-flow assays provided a 
separate measure of the rate of ATP-hydrolysis for comparison with α- and β-S1's fast and slow 
ATP binding reaction phases.  S1 was rapidly mixed with excess ATP and incubated for 
timepoints of 10 to 500 ms before quenching.  First, the long timepoint was used to determined 
the mean ADP production rate and total ADP signal amplitude of the burst phase, then three 
short timepoints were tested and a single exponential fit of the burst was used to provide a 
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preliminary kobs.  For β-S1, at 16, 33, and 68 ms timepoints ADP production was quantified as 16, 
43, and 61% of the total burst amplitude, giving a kobs = ~15 s-1.  By extrapolating K1k+2 to the 
tested ATP concentration, β-S1's ADP production is roughly 1/3 of what would be expected for 
the fast phase (52.5 s-1), while an extrapolation of the slow phase as the rate-limiting step of the 
scheme in Figure 41 predicts a kobs of ~10.5 s-1.  The slow phase for β-S1 can therefore be 
attributed to ATP hydrolysis, k+3+k-3.  For α-S1, a single short timepoint of 13 ms was sufficient 
to account for 33% of total burst amplitude and to assign the fast, single phase for α to the 
hydrolysis step.  k+2 for α-S1 therefore must have a rate constant greater than that of the 
hydrolysis step.  Therefore k+2 could only be quantified by this method as:  k+2 > 200 s-1 (Table 
5). 
Actin-independent ADP binding (Step 5) 
 In order to investigate the interaction of α- and β-S1 with ADP in the absence of actin we 
wanted to determine the affinity of S1 for ADP, governed by the dissociation constant, K5, and 
the rate constant governing ADP-dissociation from S1 in Step 5, k+5 (Figure 43). 
 
Figure 43: Actin-independent ADP binding and dissociation schemes. The participants in the 
reactions described are abbreviated as M = myosin S1, D = ADP, T = ATP, and Pi = inorganic 
phosphate.  M* represents a different conformational state of myosin S1.  A. The reaction steps 
following the mixing of ATP with S1-ADP are a slow ADP-dissociation step (Step 5), a rapid 
equilibrium step where ATP binds to S1 (Step 1), a conformational change (Step 2), and 
hydrolysis of ATP into ADP and Pi (Step 3).  B.  Step 5 is governed by the dissociation constant, 
K5, and the rate constant k+5, Step 1 is governed by the association constant K1, Step 2 is 
governed by the rate constant k+2, and in Step 3 the rate of ATP hydrolysis is defined by the sum, 
k+3 + k-3. 
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 Tryptophan fluorescence was again used to observe reactions in the absence of actin.  As 
described in more detail in Chapter II, because the ADP-binding tryptophan signal was too small 
for measurement, reactions were designed to infer parameters associated with ADP binding from 
reactions observing ATP-binding tryptophan signals.  Because ADP and ATP share the same 
binding site on S1, ADP can block ATP binding and thereby inhibit the appearance of the ATP 
binding tryptophan signal. 
 ADP binding parameters of the cardiac isoforms of S1 in the absence of actin were 
experimentally investigated on the stopped-flow by loading syringe 1 with pre-incubated S1 and 
ADP, and syringe 2 with ATP, then rapidly mixing and observing tryptophan fluorescence.  This 
experimental setup is designed to produce two phases in the ATP-binding fluorescence transient, 
due to the two S1 populations in syringe 1.  Syringe 1 contains both S1 and S1-ADP in complex 
before mixing with ATP from syringe 2.  The ATP-binding signal occurs rapidly in the free S1 
population and slower in the S1-ADP population due to the extra reaction step of ADP-
dissociation.  The signal amplitudes of these fast and slow phases reflect the respective 
concentrations of the two populations in syringe 1 before mixing.  The relative concentrations of 
S1 and S1-ADP are governed by the dissociation constant K5.  As the ADP concentrations 
increase, the amplitude of the slow phase should increase and the amplitude of the fast phase 
should decrease, reflecting a shift in the two populations.  By analyzing the amplitudes of the fast 
and slow phases with respect to ADP concentration, K5 can be determined. 
 Reaction mixtures were repeated with the ADP concentration in syringe 1 varied in order 
to observe the reaction at well below the KD of S1 for ADP (K5), at saturating ADP 
concentrations and at sufficient points between the two in order to accurately model the substrate 
dependence of the amplitudes for each phase of the reaction.  Fluorescence transients resulting 
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from these mixing events were biphasic and were fit using, Equation 4.  Traces from one 
preparation of β-S1 protein are shown in Figure 44A to demonstrate the relative change in the 
signal amplitudes for the fast and slow phases as a result of changes in ADP concentration. 
 Relative amplitudes for the slow and fast phases were plotted with respect to pre-mixing 
ADP concentration and fit using Equations 6A:   and 6B: 
, respectively (Figure 43B).  From these fits we calculated mean values 
for the ADP dissociation constant, K5, of 2.8 µM and 0.5 µM for α and β, respectively (Figure 
44B).  At saturating ADP, where kobs = k+5, fits to averaged fluorescence transients yielded k+5 = 
2.7 s-1 and 0.9 s-1, for α- and β-S1, respectively (Table 5). 
 
Figure 44: ADP binding to α- and β-S1.  A.  Fluorescence transients observed upon mixing 0.2 
µM β-S1 and varied ADP (0 to 1.6 µM) with 100 µM ATP are fit using the double exponential 
function, Equation 4.  B.  The amplitudes for the slow and fast phases observed in A were plotted 
with respect to pre-mixing ADP concentration and fit using Equations 6A and 6B, respectively, 
to yield K5 = 0.53 µM.  Published in similar form in Deacon, et al. (2012)2. 
Stopped-flow kinetics of β-sS1 
 Each of these measurements was performed in a similar manner with β-sS1.  For all 
kinetic constants measured, the values were within 2-fold of those reported for β-S1.  The 
A =
Amax[ADP]
K5 +[ADP]
+Amin
A =
AmaxK5
K5 +[ADP]
+Amin
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influence of the shortened lever arm, the lack of the RLC and the known and physiologically 
appropriate isoform identity of the ELC were found to have no significant impact the kinetics of 
β-MyHC.  These data are reported in Table 5, where they are compared to fast S1 purified from 
rabbit skeletal muscle and slow S1 purified from bovine masseter, from previous studies 
performed in the Geeves lab. 
Duty ratio and cycle duration of α- and β-S1 
 Duty ratio is defined as the fraction of total ATPase cycle time a myosin spends cross-
bridged to F-actin.  Duty ratios were modeled by taking the inverse of the rate constants 
contributing to each phase of the cycle (crossbridged versus detached) extrapolated to 
physiological 5 mM ATP.  The lifetimes of each phase of the ATPase cycle were calculated by:   
Crossbridge lifetime = 1/k+5A + 1/(K1Ak+2A[ATP]/(1+K1A[ATP])) and Detached lifetime = 
1/(k+3+k-3), for a cycle at 20° C, as these constants were measured at that temperature and cannot 
simply be extrapolated to 37° C.  In the same manner it is possible to predict the total cycle time 
for these motors by the sum of these two lifetimes.  For β-S1 the cycle time of 79.9 ms is spent 
16% (±2.7%) bound to F-actin, and for α-S1 the much shorter cycle time of 6.7 ms is spent only 
10% (±3.1%) bound to F-actin.  
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Human 
cardiac α-S1 
Human 
cardiac β-S1 
Human 
cardiac β-sS1 
Rabbit 
skeletal S1a 
Bovine 
masseter β-S1b 
ATP binding to S1 
K
1
k
+2
 (µM-1s-1) 
k
+2
 (s-1) 
k+3+k-3 (s-1) 
 
2.2±0.1 
>200 
168±28 
 
1.5±0.3 
158±18 
17±2 
 
1.5±0.1 
160±23 
14 
 
1.9 
>1000 
131 
 
0.97 
117 
18 
ADP binding to S1 
K5 (µM) 
k+5 (s-1) 
 
2.8±0.7 
2.7±0.6 
 
0.5±0.1 
0.9±0.1 
 
1.0±0.1 
0.59±0.08 
 
2 
1.4 
 
2.0 
1.0 
ATP binding to actin·S1 
K
1A
k
+2A
 (µM-1s-1) 
1/K1A (µM) 
k+2A (s-1) 
Kα1A 
k+α1A (s-1) 
 
2.5±0.3 
626±143 
1500±167 
10±2 
78±30 
 
1.1±0.1 
1140±65 
1445±150 
8±2 
56±12 
 
1.6±0.3 
710±65 
1081±50 
12±2 
49±5 
 
2.4 
520 
1250 
* 
* 
 
1.24 
984 
1220 
7.7 
56 
ADP binding to actin·S1 
K5A (µM) 
k+5A (s-1) 
Kα5A 
k+α5A (s-1) 
 
152±25 
>1252 
* 
* 
 
21±3 
93±5 
7±1 
15±0.6 
 
10±3 
64±3 
3.7±0.4 
1.8±0.1 
 
120 
>1200 
* 
* 
 
9.6 
94 
5.3 
9.6 
S1 binding to F-actin 
KD(Actin)   (nM) 
KD(ADP-Actin) (nM) 
 
37±11 
1844±546 
 
8±2 
191±17 
 
17±7 
229±138 
 
33 
1000 
 
7.0 
37 
Table 5: Stopped-flow kinetics of α- and β-S1.  Recombinant α- and β-S1 and β-sS1 proteins 
were observed interacting with ATP, ADP, and pyrene-actin.  The mean values for the calculated 
kinetic constants governing these interactions are given, and the variance reported as standard 
error of the mean.  These data represent 2 to 3 biological replicates each.  For comparison, 
animal muscle derived fast, rabbit skeletal S1 and slow, bovine masseter S1 are listed from 
previous studies in the Geeves lab. Published in similar form in Deacon, et al. (2012)2. 
aAssembled from Ritchie et al. (1993)184, Millar & Geeves (1988)180 and Nyitrai et al. (2006)181. 
bFrom Bloemink et al. (2007)132. *No detectable slow component. 
Kinetic effects of the hypertrophic cardiomyopathy mutation R453C in β-sS1 
 The R453C mutation was introduced into the sS1 construct of human β and copurified 
with MYL3 as described above; all kinetic comparisons were made with respect to β-sS1.  The 
protein bearing the R453C mutation was produced and isolated as described above and purified 
with its coexpressed ELC, MYL3, which appeared at the expected molecular weight, ~25 kDa, 
by SDS-PAGE (Figure 45).   
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 Unexpectedly for a mutation associated with multiple functional domains in S1, The 
R453C mutation in β-sS1 did not produce broad kinetic alterations in the motor.  ATP-induced 
actin-sS1 dissociation, ADP binding to actin-sS1, and actin-independent ATP binding to sS1 
were each tested and all constants were determined to be within 1.5-fold of the wild-type, with 
the exception of the slow phase of ATP binding to sS1.  This slow phase, attributed in β-sS1 to 
the ATP hydrolysis step (Step 3) was measured to be ~10-fold slower as a result of the R453C 
mutation, k+3+k-3 = 14 s-1 for β-sS1 and 1.5 s-1 for β-R453C-sS1.  While all other kinetics of the 
cycle remain unchanged, this feature on which the lifetime of the detached state depends should 
therefore produce a significant change in both cycle time and duty ratio, which in the 
predominant motor of the cardiac sarcomere may impact the number of actin-myosin cross-
bridges present at any given moment in a contracting cardiac fiber. 
 
Figure 45: Purified recombinant β-
R453C-sS1 protein.  SDS-PAGE of purified 
recombinant β-R453C-sS1 appears similar  
to β-sS1 (Figure 29, lane 4) in the apparent 
molecular weights of myosin heavy chain 
and myosin light chain bands (~93 kDa and 
~25 kDa, respectively.  The sS1 construct of 
β-R453C-sS1 copurifies with the human 
recombinant ventricular ELC, MYL3. 
	  	   121	  
Interference from the eGFP-tag  
 The presence of the eGFP-tag on the fast skeletal myosin constructs necessitated the use 
of the Kodak 47B filter for fluorescence measurements on the stopped-flow.  This removed 
nearly half of the total fluorescent signal from these reactions, which therefore required higher 
quantities of protein (Figure 46).  Comparative analysis of kinetics measured from β-S1 
constructs with and without this eGFP-tag identified a single significant difference in the eGFP-
bearing construct.  The kinetic constants for ATP binding to S1 and actin-S1, actin-S1 
dissociation, actin binding, ADP-dissociation from S1 and actin-S1, and ADP binding to actin-
S1 were all similar to within 20% between the constructs.  The eGFP-bearing construct diverged 
from the eGFP-free construct in ADP binding to S1 in the absence of actin, where the presence 
of the eGFP-tag produced a ~10-fold decrease in ADP affinity, though with no concomitant 
change in the rate constant for ADP-dissociation.  Given the limitations of the filtered signal for 
these fast skeletal studies it was possible to measure ATP and ADP binding in both the presence 
and absence of actin, but not to measure actin binding or detect ATP hydrolysis.  Figure 46 
shows the overlays of ATP-induced actin-S1 dissociation reactions performed using the same 
concentrations of eGFP-bearing and eGFP-free constructs. 
 
Figure 46:  Effect of the eGFP-tag on 
stopped-flow measurements.  Using 
the same concentration of S1, nearly 4-
fold greater fluorescence amplitudes 
were obtained from S1 lacking the 
eGFP-tag, as well as improved signal 
over noise.  The presence of an 
additional apparent reaction with a 
consistent rate of -0.5 s-1 was present in 
all pyrene-actin measurements of 
eGFP-bearing S1 proteins. 
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DISCUSSION 
Human β-myosin is kinetically similar to bovine muscle derived slow, type I myosin 
 As shown in Table 5, the kinetic properties of recombinant human β-S1 and β-sS1 appear 
very similar to S1 proteins purified from slow, type-I-rich muscles, which are known to contain 
predominantly the β-MyHC isoform202, as nearly all constants among the β-myosin constructs 
agreed to within ~2-fold.  This suggests that the recombinant S1 and sS1 protein constructs we 
designed are sufficiently accurate models for studying myosin kinetics.  This also suggests that 
the kinetic properties of myosin, such as β-myosin, are highly conserved. 
Biphasic detachment step 
 The ATP-induced actin-myosin detachment of α- and β-S1 occurred in two distinct 
phases:  a fast, ATP-dependent phase and a slow, ATP-independent phase.  This feature has been 
seen previously in slow-fiber myosin purified from bovine masseter muscle, where it was 
attributed to the motion of a region of S1 with the capability to block diffusion of nucleotide in 
and out of the binding pocket, effectively opening and closing the pocket and was referred to in 
that previous work by the equilibrium constant Kα and the rate constant k+α132.  These states are 
not observed in kinetic measurements of the fast isoforms or the developmental isoforms, though 
the highly conserved nature of myosins would imply that the structures responsible for this event 
exist in those isoforms as well.  Our hypothesis to explain this divergence is that in the fast and 
developmental isoforms where this reaction is not observed, the "closed" state which would limit 
the dissociation reaction does occur in these myosins but very infrequently and/or for very short 
durations.  This reaction would therefore be present in such a small fraction of the population of 
S1 proteins in a stopped-flow reaction mixture that its signal would carry an amplitude small 
enough to be lost in the noise of the dissociation reaction.  In this way, α- and β-myosins both 
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share a common feature with slow myosins in that they exhibit biphasic ATP binding kinetics in 
the presence of actin. 
Crossbridge detachment is governed by different reactions in human α- and β-myosins 
 Crossbridge detachment is an influential step in muscle contraction.  The rate of 
crossbridge detachment in a muscle fiber's myosin isoforms is thought to determine its maximum 
shortening velocity181.  In striated muscle MyHC isoforms, the rate of the detachment step can be 
limited by the either the rate of ADP-dissociation (Step 5A) or the steps of ATP-induced actin-
MyHC dissociation (Steps 1A and 2A)181, 186, 187.  Human β-S1, like slow myosins purified from 
muscle, has a very slow detachment step characterized by tight ADP binding (the tightest 
measured in this study for wild-type motors), ADP dissociation sufficiently slow to limit the rate 
of detachment, and weak ATP binding (the lowest affinity measured in this study, with the 
exception of IIb).  This produces an elongated crossbridge lifetime and a higher duty ratio, both 
features of the slow moving, tension maintaining class of myosins46.  α-S1, although most 
similar in amino acid sequence to the slow β isoform, does not share this trait.  α-S1, like fast 
myosins purified from muscle, has a very fast detachment step, characterized instead by weak 
ADP binding, very fast ADP-dissociation, and tight ATP binding.  In each facet of crossbridge 
detachment, the human α isoform appears to be like the fast skeletal isoforms as a lower duty 
ratio, fast moving motor type46. 
α-S1 exits the detached state ~10-fold faster than β-S1 
 While the steps leading to crossbridge detachment determine the lifetime of the 
crossbridged state, the detached lifetime is defined by the rate of ATP hydrolysis.  The rate 
constant for the ATP hydrolysis step, k+3+k-3, for β-S1 again agrees closely with slow muscle 
myosins, at 17 s-1.  This predicts a long dwell time in the detached state, which in combination 
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with its slow detachment describes the theoretical contractile cycle of human β-myosin at 20° C 
as long (~80 ms) with a moderately high duty ratio (for a sarcomeric myosin) of 16% (±2.7%).  
Human α-S1, by contrast has a ~10-fold higher rate constant for the hydrolysis step.  This 
predicts a short dwell time in the detached state, which in combination with its rapid crossbridge 
dissociation kinetics predicts its theoretical cycle to be very short in comparison (6.7 ms), with a 
lower duty ratio of 10% (±3.1%).   
Human α- and β-myosins are kinetically dissimilar  
 The natural hypothesis arising from high protein sequence identity between α- and β-
myosins, in conjunction with the only modest steady-state functional differences, is that in 
general kinetic character α-myosin is likely to behave like β-myosin, though somewhat faster.  
Surprisingly, while human β-S1 closely resembles the previously measured slow, bovine 
masseter muscle S1 in nearly all kinetic parameters, α-S1 in nearly all kinetic parameters 
resembles a fast skeletal muscle myosin.  In spite of >90% identity with the slow β-MyHC and 
as low as ~80% identity with the fast skeletal isoforms, α-MyHC can be best categorized as, 
kinetically, a fast skeletal type myosin (Figure 47).  The only manner in which α differs from the 
fast skeletal mode and appears more like β is in its biphasic ATP-induced actin-S1 dissociation, 
indicating the presence of a slow nucleotide pocket opening/closing step.  This step is never seen 
in fast skeletal myosins.  It is unclear if this trait has any significance in physiological contractile 
activity. 
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Figure 47:  Relation of human α- and β-S1 kinetics to known fast and slow myosins.  Rate 
and equilibrium constants measured for mouse, rabbit, and cow myosins are compared to human 
α- and β-S1 from this study.  Constants are normalized to the values for human β-S1.  β-S1 
constants group closely with the slow muscle derived bovine masseter S1132.  α-S1 constants 
differ from β-S1 constants and group instead with rabbit fast skeletal muscle180, 184 and mouse 
cardiac muscle S12.  Published in similar form in Deacon, et al. (2012)2. 
Implications of α- and β-MyHC kinetics in cardiac muscle fibers 
 α- and β-myosins are predicted by this study to preform distinct and different roles in 
muscle contraction.  α-MyHC is predicted to act as a "fast" myosin and β-MyHC as a "slow" 
myosin.  These "slow" and "fast" roles may be very important to proper contractile function in 
the human heart, since the loss of the fast α isoform from the heart in disease is correlated with 
decreased cardiac function167.  These roles may be described as:  a "slow" myosin acts to 
efficiently but slowly generate force and maintain tension, while a "fast" myosin has the capacity 
to rapidly generate force, but is unable to maintain tension on its own.  α- and β-myosins would 
therefore complement each other in a scenario such as the human heart where large forces are 
required to achieve contraction, and where a constant demand exists to generate force and 
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rapidly cycle, contracting again and again, continuously.  While β-MyHC is capable of 
sustaining large forces, it is very slow and may not be capable of maintaining the pace of a 
constantly rapidly contracting heart on its own.  However, while α-MyHC has the capacity to 
contract very quickly and cycle very rapidly, this feature comes without the ability on its own to 
hold the tension which may be necessary for proper contraction in a large human heart.  One 
reason to think this may be the case is by a comparison to rodent hearts.  Rat hearts are far 
smaller and beat far more rapidly than human hearts.  This requires less maintenance of tension 
but faster turnover.  In the rat heart α-myosin is the predominant isoform in an approximately 9 
to 1 ratio with respect to β-myosin, the approximate inverse of the human heart's myosin 
composition203. 
ELC identity and the presence or absence of the RLC do not effect β-MyHC kinetics 
 The "short-S1" protein, β-sS1, differs from β-S1 in two ways:  it lacks the RLC binding 
region and thus lacks the RLC, and it is bound by a single isoform of ELC of the appropriate 
identity for its human cardiac muscle environment, MYL3.  These differences were predicted to 
have some impact on the kinetics of the motor, however, no kinetic constant was seen to differ 
more than 2-fold.  Since each of these parameters was essentially similar between S1 and sS1 
constructs of β, we conclude that the features of myosin kinetics studied herein are not strongly 
influenced by the identity of the ELC.  Examining the impact of a loss of RLC may however 
require weight bearing contraction conditions, since previous studies indicate the influence of 
RLC may only be apparent under loaded conditions204.  Similarly, the role of the ELC may only 
be apparent under steady-state ATPase conditions.  Ongoing collaborative studies aim to address 
the roles of the light chains by testing additional isoforms of human ELC, as well as by testing 
single-molecule kinetics under load-bearing conditions. 
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The R453C mutation in β-MyHC extends the detached lifetime and lowers the duty ratio 
 The HCM mutant, β-R453C-sS1, has a single major change in its kinetic properties with 
respect to the wild-type, β-sS1.  The R453C mutation apparently decreases the rate constant for 
ATP hydrolysis ~10-fold.  This is predicted to alter both the duration of the overall cycle and the 
duty ratio.  The duration of the cycle is predicted to increase from ~80 ms to >600 ms as a result 
of the R453C mutation with a duty ratio reduced to ~2%.  Hypothetically, in a human HCM 
patient, with a heart composed of 90% β-MyHC, where approximately half of the β-MyHC bears 
the R453C mutation, ~45% of the myosin in the heart would be affected by the mutation.  If our 
predicted cycle time for β-R453C is correct, relative to wild-type β-MyHC, then the effected 
45% of total myosin may be participating in only 13% of the crossbridge events of a healthy β-
myosin.  Since the role of the slow β isoform in muscle contraction is predicted to be as an 
efficient tension maintaining motor46, this loss of tension maintaining crossbridges may be 
sufficient to disrupt contractile function.  While the coordinated nature of the sarcomere allows it 
to contract with only a fraction of the ~300 myosins per thick filament crossbridged to actin at a 
given moment, such a major alteration to a large fraction of its motors can be anticipated to 
produce notable effects.  Ongoing collaborative studies aim to investigate such possible effects in 
vivo. 
eGFP signal difficulties 
 The presence of the eGFP-tag was found to produce a ~10-fold decrease in ADP affinity.  
There is no known biochemical basis for such an effect as a result of eGFP.  One hypothesis is 
that the eGFP was capable of coming in contact with the nucleotide binding site due to flexibility 
in the carboxy terminus of S1, but the absence of effects on other nucleotide binding reactions 
makes this far less likely.  It is far more likely that eGFP fluorescence interfered with the 
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reaction signal.  The reaction affected consistently produced the lowest signal to noise ratio of 
those tested, and therefore any influence of eGFP fluorescence on the fluorescence transients 
would be more significant to such data.  This effect could have led to the observed differences.  
For this reason, however, it is not possible to compare this feature of the kinetics of constructs 
bearing the eGFP-tag with those of constructs lacking it.  For all future kinetics studies on the 
stopped-flow, constructs lacking a fluorescent tag will be constructed to avoid this difficulty.  
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CONCLUSIONS 
The first kinetic study of pure populations of human myosin isoforms 
 The development of a system for producing recombinant striated muscle myosin motors 
has expanded the type and scope of the experiments that are accessible to the striated muscle 
myosin field.  Without the limitations on isoform type and purity imposed by isolating myosin 
from animal muscles, and without the limitations on quantity and cost from genetically modified 
systems or from human patients and volunteers, additional studies in many aspects of human 
myosin biology are now possible.   
 This study represents the first detailed kinetic measurements of pure populations of single 
human myosin isoforms and the first such study in any species of the specialized extraocular 
isoform, of the individual developmental isoforms embryonic and perinatal, and of the cardiac 
isoform α-MyHC.  The study of the kinetics of single myosin isoforms reveals distinct roles for 
individual isoforms in muscle contraction.  The general categories "slow" and "fast" have been 
used to describe the kinetic categories of these myosin isoforms, but as the data show, there is 
additional variation within those descriptors.  The terms "slow" and "fast" as descriptors of 
isoform contractile style are expanded upon in Bloemink and Geeves, 201146.  The modes of 
slow and fast myosins, described therein, follow closely with our characterizations of the 
recombinant human myosins.  For example, slow myosins are characterized by slow contraction 
with the capacity for efficiently maintaining tension (i.e. without requiring rapid fiber twitching 
and high ATPase cycling rate).  This involves both slow entry into the actin-myosin crossbridge, 
defined by slow ATP hydrolysis (low value for k+3+k-3), and slow exit from the crossbridge, 
defined by a slow ADP-dissociation step (low value for k+5A).  This latter aspect, a slow ADP-
dissociation step, which limits the rate of crossbridge detachment, is a key manner by which 
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slow myosins maintain the force of contraction in a sarcomere, by extending the lifetime of the 
actin-myosin crossbridge.  By contrast, the "fast" isoforms have several-fold faster ATP 
hydrolysis and very rapid ADP dissociation, such that it does not limit crossbridge detachment.  
When fast and slow myosins are mixed together in a contractile unit their features may be 
synergistic in the coordinated system of the sarcomere, for the efficient production of contractile 
power, as suggested by studies varying the relative compositions of α- and β-myosins in rat and 
rabbit hearts169, 170, 205.  In a simplified model of this synergistic activity, the fast α-myosin 
functions as a rapid initiator of force generation, and the concurrent activity of slow β-myosin 
holds the tension produced by the fast activity of α-myosin without the need for high twitch 
frequency, as is required in fibers containing only fast isoforms121. 
Correlation of steady-state ATPase with pre-steady-state kinetics 
 ATPase kcat values separated into two groups, "fast" and "slow."  β-myosin was the only 
slow motor tested, ranging from 2- to 5-fold slower than the other human isoforms.  kcat 
correlates well with both the ADP-dissociation step (Step 5A) and the ATP hydrolysis step (Step 
3), both of which were found to be significantly slower in β-myosin than in the other isoforms 
tested.  However, since the rate-limiting step in F-actin-activated ATPase has been identified as 
occurring in the detached state, this points to Step 3 governing kcat for the F-actin-activated 
ATPase reaction, though this cannot be substantiated by these data since the ATP hydrolysis step 
was not determined for the fast skeletal isoforms in this study.  KATPase values did not apparently 
correlate to any specific pre-steady-state constant.  Due to the differing ionic strength and 
temperature of the steady-state and pre-steady-state assay conditions, the kinetic property 
governing KATPase in the steady-state assay may function differently in the pre-steady-state assays. 
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Disease-causing mutations in human myosins 
 Studies of disease-causing mutations in mouse revealed that it was very important to 
study disease-causing mutations in the appropriate MyHC isoform.  The HCM-causing R403Q 
mutation in human β-myosin produced contradictory results when put into the mouse α- and β-
myosin genes97.  This emphasizes the importance of studying myosins and their mutations in 
their physiologically appropriate backgrounds.  Overall, the close agreement of the kinetics of 
the recombinant myosin subfragments described in this thesis with the established kinetics for 
fast and slow myosin subfragments prepared from muscle, as shown in Tables 3, 4 and 5, 
supports the notion that these recombinant motors accurately represent their respective 
counterparts in human muscle.  This system also allows for the relatively simple and inexpensive 
production of modified or mutated myosin subfragments (when compared with the cost of 
genetically modified animals).  This system is therefore highly suitable for the study of human 
disease-associated mutations. 
 The effects observed in the two disease-associated mutations tested herein both appear to 
be biologically significant.  The HCM-causing mutation R453C in human β-sS1 produced a ~10-
fold decrease in the rate constant determining the lifetime of the detached state, predicting an 8-
fold decrease in duty ratio, from 16% to 2%, and an 8-fold elongation of the predicted duration 
of each cycle.  If these alterations hold true in the physiological context of the cardiac muscle 
fiber, then this mutation in one allele of β-MyHC would be predicted to cause up to a 40% 
decrease in the number of load-bearing crossbridge events formed in the sarcomere.  While these 
in vitro kinetic data do not indicate a pathway of hypertrophy they do describe a major alteration 
in sarcomeric activity that could have consequences in the heart. 
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 The FSS-causing mutation R672H in human embryonic-S1 produced multiple alterations 
to crossbridge detachment steps.  The major factor in its disruption of embryonic myosin activity, 
however, is predicted to be its alteration to ADP affinity and ADP dissociation kinetics.  As 
described above, the major difference between "slow" and "fast" myosins is the presence or 
absence, respectively, of a slow ADP-dissociation step governing the lifetime of the crossbridged 
state.  In embryonic-S1, this mutation alters its contractile activity from "fast" to very "slow."  
The contractile characteristics of Emb-WT indicated that it may be faster in terms of detachment 
kinetics than the fast skeletal isoforms IIa, IId, and IIb by ATP binding reactions.  In Emb-
R672H, the ADP-dissociation rate constant, k+5A, becomes altered to ~10-fold lower than that of 
the slow β isoform.  This ADP-binding alteration, resulting from the R672H mutation, may be 
expected to have significant consequences in developing muscles.  According to previous studies, 
the myosin content of neonatal mouse muscle consists of primarily embryonic and perinatal 
isoforms, with ~10% β-MyHC.  If perinatal is similar to embryonic in being a fast isoform, as its 
ATPase kcat would indicate, then it is likely that these neonatal muscles would have a 9 to 1 ratio 
of fast to slow myosins.  At birth, the embryonic isoform composes ~25% of the total myosin 
and before birth this is thought to be much higher154, 155, 206.  Therefore, this mutation in one 
allele of embryonic-MyHC can be predicted to cause the balance of fast to slow myosins in 
developing muscles to shift to nearly 4 to 1.  It is unsurprising, therefore, that the phenotype 
associated with this mutation involves multiple contractures, as these predictions would 
drastically increase the tension maintaining properties of the muscle.  However, these in vitro 
measurements are not themselves sufficient to extrapolate to effects in vivo. 
 The limitations of in vitro assays such as these include the absence of regulation on F-
actin binding and the absence of load, which could each play a large role in the impact of 
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disease-causing mutations in myosins.  However, upcoming collaborative studies aim to address 
these points in the near future.  
Methods Enhancements 
 The development of the recombinant expression system and the enhancement of the F-
actin-activated ATPase assay method with stirring methods by Daniel R. Resnicow in the 
Leinwand lab represent large advancements in the methods used in the study of myosin 
preceding my involvement in this project.  Since that time the project aims have continued to 
advance.  During my graduate work we performed the first pre-steady-state kinetic 
measurements on active recombinant striated muscle myosins.  Initially using the eGFP-fusion 
S1 constructs produced for previous steady-state studies, these measurements were complicated 
by the interference of the eGFP tag.  While it was not at first apparent that the origin of the 
steady -0.5 s-1 signal was a result of eGFP fluorescence, the elimination of that signal upon the 
first use of the Kodak 47B filter satisfied us with this conclusion.  This motivated the production 
of myosin subfragments lacking the fluorescent tag.  The first experiments with β-S1 lacking the 
eGFP tag produced a ~4-fold increase in signal amplitude from pyrene fluorescence 
measurements, with additional improvement in signal to noise using the same sample 
concentrations.  By this modification, the data we were able to generate per unit of protein 
produced was increased several-fold.  This is of particular significance because the method of 
protein production is intensive. 
 For that reason, advancements in protein production are also of great significance to this 
field of study.  Advancements have been made in tissue culture materials efficiency, myotube 
infection efficiency, recombinant adenovirus production efficiency, purification efficiency, and 
in protein storage.  Briefly, this includes the main findings that:  1) C2C12 cultures used for 
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producing protein can be cultured in 10% FBS rather than 20% FBS with no loss in cell health or 
protein yield.  2) Infecting myotubes with small quantities of recombinant adenovirus is possible 
by applying the virus to cells in proportionately smaller volumes of media for up to 1 hour, with 
no loss in cell health or protein yield.  3) During purification of S1 proteins, dialysis into low salt 
buffer following nickel-affinity chromatography at high protein concentrations can cause 
precipitation of S1 protein and therefore significant loss of materials.  This precipitation can be 
decreased to large extent by performing the dialysis as a gradient from start condition to target 
condition overnight.  4) Due to the long timescale and large quantities of cell material involved 
in the protein production process in culture, coordination between production and experimental 
protein demand is a significant concern.  By establishing a method for safely freezing cell pellets, 
while retaining myosin activity, it has been possible to eliminate protein production timing 
concerns to a large extent and to accumulate sufficient quantities of protein-bearing cells for 
crystallographic studies. 
Future directions 
 This work using recombinant sources of human myosin heavy chain proteins has 
established that studies of individual myosin isoforms using pre-steady-state techniques are 
capable of revealing new activities and distinctions between and among the isoforms.  This work 
has also established the feasibility of investigating kinetic alterations resulting from disease 
causing mutations in human myosins.  To continue these studies, several additional research 
aims should be undertaken.  The fast skeletal isoforms, IIa, IId, IIb, and extraocular, should be 
further analyzed to determine the rate constant governing ATP hydrolysis, k+3 + k-3, and thereby 
assign their ATP binding reaction phases.  This would complete our kinetic analysis of the fast 
skeletal isoforms  and allow the prediction of cycle times and duty ratios to properly place these 
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isoforms into their respective kinetic categories.  This work is currently underway and simply 
awaits sufficient protein quantities to undertake the task.  Also, the current short list of disease 
causing mutations under study should be expanded to include multiple mutations leading to the 
same disease, multiple mutations in both fast and slow myosins, and similar mutations which 
lead to different diseases.  These aims are also underway through a collaboration with multiple 
research groups, taking a multidisciplined approach to the study of myosins and mutations 
causing human cardiac and skeletal diseases.  It is also of interest to study myosin by multiple 
methods of analysis.  The multidisciplined approach taken by this collaborative team aims to 
complement this in vitro work with single molecule biophysical approaches, crystallographic 
structural analysis, as well as in vivo approaches to investigating the function of myosins in 
health and disease. 
 A related topic of interest to this work is the further advancement of the recombinant 
expression of striated muscle myosins.  While the system described herein for expressing these 
proteins represents a major advancement in the study of myosins, many limitations are posed due 
to the expense and scale of the current system.  It remains of great interest to uncover the muscle 
specific cell factors necessary to produce active recombinant myosin proteins in more tractable 
cellular expression systems.  One approach that may allow for the investigation of these factors 
is the targeted knockdown of putative folding cofactors in the existing expression system, the 
C2C12 myotube, aimed at knocking out the myosin folding ability of the system.  The knockdown 
of folding cofactors could be achieved using shRNA or similar systems.  Cofactors identified by 
this approach could be supplemented, in combination, to cells not normally capable of folding 
myosins and may make it possible for myosin expression to be accomplished in new cell 
environments.  
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APPENDIX A - ABBREVIATIONS 
 
ADP  Adenosine diphosphate 
ATP  Adenosine triphosphate 
C2C12  Mouse myoblast cell line, can be differentiated into myotubes and infected with 
recombinant adenoviruses to express human myosin motors 
CMV  Cytomegalovirus, a constitutive promoter of viral origin 
CS  Calf serum 
DMEM  Dulbecco's modified Eagle's medium 
DTT  Dithiothreitol, a reducing agent used to extend the active lifetime of purified 
protein 
E1  Early gene 1 from the adenoviral genome, essential for the replication competence 
of a virion, but can be supplemented by host cell production, as is present in 
HEK293 cells 
eGFP  Enhanced green fluorescent protein 
ELC  Essential myosin light chain 
F-actin  Filamentous actin, polymerized actin monomers to mimic the thin filament for in 
vitro experiments 
FBS  Fetal bovine serum 
HCM  Hypertrophic cardiomyopathy 
HEK293  Human epithelial kidney cell line, adherant cell line which complements the 
AdEasy system for viral replication by expressing the adenoviral gene, E1 
HPLC  High performance liquid chromatography 
HS  Horse serum 
IQ domain  Myosin light chain binding peptide sequence found on the lever arm, commonly 
initiated with isoleucine and glutamate 
KCl  Potassium chloride 
MgCl2  Magnesium chloride, providing magnesium ions necessary for myosin ATPase 
activity 
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MOPS  3-(N-morpholino)propanesulfonic acid, buffer 
MyHC  Myosin heavy chain protein 
NaN3  Sodium Azide 
NaOH  Sodium hydroxide 
PFU  Plaque-forming units, a term for the quantificatino of virus based on an empirical 
metric of the infectivity of a solution 
Pi  Inorganic phosphate, in this case produced as a product of the hydrolysis of 
adenosine triphosphate into adenosine diphosphate and inorganic phosphate 
RLC  Regulatory myosin light chain 
S1  Myosin heavy chain subfragment 1 contains the motor domain and lever arm, 
including binding sites for both essential and regulatory myosin light chains, with 
which it copurifies from C2C12 cells 
SDS-PAGE Sodium dodecyl sulfate poly-acrylamide gel electrophoresis, a denaturing protein 
separation technique for visualization of individual protein constituents of a 
substance  
sS1  Myosin heavy chain short-subfragment 1 or short-S1 contains the motor domain 
and only a portion of the lever arm, including only the essential myosin light 
chain binding site 
w/v  Weight per volume, for designating which method was used in the preparation of 
a solution 
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APPENDIX B - EQUATIONS 
 
Equation 1:  Vobs =
kcat[S1]•[F−Actin]
KATPase +[F− actin]  
Equation 2:  F = A ⋅ (1− e(−kobs⋅t ) )+ F
∞
 
Equation 3A:   
Equation 3B:   
Equation 4:  F = Afast ⋅ (1− e
(−kobs ( fast )⋅t ) )+Aslow ⋅ (1− e
(−kobs (slow )⋅t ) )+ F
∞
 
Equation 5:   
Equation 6A:   
Equation 6B:   
Equation 7:  kobs = K1Ak+2A 
Equation 8:   
 
kobs =
kmax[ATP]
K1/2 +[ATP]
kobs =
K1Ak+2A[ATP]
1+K1A[ATP]
kobs
k0
= krel =
1
1+ ([ADP] / K5A )
A =
Amax[ADP]
K5 +[ADP]
+Amin
A =
AmaxK5
K5 +[ADP]
+Amin
A =
[S1]+KD +[actin]− ([S1]+KD +[actin])2 − 4[S1][actin]
2[actin]
